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ABSTRACT

Over the past two decades, drug delivery systems have become a subject of
major interest in the pharmaceutical industry for the treatment of different diseases,
such as cancer, viral infections, and genetic disorders. A wide range of compounds
show high binding affinity and great potential in in vitro non-cellular assays through
direct interacting with molecular targets. However, many compounds show low
potency in cell-based assays due to their limited delivery across the cell membrane.
The physicochemical properties of several compounds, such as size, poor water
solubility, hydrophobic nature, and negative charge, limit their cellular uptake
significantly. Thus, there is an urgent need in design and synthesis of novel molecular
transporters for efficient delivery of effective compounds to cellular targets.
The recent growth of nanotechnology products will expand the current
resources of therapeutics for the pharmaceutical industry in the next few years. The
use of nanotechnology in drug delivery is widely expected to change the future of the
pharmaceutical and biotechnology industries. The application of nanotechnology in
drug delivery has led to the discovery of nano Drug Delivery Systems (nano-DDS).
Nanocarriers exhibit unique properties and take advantage of specific
physiochemical

behavior of nanoparticles.

Properties such as,

magnetism,

conductivity, melting and boiling points, and chemical and biological reactivity
become different at nano scale due to the quantum mechanical behavior of extremely
small structures at molecular dimensions. Furthermore, nanoparticles behave

differently since they take advantage of extraordinary high surface area to mass ratio,
leading to increased surface interactions and distinct biological performance.
Nanoparticles have the potential to be manipulated through changing their size,
electronic, and hydrophobic nature. Employing nanosized carriers offer several
advantages, including enhanced intracellular delivery of poorly water-soluble drugs,
targeted delivery, transporting relatively large biologically important molecules across
the cell membrane, delivery of a combination of drugs to overcome drug resistance,
and transporting drugs through challenging epithelial and endothelial barriers.
Thus, design and development of nano-sized pharmaceutical carriers has
become attractive for chemists, biologists, and physicists. Functionalized Nano-DDS
are designed to deliver and release cargo drugs intracellularly more efficiently than the
currently available systems, leading to the enhanced drug tissue bioavailability and
eventually therapeutics efficacy.
Among all nano-DDS, Cell-Penetrating Peptide (CPP)-mediated intracellular
DDS has been widely used for the enhanced delivery of water insoluble drugs,
negatively charged molecules (e.g., DNA, siRNA, phosphopeptides), and proteins.
However, the application of (CPP)-mediated intracellular DDS in in vivo models has
been challenging due to their inherent toxicity to normal cells and organs. Several
studies have been performed to facilitate the intracellular delivery of a wide range of
low-molecular weight and macromolecular drugs using carriers through the cell
cytoplasm bypassing the endocytic pathway to avoid lysosomal degradation. In this
process, although the drug is delivered into cytoplasm protected, it still needs to be
transported to a certain organelles, such as mitochondria or nuclei, where therapeutic

function occurs. Several CPPs promote the delivery of drugs through receptormediated endocytosis. However, this mechanism requires high affinity between the
drug-carrier complex and the target in the cell membrane for endocytosis. This process
will be followed by energy-dependant formation of endosomes. However, this method
suffers from entrapment and release challenges. After delivery of the molecular cargo
into cells through endocytic pathway, and its entrapment in endosome, the cargo
molecules or drug may end up in lysosome and degraded by the lysosomal enzymes.
Thus, a limited amount of the drug can reach the cytoplasm because of inadequate
endosomal escape and lysosomal degradation. As a result, although numerous CPPs
exhibit promising results in in vitro assays, they fail in vivo because of the poor
bioavailability.
Furthermore, the nuclear delivery of cargo drugs with known CPPs has been
unsuccessful. The nucleus of a cell is an important target for drug delivery systems,
due to presence of the genetic information and transcription machinery. An efficient
cellular uptake of the drug is highly desired in nucleus where it can interact with
nucleic acids. The nuclear targeting delivery is challenging. The designed drug-CPP
complex must meet several requirements for nuclear delivery including efficient cell
internalization

by

endosomal/lysosomal

receptor-mediated
pathways,

acquiring

endocytosis
a

nuclear

(RME),
localization

escaping
signal

to

communicate with nuclear pore complexes, and eventually, being sufficiently small to
enter the nuclear membrane. Not many CPPs have been found efficient for the nuclear
delivery applications.

CPPs can be classified into two major classes, linear and cyclic CPPs. Most
reported CPPs are linear peptides that are flexible in solution and contain up to 10
amino acids. However, cyclization of peptides has been employed as a strategy to
generate constrained structures. The rigidity imposed by cyclization reduces the
flexibility and causes the system to adopt a restricted numbers of molecular
conformations. Peptide cyclization has become a unique approach to generate
conformations not available to linear peptides. Cyclic and linear peptides containing
an equal number of similar amino acids create different geometries leading to different
affinities for similar targets. Furthermore, cyclic CPPs containing specific amino acids
have shown to have a different cellular uptake mechanism compared to linear CPPs.
While most of the linear CPPs undergo endocytosis pathways in cellular uptake, some
of the cyclic CPPs have endocytosis-independent uptake and target nucleus. Thus,
cyclic peptides can be designed to be used as nuclear delivery vehicles of anticancer
compounds targeting DNA. Functionalizing cyclic peptides with tumor targeting
moieties can be used as a strategy for selective cancer cell targeting and improving
nuclear targeting of anticancer drugs.
Cyclic CPPs can be also covalently conjugated to active drug cargos to
generate prodrugs. Prodrugs are chemically modified analogs of an active metabolite
that can improve pharmacokinetics and pharmacodynamics (PK/PD) properties of the
drug. Prodrug strategy could offer several advantageous, such as enhancing water
solubility, drug delivery, and chemical stability, and reducing toxicity. However,
chemical transformation to the active drug is required in the presence of different
intracellular enzymes to convert prodrugs to their corresponding pharmacologically

potent moieties in in vivo systems. Cyclic peptide-drug conjugates can be used as
alternative prodrug approach for improving delivery of compounds with limited
cellular uptake.
This dissertation focuses on a class of cyclic peptides as intracellular molecular
transporters that can be used as prodrugs or peptide-capped gold nanoparticles. We
hypothesized that the combination of alternate hydrophobic tryptophan and positively
charged arginine or lysine residues in the sequence of the cell-penetrating cyclic
peptide was critical for improving the cell-penetrating properties of the system.
Furthermore, the presence of arginine and tryptophan facilitated the formation of gold
nanoparticles. The molecular transporting efficiency of the peptide alone and peptidecapped gold nanoparticles was evaluated for a broad range of molecular cargos
including anti-HIV drugs, anticancer agents, and negatively charged phosphopeptides.
The cyclic peptides containing alternate tryptophan and arginine residues and
their corresponding peptide-capped gold nanoparticles enhanced the delivery of water
insoluble drugs and negatively charged biologically important molecules. A broad
range of parameters including concentration, toxicity, time, and different sequences of
amino acids were explored to optimize the cellular uptake. Several characterization
methods were used to determine the interaction between drugs and carrier through the
formation of the complex. Different methods were also used to investigate the
mechanism of the cellular uptake.
This work presents examples where prodrugs containing linear peptides are
compared with their corresponding cyclic peptides in terms of biological properties

and in delivery of different drugs. For example, cyclic peptides containing certain
amino acids generated gold nanoparticles more efficiently compared to their
corresponding linear peptides. Moreover, cyclic peptide capped gold nanoparticles
exhibited higher molecular transporting potency when compared with the linear
counterparts. This dissertation will be discussed in four manuscripts:
The objective of Manuscript І (published in Molecular Pharmaceutics 2013,
10(5), 2008-2020) was to evaluate a cyclic octapeptide containing arginine and
tryptophan for their ability to transport negatively charged phosphopeptides.
Phosphopeptides are important compounds for studying protein-protein interactions.
Phosphopeptides suffer from their limited cellular uptake due to the presence of
negatively charged phosphate group in their structure. The hypothesis of this
manuscript is that cyclic peptide [WR]4 containing positively charged arginine can
interact with negatively charged cell-impermeable phosphopeptides and improve their
cellular uptake. Furthermore, the positively charged arginine and hydrophobic
tryptophan can interact with negatively charged and hydrophobic residues in the cell
membrane phospholipids and improve cell permeability of phosphopeptides. The
cellular uptake of several biologically important phosphopeptides such as
GpYLPQTV, NEpYTARQ, AEEEIY GEFEAKKKK, PEpYLGLD, pYVNVQNNH2,
and GpYEEI was evaluated in the presence and absence of [WR]4. The cyclic peptide
enhanced the cellular uptake of all phosphopeptides significantly in human leukemia
cells (CCRF-CEM) after 2 h incubation. Confocal microscopy studies in live cells
confirmed that the mixture of F′-PEpYLGLD and [WR]4 was localized in cells and
showed higher cellular uptake than the phosphopeptides alone. Several tools including

Transmission Electron Microscopy (TEM) and Isothermal Calorimetry (ITC) were
used to understand the interaction between the drug and carrier. TEM results showed
that the phosphopeptide-drug complex (PEpYLGLD-[WR]4) formed specific nanosized structures with the 125 × 60 nm dimensions. The ITC investigation proved an
exothermic interaction driven by entropy. The result of this paper showed that the
presence of the cyclic peptide enhanced the cellular uptake of phosphopeptides
significantly. To this end, it was discovered that [WR]4 can be employed as a cellular
delivery tool of negatively charged phosphopeptides through non-covalent interaction.
However, the evaluation of the covalent conjugation between the drug and cyclic
peptide remained unexplored.
Manuscript ІІ (published in Molecular Pharmaceutics 2013, 10(2), 488-499)
embarked on taking advantage of both the cell-penetrating properties of the peptide
and prodrug strategy. The hypothesis underlying this project is that cyclic CPP-drug
conjugates can be used as potential prodrug to improve the cellular delivery of
anticancer compounds. Doxorubicin (Dox), a potent anticancer drug, was covalently
linked with the cyclic peptide containing alternate tryptophan and arginine
([W(RW)4]) to afford their corresponding prodrug cyclic [W(RW)4]−Dox. To study
the effect of the cyclic nature of the peptide, linear peptide attached to Dox (linear
(RW)4−Dox) was also synthesized for comparative studies. The biological activities of
cyclic [W(RW)4]−Dox and linear (RW)4−Dox prodrugs including their cellular uptake
and anticancer potency were compared in cell-based assays. Comparative
antiproliferative assays between covalent (cyclic [W(RW)4]−Dox and linear
(RW)4−Dox) and the corresponding noncovalent physical mixtures of the peptides and

Dox were performed. Cyclic [W(RW)4]−Dox inhibited the CCRF-CEM (62−73%),
ovarian adenocarcinoma (SK-OV-3) (51−74%), colorectal carcinoma (HCT-116)
(50−67%), and breast carcinoma (MDA-MB-468) (60−79%) cells at a concentration of
1 μM after 72−120 h of incubation. Cyclic [W(RW)4]−Dox exhibited higher
antiproliferative activity than linear (RW)4−Dox in all cancer cells after 72 h..
Furthermore, the cellular uptake of [W(RW)4]−Dox was observed to be higher than
that of the linear prodrug after 24 h incubation in SK-OV-3 cells, suggesting that the
cyclic nature offers major advantageous when compared with the corresponding linear
ones. The result of this manuscript revealed that cyclic prodrug (cyclic
[W(RW)4]−Dox) can be used as a potential prodrug candidate for enhancing the
cellular retention of the drug in the treatment of ovarian cancer.
In Manuscript Ш (published in Molecular Pharmaceutics, 2013, 10(2), 500511), we investigated the application of cyclic peptides in generating gold
nanoparticles. We hypothesize that cyclic peptides containing specific amino acids
can be used as reducing agents and generate peptide-capped gold nanoparticles (CPAuNPs) from gold ion (Au3+). Several cyclic peptides including [WR]4, [FK]4, [AK]4,
[EL]4, [RFEF]2, [EK]4, and [FR]4 containing hydrophobic residues (W, F, L) and
charged residues (K, R, E) where A = alanine, E = glutamic acid, F = phenylalanine, K
= lysine, L = leucine, R = arginine, W= tryptophan were investigated for their ability
to generate gold nanoparticles. Among all of them, only [WR]4 was discovered to be
appropriate for the synthesis of CP-AuNPs. Flow cytometry studies showed that the
cellular uptake of fluorescence-labeled anti-HIV drugs such as lamivudine,

emtricitabine, and stavudine was significantly enhanced in human ovarian
adenocarcinoma (SK-OV-3) cells in the presence of [WR]4-AuNPs. For instance, the
cellular uptake of fluorescence labeled lamivudine-loaded [WR]4-AuNPs showed 12fold higher cellular uptake compared to fluorescence labeled lamivudine alone in
CCRF-CEM cells after 2 h incubation. The morphology and size of nanoparticles were
characterized using TEM.. TEM results showed [WR]4-AuNPs form nano-sized
structures with approximate size 5-50 nm. [WR]4-AuNPs (100 μM) did not show
significant toxicity in CCRF-CEM, SK-OV-3, and normal human colon myofibroblast
(CCD-18Co) cells after 24-72 h incubation. To this point, we understand that the cellpenetrating peptide-capped gold nanoparticles have potential to be used as prodrugs
for delivery of antiviral and anticancer drugs through noncovalent conjugation.
However, this strategy was required to be evaluated for non-cell penetrating peptides.
Thus, we used a sequence of amino acids for designing a non-cell-penetrating peptide
that generated peptide-capped gold nanoparticles with molecular transporting
property.
In

Manuscript

ІV,

(published

in

Molecular

Pharmaceutics,

DOI: 10.1021/mp400199e), a green method for the synthesis of non-cell penetrating
peptide-capped gold nanoparticles was reported. We hypothesize that a non-cell
penetrating peptide containing lysine and tryptophan namely linear (KW)5 and cyclic
[KW]5 can be converted to a cell-penetrating molecular transporter upon generation of
cyclic peptide-capped gold nanoparticles (linear (KW)5-AuNPs and cyclic [KW]5AuNPs). A comparative flow cytometry results revealed that the cellular uptake of
fluorescence-labeled anti-HIV drugs (emtricitabine (FTC) and lamivudine (3TC)) in

CCRF-CEM cells, and a negatively charged cell-impermeable phosphopeptide
(GpYEEI) in SK-OV-3 cells was significantly higher in the presence of cyclic [KW]5AuNPs than that of linear (KW)5-AuNPs, parent cyclic [KW]5, and linear (KW)5
peptides. For example, the cellular uptake of F-GpYEEI was enhanced 12.8-fold by
cyclic[KW]5-AuNPs when compared with F-GpYEEI alone. Microscopy results
showed that fluorescence-labeled-3TC-loaded cyclic[KW]5-AuNPs were localized in
nucleus in SK-OV-3 cells after 1 h incubation. However, linear(KW)5-AuNPs
delivered the majority of fluorescence-labeled-3TC into cell cytoplasm. The results
from this work suggest that non-cell penetrating peptides can be converted to efficient
drug carriers by forming peptide-capped gold nanoparticles.
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Figure 1. General Application of [WR]4.

In summary, the studies described in this dissertation provided insights about
the application of a new generation of cyclic peptides for the delivery of a broad range
of drugs and biomolecules. The cyclic peptide containing alternate tryptophan and
arginine residues was found to be efficient molecular transporters and nuclear delivery
agents (Figure 1). In addition, we have demonstrated that a non-cell penetrating cyclic
peptide can be converted to an efficient intracellular drug transporter through
generation and capping of the gold nanoparticles. A detailed investigation on the
cyclic nature of the peptide compared to the linear one in terms of their chemical
behavior and biological activity was provided. Overall, a concrete strategy has been
established by developing non-toxic cyclic peptide molecular transporters that can be
used in prodrug strategy or gold nanoparticle formation. The scientific knowledge was
advanced in the area of application of cell-penetration peptides in prodrug strategy and
designing nanocarriers.
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Abstract
Phosphopeptides are valuable reagent probes for studying protein−protein and
protein−ligand interactions. The cellular delivery of phosphopeptides is challenging
because of the presence of the negatively charged phosphate group. The cellular
uptake of a number of fluorescent-labeled phosphopeptides, including F′-GpYLPQTV,
F′-NEpYTARQ, F′-AEEEIYGEFEAKKKK, F′-PEpYLGLD, F′-pYVNVQNNH2, and
F′-GpYEEI (F′ = fluorescein), was evaluated in the presence or absence of a [WR]4, a
cyclic peptide containing alternative arginine (R) and tryptophan (W) residues, in
human leukemia cells (CCRF-CEM) after 2 h incubation using flow cytometry. [WR]4
improved significantly the cellular uptake of all phosphopeptides. PEpYLGLD is a
sequence that mimics the pTyr1246 of ErbB2 that is responsible for binding to the Chk
SH2 domain. The cellular uptake of F′-PEpYLGLD was enhanced dramatically by 27fold in the presence of [WR]4 and was found to be time-dependent. Confocal
microscopy of a mixture of F′-PEpYLGLD and [WR]4 in live cells exhibited
intracellular localization and significantly higher cellular uptake compared to that of
F′-PEpYLGLD alone. Transmission electron microscopy (TEM) and isothermal
calorimetry (ITC) were used to study the interaction of PEpYLGLD and [WR]4. TEM
results showed that the mixture of PEpYLGLD and [WR]4 formed noncircular
nanosized structures with width and height of 125 and 60 nm, respectively. ITC
binding studies confirmed the interaction between [WR]4 and PEpYLGLD. The
binding isotherm curves, derived from sequential binding models, showed an
exothermic interaction driven by entropy. These studies suggest that amphiphilic
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peptide [WR]4 can be used as a cellular delivery tool of cell-impermeable negatively
charged phosphopeptides.
KEYWORDS: cellular uptake, cyclic peptides, nanoparticles, phosphopeptides, SH2
domain
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Introduction
Peptide amphiphiles (PAs) are composed of a combination of amino acids
carrying hydrophobic/hydrophilic and positively/ negatively charged residues.1 PAs
have been found to be promising tools in drug and gene delivery due to their
biocompatibility and bioactivity.2−4 These compounds are not toxic to cells at their
experimental concentration and are able to cross the cell membrane because of their
unique structural properties.
Hydrophobic unit of PAs can contain long chain fatty acids or amino acids
with hydrophobic side chain residues. This unit generates a pocket that could be
responsible for the entrapment of drugs and facilitates the internalization into the cell
membrane.5 At the same time, the presence of positively charged arginine facilitates
the interaction between the peptide and the negatively charged phospholipids on the
cell membrane. The application of positively charged linear cell-penetrating peptides
(CPPs) as drug carriers for biologically active cargos has been reported previously.6−9
Polyarginines, TAT (trans-acting activator of transcription), and Penetratin have been
found to enhance the cellular uptake of a diverse range of drugs.10−12 Thus, the
appropriate combination of amino acids in the structure of peptide determines the
efficiency and function of the delivery system.
Phosphopeptides are valuable reagent probes mimicking phosphoproteins for
studying protein−protein and protein−ligand interactions

13,14

and determination of

substrate specificity of the Src homology 2 (SH2) domain,15 phosphatases,16,17 and
phosphotyrosine binding (PTB) domains.18,19 The use of phosphopeptides has been

4

challenging due to the fact that they have limited cellular uptake because of the
presence of the negatively charged phosphate group. Several chemical modifications
have been used to enhance the intracellular delivery of phosphopetides through
covalent conjugation to other transporter peptides.20−22 These strategies suffer from
several disadvantages including multistep synthesis of the fusion conjugates, low
loading yields, and the requirement of cleavage through chemical or enzymatic
reactions to release phosphopeptides.23
Peptidomimetic prodrugs have been reported for intracellular delivery of aryl
phosphoramidates24 and difluoromethyl phosphonates.25 Arrendale and co-workers
developed a (difluoromethylene)phosphoserine prodrug to deliver negatively charged
phosphoserine peptidomimetic intracellularly. FOXO3a is a transcription factor that is
phosphorylated by Akt1 and binds to 14-3-3-adaptor protein. The released modified
phosphopeptide was able to release FOXO3a from 14-3-3 protein, leading to cell death
in

leukemia

cells.26,27

Other

phosphoserine

and

phosphothreonine

masked

phosphopeptides have been evaluated in studying kinase regulation.28,29
Considering the critical roles of the phosphopeptides in cellular signaling
pathways, we have previously reported amphiphilic linear peptide analogs to improve
the intracellular uptake of negatively charged phosphopeptides through noncovalent
conjugation.30 The linear positively charged peptides were designed based on the Src
SH2 domain phosphotyrosine (pTyr) binding pocket.
We introduced a new class of homochiral cyclic peptides containing arginine
(R) and tryptophan (W) such as [WR]4 that were appropriate carriers for a wide range
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of drugs.31 This system showed that the optimized balance between positive charge
and hydrophobicity was critical for the peptide to enhance the intracellular delivery of
drugs through interaction with the cell membrane and penetration into the lipid
bilayer. Cyclic [WR]4 provided major advantages compared to their linear
counterparts, including higher enzymatic stability, bypassing endosomal uptake,
improved cell permeability, and nuclear targeting.31
In continuation of our efforts to introduce new applications of [WR]4 for the
delivery of biomolecules, we report here using [WR]4 for improving the cellular
delivery of negatively charge phosphopeptides. Addition of negatively charged
phosphopeptides to the positively charged [WR]4 led to the formation of
nanostructures through intermolecular interactions. To the best of our knowledge, this
is the first report of using a cell-penetrating cyclic peptide for cellular delivery of
impermeable phosphopeptides.

EXPERIMENTAL SECTION
General. All amino acids were purchased from Chem-Impex International, Inc.
HBTU was purchased from Oakwood products, Inc. All other chemicals and reagents
were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI). The chemical
structures of final products were confirmed by high resolution MALDI AXIMA
performance TOF/TOF mass spectrometer (Shimadzu Biotech). Details of procedures
and spectroscopic data of the respective compounds are presented below. Final
compounds were purified on a Phenomenex Prodigy 10 μm ODS reversed-phase
6

column (2.1 cm × 25 cm) with a Hitachi HPLC system using a gradient system of
acetonitrile (CH3CN) or methanol and water (CH3OH/H2O) (0−100%, pH 7.0, 60
min). The purity of final products (≥95%) was confirmed by analytical HPLC. The
analytical HPLC was performed on a Hitachi analytical HPLC system using a C18
Shimadzu Premier 3 μm column (150 cm × 4.6 mm) and a gradient system
(water/CH3CN), and a flow rate of 1 mL/min with detection at 220 nm. Cyclic peptide
[WR]4 was synthesized according to our previously reported procedure.31 As
representative examples, the synthesis of Ac-PEpYLGLD and F′-PEpYLGLD is
outlined here.
Synthesis of Ac-PE(pY)LGLD and F′-PE(pY)LGLD. Side chain protected peptide
PE(pY)LGLD was assembled on Fmoc-Asp(OtBu)-Wang resin (740 mg, 0.54
mmol/g, 0.4 mmol) by solid-phase peptide synthesis strategy using Fmoc-protected
amino acids [Fmoc-Leu-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Tyr(PO3tBu2)-OH,
Fmoc-Glu(OtBu)-OH, and Fmoc- Pro-OH] on a PS3 automated peptide synthesizer at
room

temperature

using

2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate (HBTU) and N-methylmorpholine (NMM, 0.4 M) in N,Ndimethylformamide (DMF) as coupling and activating agents, respectively (Scheme
1). After the assembly of the side chain protected peptide sequence, the Fmoc
protecting group at the N-terminal proline was removed using piperidine in DMF
(20% v/v). The resin was washed with DCM (3 × 15 mL) and MeOH (3 × 15 mL) for
further modification using either capping reagent (acetic anhydride) or fluorescein
labeling reagent (5(6)-carboxyfluorescein isobutyrate). The resin was dried overnight
under vacuum and divided into two parts. The capping reaction was carried out on the
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first

portion

using

acetic

anhydride

((CH3CO)2O)

(953

μL)

and

N,N-

diisopropylethylamine (DIPEA) (1,742 μL) (50/50 equiv) in DMF (10 mL). The
mixture containing peptide-attached resin and reagents was shaken for 30 min,
followed by washing with DMF (5 × 15 mL), DCM (5 × 15 mL), and MeOH (3 × 15
mL), respectively. The resin was dried under vacuum at room temperature for 24 h.
The second portion of the resin was swelled in DMF (2 × 20 mL) for 2 h. The
preactivation reaction was performed on the fluorescein reagent using a mixture of
5(6)-carboxyfluorescein isobutyrate (5 equiv), 1-hydroxy-7-azabenzotriazole (HOAt,
5 equiv)/7- azabenzotriazol-1-yloxy tripyrrolidinophosphonium hexafluorophosphate)
(PyAOP, 5 equiv)/DIPEA, 10 equiv) in DMF:DCM (5:1 v/v, 12 mL) for 10 min. The
activated fluorescein reagent was added to the peptide-attached resin and stirred at
room temperature for 3 h. After the completion of the reaction, the resin was washed
by DMF (5 × 15 mL), DCM (3× 15 mL), and MeOH (5 × 15 mL), respectively. The
protecting group (isobutyrate) was removed from the carboxyfluorescein by treating
the peptide-attached resin with 20% piperidine in DMF (5 × 15 mL, 25 min each).
Finally, the resin was washed with DMF (5 × 15 mL), DCM (5 × 15 mL), and MeOH
(5 × 15 mL), respectively, followed by drying under a high vacuum at room
temperature for 24 h. The cleavage reagent R cocktail containing trifluoroacetic acid
(TFA)/thioanisole/ethandithiol (EDT)/anisole (90:5:3:2 v/v/v/v, 12 mL) was added to
both portions of the resin, and the mixtures were stirred at room temperature for 2 h.
The resins were filtered and washed with Reagent R (2 mL) again. The filtrates were
evaporated to reduce the volume under dry nitrogen. The crude peptides were
precipitated by adding cold diethyl ether (200 mL, Et2O) and centrifuged at 4000 rpm
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for 5 min, followed by decantation to obtain the solid precipitates. The solid materials
were further washed with cold ether (2 × 100 mL) for 2 times. The peptides were
lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) on a Phenomenex
Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system
to yield the linear capped Ac-PE(pY)LGLD and fluorescein-labeled F′-PE(pY)LGLD
peptides, respectively. Similarly, other fluorescein-labeled peptides were synthesized
according to this procedure.
Ac-PE(pY)LGLD

(Shown

Here

as

PE(pY)LGLD).

MALDITOF

(m/z)

[C39H58N7NaO17P]: calcd [M + Na]+, 950.3524; found, 950.3524.
F′-PE(pY)LGLD. MALDI-TOF (m/z) [C58H67N7O22P]: calcd [M + H]+, 1244.4077;
found, 1244.4080. [C58H66N7NaO22P]: calcd [M + Na]+, 1266.3896; found, 1266.3899.
F′-G(pY)LPQTV. MALDI-TOF (m/z) [C57H67N8NaO20P]: calcd [M + Na]+,
1237.4107; found, 1237.4108. [C57H67KN8O20P]: calcd [M + K]+, 1253.3846; found,
1253.3846.
F′-NE(pY)TARQ. MALDI-TOF (m/z) [C57H68N12O23P]: calcd [M + H]+, 1319.4258;
found, 1319.4258.
F ′-AEEEI(pY)GEFEAKKKK. MALDI-TOF (m/z) [C102H139N19O36P]: calcd [M + H]+,
2236.9368; found, 2236.9370.
F′-PS(pY)VNVQN-NH2. MALDI-TOF (m/z) [C61H74N12O22P]: calcd [M + H]+,
1357.4778 ; found, 1357.4781.
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F′-G(pY)EEI. MALDI-TOF (m/z) [C48H51N5O20P]: calcd [M+ H]+, 1048.2865; found,
1048.2872.

Cell Culture and Cytotoxicity Assay.
Cell Culture. Human leukemia carcinoma cell line CCRF-CEM (ATCC No. CCL119), ovarian adenocarcinoma SK-OV-3 (ATCC No. HTB-77), colorectal carcinoma
HCT-116 (ATCC No. CCL-247), and normal human colon myofibroblast (CCD18Co, ATCC No. CRL-1459) were obtained from American Type Culture Collection.
Cells were grown in 75 cm2 cell culture flasks with EMEM (Eagle’s minimum
essential medium), supplemented with 10% fetal bovine serum, and 1%
penicillin/streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin
in 0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 °C.
Flow Cytometry Studies. Human leukemia adenocarcinoma (CCRF-CEM, 1 × 107
cells) or human ovarian adenocarcinoma cells (SK-OV-3, 3 × 105 cells) were taken in
6-well plates in opti-MEM or serum-free RPMI medium. Then the fluorescencelabeled phosphopeptides (F′-PE(pY)LGLD, F′-G(pY)-LPQTV, F′-NE(pY)TARQ, F′PS(pY)VNVQN-NH2, F′-AEEEI(pY)G EFEAKKKK, or F′-G(pY)EEI) (5−10 μM)
were added to the different wells containing [WR]4 (25−50 μM) in media. The plates
were incubated for 1−2 h at 37 °C. Cells and fluorescence-labeled phosphopeptides
alone were used as negative controls. After 1−2 h incubation, the medium containing
the peptide was removed. The cells were digested with 0.25% trypsin/EDTA (0.53
mM) for 5 min to remove any artificial surface binding. Then the cells were washed
10

twice with PBS. Finally, the cells were resuspended in flow cytometry buffer and
analyzed by flow cytometry (FACSCalibur: Becton Dickinson) using FITC channel
and CellQuest software. The data presented were based on the mean fluorescence
signal for 10,000 cells collected. All assays were performed in triplicate. A similar
procedure was used for linear (WR)4 and linear tripodal peptide LPA4 FACS studies.
Cell Cytotoxicity Assay of [WR]4 + PEpYLGLD Mixture. SK-OV-3 (5,000 cells),
CCRF-CEM (40,000 cells), HCT-116 (4,000), and CCD-18Co (3,000 cells) were
seeded in 0.1 mL per well in 96-well plates 24 h prior to the experiment. The old
medium (EMEM containing fetal bovine serum (FBS) (10%) for SK-OV-3, HCT-116,
and CCD-18Co was removed. The stock solutions were prepared at high
concentrations to generate maximum intermolecular interactions and then were diluted
to desired concentrations for cellular studies. [WR]4 (25 μM) + PEpYLGLD (5 μM) or
[WR]4 (50 μM) + PEpYLGLD (10 μM) in serum containing medium was added, and
the cells were incubated for 24 h at 37 °C in a humidified atmosphere of 5% CO2. In
the case of CCRF-CEM (nonadherent cells), the final concentration was calculated
after addition of the compounds. Cell viability was then determined by measuring the
fluorescence intensity of the formazan product at 490 nm using a SpectraMax M2
microplate spectrophotometer. The percentage of cell survival was calculated as [(OD
value of cells treated with the test mixture of compounds) − (OD value of culture
medium)]/[(OD value of control cells) − (OD value of culture medium)] × 100%.
Cellular Uptake Studies in the Presence of Inhibitors. Human ovarian adenocarcinoma
cells (SK OV-3) were seeded in 6-well plates (3 × 105 cells/well) in opti-MEM. The
cells were preincubated by various inhibitors including nystatin (50 μg/mL),
11

chloroquine (100 μM), chlorpromazine (30 μM), methyl-β-cyclodextrin (2.5 mM), and
5-(N-ethyl-N-isopropyl) amiloride (EIA, 50 μM) for 30 min. The treatment was
removed, and the cells were incubated with [WR]4 (25 μM), F′-PE(pY)LGLD (5 μM),
and a similar concentration of inhibitors for 1 h. To induce ATP depletion, the cells
were preicubated with 0.5% of 150 mM sodium azide in opti MEM prior to the
addition of the compound followed by 1 h incubation. Consequently, a similar FACS
protocol was performed as described above.
Confocal Microscopy on Live Cells. Adherent SK-OV-3 cells were seeded with
EMEM media overnight on coverslips in 6-well plates. Then the media were removed
and washed with opti-MEM. The cells were treated with F′-PEpYLGLD (5 μM) in the
presence or absence of [WR]4 (25 μM) for 1 h at 37 °C. The stock solutions were
prepared at high concentrations to generate maximum intermolecular interactions and
then were diluted to desired concentrations for cellular studies. After 1 h incubation,
the media containing the treatments were removed followed by washing with PBS
three times. Then the coverslips were mounted on a microscope slide with mounting
media with the cell-attached side facing down. Laser scanning confocal microscopy
was carried out using Carl Zeiss LSM 510 system. The cells were imaged using FITC
and phase contrast channels.
Transmission Electron Microscopy (TEM). TEM samples were prepared by drop
casting of PEpYLGLD (1 mM in H2O), [WR]4 (1 mM in H2O), or mixture of
PEpYLGLD and [WR]4 (1 mM in H2O) solution (incubated for one day) (10 μL) onto
the Formvar coated carbon grid of mesh size 300, which was allowed to sit for 2 min.
Excess solvent was carefully removed by capillary action (filter paper). Grids were
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allowed to dry at room temperature overnight. All images were taken using a JEOL
transmission electron microscope (Tokyo, Japan) maintained at 80 kV. After drop
casting of peptide solutions, grids were then stained with uranyl acetate (20 μL) for 2
min. Excess stain was removed, and the grids were allowed to dry overnight.
Isothermal Titration Calorimetry (ITC). ITC was performed on a Microcal VP-ITC
microcalorimeter (Microcal, Northampton, MA). Data acquisition and instrument
control were carried out using a dedicated Origin software package. All the
experiments were performed at 30 °C using cyclic peptide [WR]4 (500 μM) and
PEpYLGLD (6 mM). Both PEpYLGLD and [WR]4 were dissolved in water. A
solution containing [WR]4 (1.42 mL) was transferred into the sample cell. A solution
of PEpYLGLD (6 mM, 10 μL) was injected from the syringe (280 μL) into the stirred
sample cell (stirring speed 307 rpm). The reference cell was filled with deionized
water. A 180 s time interval between injections was applied in order to allow the
system to reach thermal equilibrium after each addition. Corrections were made for the
dilution heat of the phosphopeptide, which was determined in control experiments
under similar conditions. Analysis of the integrated heat data was performed using the
Origin 7 package provided with the ITC instrument. Experimental data was fitted
using a nonlinear least-squares minimization algorithm to a theoretical titration curve.
Different binding models were assumed, involving a single set of identical sites, two
sets of independent sites, or sequential binding events. The equations were included in
the commercial ITC Data analysis software package of Origin 7.0. The chi-square
parameter χ2 was used to establish the best fit.
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Circular Dichroism. CD spectra were recorded on a JASCO J-810 spectropolarimeter
using 1 mm path length cuvettes. The scan speed was 100 nm/min, and spectra were
averaged over 8 scans. All experiments on the samples including [WR]4 (25 μM, H2O)
and PEpYLGLD (25 μM, H2O) were tested at room temperature. The CD for
background reference (water) was measured and subtracted from the sample.
Molecular

Modeling.

Initial

coordinates

for

[WR]5

were

obtained

using

GAUSSVIEW.32 Ab initio Hartree−Fock molecular orbital calculations with complete
geometry optimizations were performed with 6-31G33 basis set on monomer [WR]5
utilizing GAUSSIAN’03 software. Geometry of monomers was completely optimized.
All bond lengths, bond angles, and dihedral angles were allowed to relax without any
constraint.

RESULTS AND DISCUSSION
Chemistry. A number of fluorescence labeled phosphopeptides, F′-GpYLPQTV, F′
NEpYTARQ, F′-AEEEIYGEFEAKKKK, F′-PEpYLGLD, F′-pYVNVQN-NH2, and
F′-GpYEEI, where F′ is fluorescein (Figure 1), were synthesized according to the
previously reported procedure.34 These phosphopeptides were selected based on the
sequence of phosphoprotein binding motif of protein tyrosine kinases that binds to the
SH2 domain of other protein tyrosine kinases and leads to enzyme activation.35
As representative examples, the synthesis of Ac-PEpYLGLD (mentioned here
as PEpYLGLD) and F′-PEpYLGLD is outlined here (Scheme 1). In general, the
peptides were assembled on Wang resin using Fmoc solid-phase synthesis. Fmoc
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protection group at the N-terminal was removed. Subsequent capping reaction by
acetic anhydride or conjugation reaction with 5(6)-carboxyfluorescein isobutyrate was
performed in the presence of HOAt, PyAOP, and N,N-diisopropylethylamine (DIPEA)
in DMF:DCM (5:1 v/v) followed by deprotection, and cleavage from the resin in the
presence of reagent R containing TFA/thioanisole/EDT/ anisole (90:5:3:2 v/v/v/v)
afforded crude products, which were purified by preparative reversed-phase HPLC.
The structures of the compounds were confirmed by high-resolution MALDI
TOF/TOF and/or high-resolution electrospray mass spectrometry. We have previously
reported the synthesis of [WR]4.31 A similar procedure was employed for the synthesis
of other phosphopeptides by using appropriate resins and side chain protected amino
acids.
Cellular Uptake Studies. The cellular uptake of synthesized fluorescence-labeled
phosphopeptides (10 μM) was examined in the presence and absence of [WR]4 (50
μM) in human leukemia carcinoma (CCRF-CEM) cells after 2 h incubation at 37 °C
using flow cytometry. After the incubation, cells were treated with trypsin to remove
the cell surface-bound compound. [WR]4 enhanced the cellular uptake of all
phosphopeptides,

including

F′-GpYLPQTV,

F′-NEpYTARQ,

F′-

AEEEIYGEFEAKKKK, F′-pYVNVQN-NH2, and F′-GpYEEI by 7-, 5-, 10-, 4-, and
19-fold, respectively. Fluorescence activated cell sorting (FACS) analysis showed that
the cellular uptake of F′-PEpYLGLD in the presence of [WR]4 was increased
dramatically by 27-fold when compared to F′-PEpYLGLD alone (Figure 2). These
data indicate that the cellular uptake of the phosphopeptides was improved in the
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presence of [WR]4 in a sequence dependent manner possibly due to different binding
affinity between the phosphopeptides and [WR]4.
Because of dramatic effect of [WR]4 on improving the cellular delivery of F′PEpYLGLD, this phosphopeptide was selected for further studies. PEpYLGLD is a
sequence that mimics the pTyr1246 of ErbB2 that is responsible binding to the Chk
SH2 domain.14 The cellular uptake of F′-PEpYLGLD (10 μM) was also evaluated in
the presence of the linear (WR)4 (50 μM) using FACS under similar conditions and
compared with that of cyclic [WR]4 (Figure 3). The results showed that the linear
(WR)4 enhanced the cellular uptake of F′-PEpYLGLD by 17-fold in CCRF-CEM cells
after 1 h incubation. However, the cyclic [WR]4 was found to enhance the cellular
uptake of F′-PEpYLGLD approximately 24-fold after 1 h incubation under similar
conditions, suggesting the cyclic nature of the peptide is important for improving the
cellular delivery of the phosphopeptide.
We have previously reported that Lys-(CH2)11-Arg-(CH2)11-Arg, a linear
tripodal amphipathic peptide containing two arginine and one lysine residues (LPA4),
enhanced the cellular delivery of a phosphopeptide (F′-GpYEEI) in the human breast
carcinoma cells BT-20 (ATCC No. HTB-19) cells by 10-fold.30 A comparative FACS
study exhibited that the cellular uptake of F′-PEpYLGLD (10 μM) enhanced
approximately 6 times in the presence of LP4 (50 μM) in CCRF-CEM cells after 1 h
incubation. Thus, the transporting efficiency of LPA4 for F′-PEpYLGLD was
significantly less than that of the cyclic [WR]4 that showed 24-fold higher cellular
delivery of the same phosphopeptide after 1 h incubation (Figure 3).
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To evaluate the cytotoxicity of PEpYLGLD and [WR]4, cell viability assay
was employed in three different cancer cell lines, including CCRF-CEM, SK-OV-3,
HCT-116 cells, and CCD-18Co cells at the experimental concentration of PEpYLGLD
(5 μM) and [WR]4 (25 μM). We have previously shown that cyclic [WR]4 is not
cytotoxic in HCT-116, CCRF-CEM, and SK-OV-3 cells at similar concentrations.31
The mixture of [WR]4 (25 μM) and PEpYLGLD (5 μM) or [WR]4 (50 μM) and
PEpYLGLD (10 μM) did not show any significant toxicity in normal cells and HCT116 carcinoma cells after 24 h incubation at 37 °C (Figure 4). While [WR]4 (25 μM)
and PEpYLGLD (5 μM) did not exhibit any cytotoxicity in SK-OV-3 and CCRFCEM cells, the mixture showed 10−12% toxicity when higher concentrations of
phosphopeptide (10 μM) and [WR]4 (50 μM) were used. Thus, a concentration of
PEpYLGLD (5 μM) and [WR]4 (25 μM) was used in SKOV-3 and CCRF-CEM cells
in all cellular uptake and confocal microscopy studies.
To investigate whether the performance of [WR]4 is cell-type dependent, the
intracellular uptake of a lower concentration of F′-PEpYLGLD (5 μM) was examined
in human ovarian adenocarcinoma (SK-OV-3) cells in the presence or absence of
[WR]4 (25 μM). After 1 h incubation at 37 °C, FACS showed 22-fold higher
fluorescence signals in the cells treated with F′-PEpYLGLD-loaded [WR]4 compared
to those treated with F′-PEpYLGLD alone, suggesting that the uptake of F′PEpYLGLD is also enhanced by [WR]4 in SK-OV-3 cells (Figure 5a).
The cellular uptake and internalization of many CPPs along with the
conjugated cargo occurs predominantly via an endocytic pathway that involves
macropinocytosis, caveolae pathway, clathrin-mediated endocytosis, or lipid-raft
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dependent endocytosis. The nature of the cell lines and the presence and type of the
cargo could affect the specific mechanism employed by the CPP.36 We have
previously shown that the cellular uptake of [WR]4 was independent of endocytosis.31a
Thus, the mechanism of the cellular uptake of the complex mixture of [WR]4 and F′PEpYLGLD was evaluated in the presence of different inhibitors to determine whether
the cargo changes the uptake mechanism
To perform the ATP depletion, sodium azide was incubated with cells for 30
min prior to the incubation with the complex followed by 1 h incubation. Significant
intracellular uptake of F′-PEpYLGLD in the presence of [WR]4 in SK-OV-3 cells
(Figure 5a) was still observed in the presence of sodium azide, suggesting that the
cellular uptake is not significantly reduced by inducing ATP depletion.
Furthermore, [WR]4 was still able to improve the cellular uptake of F′PEpYLGLD in SK-OV-3 cells in the presence of different endocytic inhibitors, such
as nystatin, EIA, chlorpromazine, chloroquine, and methyl β-cyclodextrin, ruling out
clathrin-mediated or caveolae-mediated endocytosis, and macropinocytosis as the
major mechanism of uptake after 1 h incubation (Figure 5a). The cellular delivery of
the phosphopeptide in the presence of [WR]4 and inhibitors was still higher than F′PEpYLGLD alone, suggesting the mechanism of cellular uptake is not exclusively
endocytosis. This is a key advantage of [WR]4 compared to known CPPs, which are
dependent on endocytotic entry. Another proposed mechanism for cellular uptake of
CPPs is direct membrane transduction. The amphipathic nature of [WR]4 and
interactions of arginine and tryptophan residues in [WR]4 with the corresponding
negatively charged phospholipids and hydrophobic residues in lipid bilayer may have
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contributed to the initial entry into the cell membrane. Hydrophobic interactions
between tryptophan residues and the lipids could lead to possible distortion of the
outer phospholipid monolayer, followed by peptide internalization and enhanced
cellular uptake of the cargo. Model studies have suggested that the direct transduction
occurs through carpet-like perturbations, pore formation, or inverted micelles formed
in the bilayer membrane.36 Further mechanistic studies will provide insights for
designing the next generation of cyclic peptides as molecular transporters of
phosphopeptides.
The cellular uptake of F′-PEpYLGLD was found to be rapid and timedependent. F′-PEpYLGLD (5 μM) was incubated with [WR]4 (25 μM) at different
incubation times including 10 min, 30 min, and 1 h. FACS results showed that the
cellular uptake of F′-PEpYLGLD was increased in a time-dependent pattern (Figure
5b). On the other hand, the cellular uptake of F′-PEpYLGLD was not changed
significantly in the absence of [WR]4.
Confocal microscopy in live cells was used to monitor the cellular uptake of
F′-PEpYLGLD in the presence and absence of the peptide. Incubation of a mixture of
F′-PEpYLGLD [WR]4 showed significantly higher cellular uptake when compared to
that of F′-PEpYLGLD alone as shown by intracellular fluorescence. Comparison of
the intracellular localization of F′-PEpYLGLD-loaded [WR]4 to F′-PEpYLGLD alone
after 1 h incubation at 37 °C confirmed that the presence of the cyclic peptide is
critical for the enhanced cellular permeability (Figure 6).
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Circular dichroism (CD), transmission electron microscopy (TEM), and
isothermal titration calorimetry (ITC) were used to gain a better insight about the
interaction of [WR]4 and PEpYLGLD. CD was used to get a better understanding of
the secondary structure change in [WR]4 and PEpYLGLD upon mixing and
intermolecular interactions. All spectra were corrected for background by subtraction
of the blank. CD results showed that PEpYLGLD (25 μM) loaded with [WR]4 (25
μM) showed a different CD pattern compared to those of parent analogs, [WR]4 (25
μM) and PEpYLGLD (25 μM). While PEpYLGLD did not show any specific
structure, both PEpYLGLD loaded [WR]4 and [WR]4 exhibited a maximum at 230 nm
and a minimum at 203−205 nm, suggesting that [WR]4 maintain the secondary
structure partially upon binding with in PEpYLGLD. These secondary structures are
distinct from known α and β structures. However, the pattern of the spectra shows
some major differences between PEpYLGLD loaded [WR]4 and [WR]4 at <190 nm
and in intensity of ellipticity in maximum and minimum peaks (Figure 7).
The interaction between PEpYLGLD and [WR]4 was visualized by using
TEM. The stable mixture of [WR]4 and PEpYLGLD was prepared at a high
concentration to achieve the maximum interaction. An optimized balance between the
hydrophobic and electrostatic interactions generated by the drug and the carrier led to
the formation of nanosized particles. [WR]4 generated self-assembled nanostructures
after one day incubation at room temperature. Initial TEM imaging of negatively
stained [WR]4 (1 mM aqueous solution) showed circular vesicle-like structures with
approximate size of 25−60 nm. TEM images of PEpYLGLD (Figure 8a) exhibited
amorphous structures with approximate size of 40 nm. When PEpYLGLD was added
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to [WR]4 in solution, PEpYLGLD-loaded [WR]4 formed some larger noncircular
nanosized structures with approximate width and height of 125 and 60 nm,
respectively, possibly through electrostatic and/or hydrophobic intermolecular
interactions between the positively charged cyclic peptide and negatively charged
phosphopeptides (Figure 8b). TEM images further confirm that the structures of
[WR]4 modify upon binding with PEpYLGLD, generating new nanostructures.
ITC was used to measure the binding constants between PEpYLGLD and
[WR]4 in complex formation. The ITC measurements were carried out at 30 °C by
adding an aqueous solution PEpYLGLD (6 mM) to [WR]4 (500 μM) solution in water.
The equation for three sequential binding events was found to be the best fit for the
data as shown by the Origin software. The chi squared χ2 value was found to be 1.6 ×
102 produced by three sequential models. The binding constant values for three
sequential events were determined as K1 = 7.1 × 103 M−1, K2 = 4.9 × 103 M−1, and K3
= 1.1 × 104 M−1 (Figure 9). The enthalpies (ΔH) for the binding were −0.17, 0.30, and
−0.23 kcal/mol, and the entropies (TΔS) were 5.2, 5.4, and 5.3 kcal/mol, respectively.
Therefore, the Gibbs free energies (ΔG) calculated from ΔH and TΔS were −5.4, −5.1,
and −5.6 kcal/mol for each binding site. ITC data suggest that PEpYLGLD and [WR]4
form a complex through multistep intermolecular interactions including hydrophobic
interactions driven by entropy as shown previously.37 These data indicate that, in
addition to the electrostatic interactions between positively charged cyclic peptide and
negatively charged phosphopeptide, hydrophobic forces also contribute to the complex
formation possibly due to the interactions of the hydrophobic tryptophan and leucine
residues in [WR]4 and PEpYLGLD, respectively. ITC and TEM results are relevant to
21

cellular studies since the stock solutions were prepared at high concentrations to
generate maximum intermolecular interactions and then were diluted further to obtain
desired concentration for cell-based assays.
Molecular modeling studies of [WR]5, a similar model cyclic peptide, were
used to gain better insights of three-dimensional structure of this class of peptides.
Initial coordinates for [WR]5 were obtained followed by ab initio Hartree−Fock
molecular orbital calculations with complete geometry optimizations utilizing
GAUSSIAN’03 software.32 Two different conformations were obtained (Figure 10).
The lowest energy conformation did not allow any intramolecular H-bonding. Higher
energy conformation (25 kcal/mol) showed intramolecular H-bonding between
cationic and neutral side chains. Side chains have to reorganize for efficient
intramolecular hydrogen bonding resulting in higher energy conformation. In the
lowest energy conformation tryptophan side chains are disposed perpendicular to
backbone. Higher energy conformation being more planar seems more suited for
stacking.

Conclusions
In summary, a new carrier system for the delivery of cell impermeable
phosphopeptides was discovered using cyclic octapeptide [WR]4 containing
alternative tryptophan and arginine residues. The cellular uptake of F′-PEpYLGLD
was enhanced by 27-fold in the presence of [WR]4, and was found to be timedependent. Positively charged cyclic peptide formed nanostructures in the presence of
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negatively charged PEpYLGLD as shown by TEM. Binding affinity between [WR]4
and PEpYLGLD was further confirmed by ITC studies. To the best of our knowledge,
this is the first report of using cyclic peptides for noncovalent cellular delivery of cell
impermeable phosphopeptides. These data provide insights about using cellpenetrating cyclic peptides as PAs for delivery of negatively charged cell impermeable
phophopeptides.
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ABBREVIATIONS USED
BT-20, human breast carcinoma cell line; CCRF-CEM, human leukemia carcinoma
cell line; CD, circular dichroism; CCD-18Co, normal human colon myofibroblast;
CPPs,

cell-penetrating

diisopropylethylamine;

peptides;
DMF,

DCM,

dichloromethane;

N,N-dimethylformamide;

EIA,

DIPEA,

N,N-

5-(N-ethyl-N-

isopropyl)amiloride; F′, fluorescein; FACS, fluorescence activated cell sorter; FBS,
fetal bovine serum; DCM, dichloromethane; EDT, ethandithiol; HBTU, 2-(1Hbenzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexfluoro

phosphate;

HCT-116,

human colorectal carcinoma; HOBt, hydroxybenzotriazole; HOAt, 1-hydroxy-7
azabenzotriazole; ITC, isothermal calorimetry; NMM, N-methylmorpholine; PAs,
peptide amphiphiles; PTB, phosphotyrosine binding; PyAOP, 7-azabenzotriazol- 1yloxy tripyrrolidinophosphonium hexafluorophosphate); SH2, Src homology 2; SKOV-3, human ovarian adenocarcinoma; TFA, trifluoroacetic acid; TEM, transmission
electron microscopy.
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Figure Legends:
Figure 1: Chemical structure of [WR]4 and phosphopeptides synthesized by Fmocbased peptide chemistry
Figure 2: Comparative cellular uptake of F′-phosphopeptides (10 μM) in the presence
of [WR]4 (50 μM) in CCRF-CEM cells after 2 h
Figure 3: Cellular uptake of F′-PEpYLGLD (10 μM) in the presence of cyclic [WR]4
(50 μM), linear (WR)4 (50 μM), or a tripodal linear peptide (LP4) (50 μM) in CCRFCEM cells after 1 h incubation
Figure 4: Cytotoxicity assay of the mixture of PEpYLGLD (5 and 10 μM) and [WR]4
(25 and 50 μM) in CCRF-CEM, HCT-116, SK-OV-3, and CCD-18Co cells after 24 h.
Figure 5: (a) Cellular uptake of F′-PEpYLGLD (5 μM) + [WR]4 (25 μM) in the
absence or presence of different endocytic inhibitors and sodium azide in SK-OV-3
cells after 1 h. (b) FACS analysis of cellular uptake assays of F′-PEpYLGLD (5 μM)loaded [WR]4 (25 μM) compared to F′-PEpYLGLD (5 μM) alone in CCRF-CEM
Figure 6: Confocal microscope images of F′-PEpYLGLD (5 μM) uptake by SK-OV-3
cells in the presence of [WR]4 (25 μM)
Figure 7: CD pattern of PEpYLGLD and [WR]4 compared to the PEpYLGLD-loaded
[WR]4
Figure 8: (a) Negatively stained TEM images of [WR]4 (1 mM), PEpYLGLD (1
mM), and PEpYLGLD-loaded [WR]4 (1 mM) in water after one day. (b) Proposed
mechanism of interactions between PEpYLGLD and [WR]4
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Figure 9: The binding isotherm obtained from titration of PEpYLGLD (6 mM) with
[WR]4 (500 μM) using a three sequential-binding sites model
Figure 10: Two different conformers of [WR]5

Scheme Legends:
Scheme 1: Solid-Phase synthesis of Ac-PE(pY)LGLD and F′-PE(pY)LGLD
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Abstract
Doxorubicin (Dox) is a hydrophilic anticancer drug that has short retention time due to
the efficient efflux in some cancer cells (e.g., ovarian adenocarcinoma SK-OV-3).
Cyclic [W(RW)4] and the corresponding linear peptide (RW)4 were conjugated with
Dox through an appropriate linker to afford cyclic [W(RW)4]−Dox and linear
(RW)4−Dox conjugates to enhance the cellular uptake and cellular retention of the
parent drug for sustained anticancer activity. Comparative antiproliferative assays
between

covalent

(cyclic[W(RW)4]−Dox

and

linear

(RW)4−Dox)

and

the

corresponding noncovalent physical mixtures of the peptides and Dox were
performed. Cyclic [W(RW)4]−Dox inhibited the cell proliferation of human leukemia
(CCRF-CEM) (62−73%), ovarian adenocarcinoma (SK-OV-3) (51−74%), colorectal
carcinoma (HCT-116) (50−67%), and breast carcinoma (MDA-MB-468) (60−79%)
cells at a concentration of 1 μM after 72−120 h of incubation. Cyclic [W(RW)4]−Dox
exhibited higher antiproliferative activity than linear (RW)4−Dox in all cancer cells
with the highest activity observed after 72 h. Flow cytometry analysis showed 3.6-fold
higher cellular uptake of cyclic [W(RW)4]−Dox than Dox alone in SK-OV-3 cells
after 24 h incubation. The cellular hydrolysis study showed that 99% of cyclic
[W(RW)4]−Dox was hydrolyzed intracellularly within 72 h and released Dox. These
data suggest that cyclic [W(RW)4]−Dox can be used as a potential prodrug for
improving the cellular delivery and retention of Dox.
KEYWORDS: anticancer, cellular uptake, doxorubicin, cyclic peptides, cellpenetrating peptides
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INTRODUCTION
Doxorubicin (Dox) is a well-known anthracycline and widely used anticancer
agent for the treatment of a wide variety of cancers, such as breast carcinoma,
leukemia, and other solid tumors.1 The major mechanism of Dox activity is the
inhibition of topoisomerase II (TOPO II)−DNA complex, causing DNA damage
through intercalating with the DNA double helix.2
One of the major limitations of cancer chemotherapy treatment is the
development of resistance to a certain dose of anticancer drugs, such as Dox. Several
mechanisms of drug resistance have been introduced at different levels, including
alteration of the target protein, decreased membrane permeability and drug
metabolism, and/or efflux pumping.3−5 Dox is not being used widely for treating other
tumors like ovarian carcinoma, liver cancer, and stomach cancer in the clinic,6,7 due to
the development of resistance associated with Dox. Furthermore, the use of Dox for
clinical application revealed undesired pharmacokinetics properties, such as rapid
distribution, excretion, and low bioavailability of the drug, due to the hydrophilic
nature, high volume of distribution, and short half-life.8−10 Thus, a high cumulative
dose of Dox is required in cancer chemotherapy to achieve a sufficient therapeutic
effect, which leads to dose-dependent side effects, such as such as cumulative
cardiotoxicity, nephrotoxicity, and extravasation.11,12
Moreover, intracellular Dox accumulation is dependent on a number of factors
including cellular uptake, retention, relocalization, and efflux from the cell. Among
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these factors, intracellular uptake of Dox suffers from efflux pumping in some cancer
cells, such as ovarian carcinoma cells, leading to decreased intracellular Dox levels
that could be related to the overexpression of energy-dependent drug efflux pump
proteins such as P-glycoprotein (P-gp). This integral membrane protein removes drugs
and thus reduces intracellular anticancer drug concentrations.13
Efficacy and toxicity of an anticancer drug can be modified through using drug
delivery systems and altering the physicochemical properties, such as lipophilicity,
cellular uptake, and prolonging activity through chemical conjugation with various
chemical moieties. One of the main applications of drug delivery systems is to avoid
the P-gp and multidrug resistance proteins (MRPs) that are involved in drug efflux to
overcome the resistance problem and P-gp-mediated drug efflux.14−16
Prodrug strategy as one of the drug delivery systems through chemical
conjugation with a parent drug17,18 has been widely used in Dox delivery.6,19 Several
conjugation methods have been used to improve Dox delivery, including using gold
nanoparticles,20 gold nanospheres,21 liposomes,22 peptides,

23−27

and dendrimers.28

Conjugation of Dox with cellpenetrating peptides (CPPs) has been employed as one of
the privileged methods to translocate a wide variety of cargo molecules into various
cell lines.16 For instance, Dox has been conjugated with different linear CPPs
including penetratin,24 tat,29 and polyarginine,30 and maurocalcine.31
However, development of efficient and safe prodrug carriers to enhance
delivery and retention of Dox into drug-resistant tumor cells and to reduce efflux
remains less explored. We previously reported the application of a number of cyclic
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peptides as noncovalent nuclear targeting molecular transporters32 of Dox. Cyclic
peptides containing arginine and tryptophan [WR]n (n = 3−5) were found to be
appropriate noncovalent carriers for Dox, however, the drug intracellular retention and
toxicity behavior for cyclic peptide−Dox covalent conjugates remain unexplored.
Herein, we report the synthesis of linear and cyclic peptides through the covalent
conjugation with a 3-carbon chain linker at the 14-hydroxyl group, evaluation of their
in vitro anticancer activities in multiple cancer cell lines, and cellular uptake and
retention. The prodrug conjugates were designed to improve cellular uptake, to
prolong biological activity, and to reduce intrinsic cellular efflux of Dox.

EXPERIMENTAL SECTION
Synthesis of Linear (RW)4 Peptide. The linear peptide was assembled on Fmoc-Rink
amide resin (0.56 g, 0.54 mmol/ g, 0.3 mmol) by solid-phase peptide synthesis
strategy using Fmoc-protected amino acids [Fmoc-Trp(Boc)-OH and Fmoc- Arg(Pbf)OH] on a PS3 automated peptide synthesizer at room temperature (Scheme 1). Linear
peptide sequence was assembled on the resin after removing the Fmoc group at the
end of the sequence (NH2-RWRWRWRW) (RW)4, using 20% piperidine in DMF. The
resin was washed with DCM (3 × 15 mL) and MeOH (3 × 15 mL) for complete
cleavage of peptide from the resin and side chain protecting groups. The resin was
dried in vacuum for 24 h. A cleavage cocktail, namely, reagent R containing
TFA/thioanisole/EDT/anisole (90:5:3:2 v/v/v/v, 12 mL), was added to the resin. The
mixture was shaken at room temperature for 2 h. The resin was collected by filtration
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and consequently washed with 2 mL of reagent R again. Collected filtrates were
evaporated to reduce the volume under dry nitrogen. The crude peptide was
precipitated by adding cold diethyl ether (200 mL, Et2O) and centrifuged at 4000 rpm
for 5 min followed by decantation to obtain the solid precipitate. The solid material
was further washed with cold ether (2 × 100 mL) for 2 times. The peptide was
lyophilized and purified by reversed-phase Hitachi HPLC using a gradient system as
described in the Supporting Information to yield linear (RW)4 peptide.
(RW)4. MALDI-TOF (m/z) [C68H91N25O8]: calcd, 1385.7482; found, 1386.8219 [M +
H]+.
Synthesis of Cyclic Peptide [W(RW)4K]β-Ala. The linear-protected peptides
sequence was assembled using a PS3 automated peptide synthesizer. The linear
protected peptide (Dde-K(Boc-β-Ala)(WRWRWRWRW) was assembled on the HTrp(Boc)-2-chlorotrityl chloride resin (513 mg, 0.78 mmol/g, 0.40 mmol) in 0.40
mmol scale (Scheme 2). After the final coupling with Boc-β-Ala-OH, the resin was
washed with DMF (3 × 25 mL, each time 5 min). Then the Dde group at the lysine Nterminal was deprotected by using hydrazine monohydrate (2% v/v) solution in DMF
(3 × 25 mL, each time 5 min). The resin was washed with DMF (5 × 50 mL) followed
by washing with DCM (3 × 50 mL). The side chain protected peptide was cleaved
from trityl resin by using cleavage cocktail reagent, acetic acid/TFE/DCM (1:2:7
v/v/v, 50 mL), by shaking for 1 h at room temperature to yield the side chain protected
linear peptide. The resin was collected by filtration and washed with TFE/DCM (2:8
v/v, 2 × 10 mL). The combined filtrates were evaporated under reduced pressure.
Hexane (2 × 25 mL) and DCM (1 × 25 mL) were added to the residue to remove the
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acetic acid from the cleaved crude peptide. The crude peptide was obtained as a white
solid and was dried in vacuum overnight. The compound was directly used for the
next cyclization reaction. The linear peptide was dissolved in DMF/DCM (5:1 v/v,
250 mL). 1-Hydroxy-7-azabenzotriazole (HOAt, 223 mg, 1.64 mmol, 4 equiv) and
1,3-diisopropylcarbodiimide (DIC, 290 μL, 1.86 mmol, 4.5 equiv) were added to the
mixture, and the solution was stirred at room temperature for 6 h. The completion of
the cyclization was checked by MALDI-TOF. After the reaction was completed, the
solvents were removed under reduced pressure by using a rotary evaporator. The crude
product was dried overnight in vacuum before the final cleavage reaction. The
cleavage reaction was performed by using reagent R as previously described. The
crude peptides were lyophilized and purified by reversed-phase Hitachi HPLC (L2455) as described in the Supporting Information to yield cyclic peptide
[W(RW)4K(β-Ala)].
MALDI-TOF (m/z) [C88H115N29O11]: calcd, 1753.9331; found, 1756.6570 [M + 3H]+.
Synthesis of N-Fmoc-Dox-14-O-hemiglutarate. The synthesis of this N-Fmoc Dox
derivative was carried out according to the previously reported procedure.33 In brief;
Dox hydrochloride (100 mg, 0.17 mmol) was dissolved in anhydrous DMF (4 mL) in
a round-bottom flask and stirred at room temperature under nitrogen atmosphere.
Fmoc-OSu (60 mg, 0.18 mmol) was added to the reaction mixture followed by
dropwise addition of anhydrous N,N-diisopropylethylamine (DIPEA, 60 μL, 0.34
mmol). Aluminum foil was used to cover the reaction vessel from light, and stirring of
the reaction mixture was continued at room temperature. The reaction was stopped,
and the solvent was removed after 4 h. The remaining oily liquid was triturated with
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0.1% TFA solution in water (v/v) to afford crystalline solid compound. The crystalline
solid was collected through filtration and washed with cold diethyl ether to remove
traces of excess of Fmoc-OSu. HPLC analysis showed that the crude product was pure
(95%). The Fmoc-N-Dox (110 mg, 0.14 mmol) was reacted with glutaric anhydride
(19.7 mg, 0.17 mmol) in the presence of anhydrous DIPEA (46 μL, 0.26 mmol) in
anhydrous DMF (5 mL) for 16 h under nitrogen atmosphere. Analytical HPLC
analysis showed that the reaction was completed after 16 h. The solvent was removed
under reduced pressure, and the oily liquid was triturated with 0.1% TFA solution in
water (v/v) to precipitate the crude solid material. The crude solid material was filtered
and dried in high vacuum. The material was purified by HPLC to afford pure N-FmocDox-14-O-hemiglutarate (95%).
General Procedure for Coupling of the Peptides to Dox. N-Fmoc-Dox-14-Ohemiglutarate (1 equiv), cyclic or linear peptide (1 equiv), benzotriazol-1yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 1.35 equiv), and
hydroxybenzotriazole (HOBt, 2.70 equiv) were added to the glass vial under nitrogen
atmosphere (Scheme 3). Anhydrous DMF (1−2 mL) was used as a solvent, and the
reaction mixture was stirred to dissolve the compounds followed by the addition of
DIPEA (8 equiv). Then, the reaction mixture was stirred for 1.5 h in the absence of
light. The solvent was removed under reduced pressure, and cold diethyl ether was
added to the residue. The crude peptide was precipitated and centrifuged to obtain the
crude solid peptide conjugate. The peptide was dried under nitrogen gas. To remove
the Fmoc group, a solution of piperidine in DMF was used (20% v/v, 2 mL for 5 min).
The solution color turned to blue, and the reaction was terminated by adding drops of
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TFA solution in DMF (20% v/v) until the solution color turned to light red. The
solvent was removed under reduced pressure, and oily liquid was dissolved in
acetonitrile/water (50% v/v). The HPLC purification afforded the final linear peptide
or cyclic peptide−Dox conjugates.
Cyclic [W(RW)4]−Dox Peptide. 1H NMR (DMSO-d6, 500 MHz, δ ppm): 0.80−0.97
(m, 8H, CH2CH2CH2NH, Arg), 1.10−1.25 (m, 13H, CH2CH2CH2NH, Arg, Lys, 6′CH3), 1.89−2.25 (m, 4H, H-8 and H-2′), 2.40−2.67 (m, 14H, CH2CO and
CH2CH2CH2NH), 2.90−3.20 (m, 12H, CH2, Trp, H-10), 3.55−3.52 (m, H-3′, H-4′
overlapped with DMSO peaks), 3.99 (s, 3H, OCH3), 4.20−4.40 (m, 6H, αCH, Arg,
Lys, H-5′), 4.85−4.98 (m, 5H, αCH, Trp), 5.10−5.48 (m, 3H, H-7, OCH2CO),
5.61−5.65 (m, 1H, H-1′), 6.27 (br s, 12 H, NH), 6.85−7.70 (m, aromatic, 25 H, Trp,
aromatic CH), 7.75−8.00 (m, 4H, aromatic CH), 10.74 (br s, 5H, NH, Trp), 13.27 (s,
2H, PhOH). MALDI-TOF (m/z) [C120H148N30O24]: calcd, 2393.1283; found,
2393.5332 [M]+.
Linear (RW)4−Dox. MALDI-TOF (m/z) [C100H124N26O21]: calcd, 2024.9434; found,
2024.6139 [M]+.
Cell Culture. Human leukemia carcinoma cell line CCRFCEM (ATCC no. CCL119), breast adenocarcinoma MDAMB-468 (ATCC no. HTB-132), ovarian
adenocarcinoma SKOV-3 (ATCC no. HTB-77), and colorectal carcinoma HCT-116
(ATCC no. CCL-247) were obtained from American Type Culture Collection. The
cells were grown on 75 cm2 cell culture flasks with RPMI-16 medium for leukemia
and EMEM medium for other cell lines and supplemented with 10% fetal bovine
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serum (FBS) and 1% penicillin−streptomycin solution (10,000 units of penicillin and
10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air
at 37 °C.
Antiproliferation Assay. Antiproliferative activities of covalently synthesized cyclic
[W(RW)4]−Dox, linear (RW)4−Dox derivatives, and noncovalent mixtures of cyclic
[RW]4 + Dox and linear (RW)4 + Dox were evaluated in MDA-MB-468, CCRF-CEM,
SK-OV-3, and HCT-116 cells, and the results were compared with that of Dox alone.
The assay was carried out using CellTiter 96 AQueous One Solution Cell Proliferation
Assay Kit (Promega, USA). As a representative example, SK-OV-3 cells were
suspended in 5 × 103/mL (CCRF-CEM, 4 × 104/mL), and 100 μL of the cell
suspension was placed in each well of the 96 well culture plates. The cells were
incubated with Dox (1 μM), cyclic [W(RW)4]−Dox (1 μM), linear (RW)4−Dox (1
μM), cyclic [RW]4 (1 μM) + Dox (1 μM), and linear (RW)4 (1 μM) + Dox (1 μM) in
2% DMSO and tested in triplicate. For the physical mixtures, an appropriate volume
of Dox stock solution was mixed with an appropriate volume of an aqueous solution
of cyclic and linear peptides physically to obtain a final concentration of Dox (1 μM)
and the peptide (1 μM). The mixture was vigorously mixed and vortexed until the
solution became homogeneous/ clear red color. Subsequently, the mixture was
incubated for 30 min at 37 °C before addition to the cells. Incubation was carried out
at 37 °C in an incubator supplied with 5% CO2 for 24−120 h. At the end of the sample
exposure period (24−120 h), 20 μL of CellTiter 96 aqueous solution was added. The
plate was returned to the incubator for 1 h in a humidified atmosphere at 37 °C. The
absorbance of the formazan product was measured at 490 nm using a microplate
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reader. The percentage of cell survival was calculated as [(OD value of cells treated
with the test compound) − (OD value of culture medium)]/[(OD value of control cells)
− (OD value of culture medium)] × 100%.
Cell Cytotoxicity Assay. The cytotoxicity of Dox and cyclic [W(RW)4]−Dox against
MDA-MB-468, HCT-116, CCRF-CEM, and SK-OV-3 was determined by MTS assay
using CellTiter 96 AQueous One Solution Cell Proliferation Assay Kit (Promega,
USA). All cells were plated overnight in 96 well plates with a density of 5000 cells per
well in 0.1 mL of appropriate growth medium at 37 °C. Different concentrations of
Dox or cyclic [W(RW)4]−Dox (up to a maximum of 10 μM) were incubated with the
cells for 2 h. Compounds were removed from medium by replacing with fresh
medium, and the cells were kept in an incubator for another 72 h. The cells without
compounds were included in each experiment as controls. After 72 h of incubation, 20
μL of MTS was added and incubated for 2 h. The absorbance of the formazan product
was measured at 490 nm using microplate reader. The percentage of cytotoxicity was
calculated as [(OD value of untreated cells) − (OD value of treated cells)]/(OD value
of untreated cells) × 100%.
Confocal Microscopy. SK-OV-3 cells were seeded with EMEM media overnight on
coverslips in six well plates. Then the medium was removed and washed with optiMEM. The cells were treated with Dox or cyclic [W(RW)4]−Dox (5 μM) in optiMEM for 1 h at 37 °C. After 1 h incubation, the media containing the compound were
removed followed by washing with PBS three times. Then coverslips were placed on a
drop of mounting medium on a microscope slide with cell-attached side facing down.
Laser scanning confocal microscopy was carried out using a Carl Zeiss LSM 510
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system. The cells were imaged using rhodamine and phase contrast channels. In the
case of drug efflux studies, after a 1 h incubation period, the medium containing drugs
was removed and washed with opti-MEM. Then fresh medium with serum was added
into the cells. After 24 h, the medium was removed and washed with PBS three times,
and then the cells were visualized under confocal microscopy.
Fluorescence Activated Cell Sorter (FACS) Analysis of Cellular Uptake
Experiment. Ovarian carcinoma cells were plated overnight in six well plates (2 × 105
cells/well) in EMEM media. Then Dox (5 μM), cyclic [W(RW)4]−Dox (5 μM), linear
(RW)4−Dox (5 μM), cyclic [RW]4 (5 μM) + Dox (5 μM), and (RW)4 (5 μM) + Dox (5
μM) were added in serum-free RPMI to the cells. For the physical mixtures, an
appropriate volume of Dox stock solution was mixed with an appropriate volume of an
aqueous solution of cyclic and linear peptides physically to obtain a final
concentration of Dox (5 μM) and CPPs (5 μM). The mixture was vigorously mixed
and vortexed until the solution became homogeneous/clear red color. Subsequently,
the mixture was incubated for 30 min at 37 °C before addition to the cells. The plates
were incubated for 1 h at 37 °C. After 1 h incubation, the media containing drugs were
removed. The cells were digested with 0.25% trypsin/0.53 mM EDTA for 5 min to
detach from the plate. Then the cells were centrifuged and washed twice with PBS.
Finally, the cells were resuspended in flow cytometry buffer and analyzed by flow
cytometry (FACSCalibur: Becton Dickinson) using FL2 channel and CellQuest
software. The data presented are based on the mean fluorescence signal for 10,000
cells collected. All assays were performed in triplicate.
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Fluorescence Activated Cell Sorter (FACS) Analysis of Cell Cycle Arrest.
Colorectal carcinoma cells (2 × 105 per well) were treated with cyclic [W(RW)4]−Dox
at 1 μM for 1 h followed by 24 h incubation in drug-free medium. Cells were fixed in
ice-cold ethanol:PBS (70:30, v/v) for 30 min at 4 °C, further resuspended in PBS with
100 μg/mL RNase and 40 μg/ mL propidium iodide, and incubated at 37 °C for 30
min. The DNA content (for 10,000 cells) was analyzed using a FACSCalibur
instrument equipped with FACStation with FACSCalibur software (BD Biosciences,
San Diego, CA, USA). The analyses of cell cycle distribution were performed in
triplicate (n = 2 plates per experiment) for the sample treatment. The coefficient of
variation, according to the ModFit LT Version 2 acquisition software package (Verity
Software House, Topsham, ME, USA), was always less than 5%.
Topo II Decatenation Assay. The topoisomearase II assay kit (Catalog No. 1001-1)
was purchased from TopoGEN, Inc. (Port Orange, FL). Eukaryotic Topo II was
assayed by decatenation of kDNA and monitoring the appearance of a smaller DNA
(decatenated DNA circles). Reaction mixtures containing kDNA (0.1 μg) in a final
volume of 20 μL and 1× reaction buffer containing Tris-HCl (50 mM, pH 8.0), NaCl
(150 mM), MgCl2 (10 mM), dithiothreitol (0.5 mM), and ATP (2 mM) were incubated
for 30 min at 37 °C without and with Dox, and cyclic [W(RW)4]−Dox at 10, 20, 30,
40, and 50 μM final concentration. Reactions were terminated with the addition of 0.4
volume of stop buffer (5% sarkosyl, 0.125% bromophenol blue, and 25% glycerol).
One unit of Topo II is defined as the amount of enzyme required to fully decatenate
0.1 μg of kDNA in 30 min at 37 °C. The decatenation products were analyzed on 1%
agarose gels having 0.5 μg of ethidium bromide/mL. Eukaryotic Topo II products
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were separated at 108 V, which allowed rapid resolution of catenated networks from
the minicircles. Gels were photographed by ethidium bromide fluorescence on
Typhoon Imager.
Stability Studies. The stability of cyclic [W(RW)4]−Dox was evaluated using
phosphate-buffered saline (PBS) and fetal bovine serum (FBS). PBS and FBS were
purchased from Invitrogen and ATCC (Manassas, VA). FBS (1 mL, 100%) and PBS
(1 mL, pH 7.0) were incubated with cyclic [W(RW)4]−Dox (75 μL, 1 mM in water) at
37 °C followed by intermediate mixing. An aliquot of 75 μL of the mixture was taken
out at different time intervals (10 min to 96 h) and diluted with water (75 μL). The
mixture was analyzed by using analytical HPLC detecting the wavelength of 490 nm.
The area under the curve (AUC) was calculated and used to find out the percentage of
released Dox and remaining prodrug at a given time. Figure S1 (Supporting
Information) was plotted between relative percentage of released Dox and cyclic
[W(RW)4]−Dox based on HPLC analysis.
Cellular Hydrolysis. Intracellular hydrolysis of cyclic [W(RW)4]−Dox and
accumulation of Dox and the peptide−Dox conjugate were determined in CCRF-CEM
cells by HPLC analysis. CCRF-CEM cells were grown in 75 cm2 culture flasks with
serum-free RPMI medium to ∼70−80% confluence (1.37 × 107 cells/mL). The
medium was replaced with fresh RPMI medium having cyclic [W(RW)4]−Dox (1
μM), and the cells were incubated at 37 °C for 4 h. The medium containing cyclic
[W(RW)4]−Dox was carefully removed by using centrifugation and replaced with
fresh RPMI serum-free medium. The cells were partitioned/transferred to culture
plates (six well) having 1.37 × 107 cells per well in 5 mL of medium and incubated for
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the indicated time. After incubation, the cells were collected by centrifugation. The
medium was removed carefully by decantation, and cell pellets were washed with icecold PBS to remove any medium. The cell pellets were thoroughly extracted with an
equal volume of methanol, chloroform, and isopropanol mixture (4:3:1 v/v/v) and
filtered through 0.2 μm filters. The relative Dox and cyclic [W(RW)4]−Dox
concentrations in cell lysates were quantified by analytical HPLC analysis as
described in the Supporting Information at 490 nm using the water/acetonitrile solvent
method.

RESULTS AND DISCUSSION
Chemistry. Linear and cyclic peptides were synthesized by Fmoc/tBu solid-phase
peptide synthesis. Scheme 1 depicts the synthesis of linear peptide (RW)4 on the Rink
amide resin. The linear peptide sequence was assembled using a PS3 peptide
synthesizer. The last Fmoc group on the N-terminal was deprotected by piperidine
(20% v/v, DMF). The resin was dried, washed, and cleaved by cleavage cocktail
(reagent R) to afford the linear (RW)4, which was purified by reversed-phase Hitachi
HPLC. For the synthesis of the cyclic peptide, first the linear protected peptide (DdeK(Boc-β-Ala)(WRWRWRWRW) was assembled on the H-Trp(Boc)-2-chlorotrityl
chloride resin. The Dde group of N-terminal lysine was removed in the presence of
hydrazine (2% in DMF). The side chain protected peptide was cleaved from the resin
using AcOH/TFE/DCM (1:2:7 v/v/v) cocktail. The cyclization of the side chain
protected peptide was performed under pseudodilute conditions in the presence of
HOAt and DIC (Scheme 2). The cyclic peptide was cleaved in the presence of reagent
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R, purified using reversed-phase HPLC, and used for the conjugation with Dox. NFmoc-Dox-14-O-hemiglutrate was prepared as described previously.33 In brief, the
reaction of glutaric anhydride with Fmoc-protected Dox was carried out to produce the
Dox hemiglutarate ester with a free COOH, which after HPLC purification and
lyophilization was used for coupling with linear and cyclic peptides. The conjugation
of the peptides with N-Fmoc-Dox-14-O-hemiglutrate was achieved in a similar pattern
(Scheme 3). The equimolar amount of the peptide and Dox was coupled through
formation of an amide bond between the amino group of peptides and carboxylic acid
in the Fmoc-protected Dox. The carboxylic group in Fmoc-protected Dox was
preactivated in the presence of HOAt/PyBOP/DIPEA in DMF for 15 min before
reacting with the peptides. After conjugation, the Fmoc protecting group was removed
using piperidine and was then acidified. The coupled peptide was purified using HPLC
and lyophilized. The structures of all the final compounds were confirmed by a highresolution MALDI TOF/TOF mass spectrometer. The purity of the final product
(≥95%) was confirmed by reversed-phase analytical HPLC using a gradient system
with water (0.1% TFA) and acetonitrile as eluting solvents.

Biological Activities. Cytotoxicity and Antiproliferative Activity of Peptide−Dox
Derivatives. Cyclic [WR]4 and cyclic [W(RW)4K](β-Ala) did not show any significant
toxicity in MDA-MB-468, HCT-116, CCRF-CEM, and SK-OV-3 cells at a
concentration of 10 μM (Figure 1) after different incubation times including 24 h, 72
h, and 120 h. These data are consistent with previously reported data of cyclic
[WR]4.32 Thus, a noncytotoxic concentration of 1 μM was selected for cell-based
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studies of cyclic peptide conjugate cyclic [W(RW)4]−Dox and the physical mixture
cyclic [RW]4 + Dox.
We recently compared the toxicity of [WR]4 versus commonly used
cellpenetrating

peptides

and

transporters

including

polyArg

CR7,

TAT

(YGRKKRRQRRRC) (100 μM), and oligofectamine 2000 (Invitrogen, a cationic lipid
formulation).34 [WR]4 did not show any significant toxicity in human ovarian
adenocarcinoma (SK-OV-3) and human leukemia (CCRFCEM) cancer cells and
normal human colon myofibroblast (CCD-18Co) cells, while other cell-penetrating
peptides polyArg CR7, TAT (YGRKKRRQRRRC), and oligofectamine 2000
(Invitrogen, a cationic lipid formulation) reduced the viability by 21−55%. The
activity of compounds on the cell proliferation of different cancer cells, CCRF-CEM,
SK-OV-3, HCT-116, and MDA-MB-468, was investigated for up to 120 h at the
concentration of 1 μM. The activity of synthesized compounds, linear (RW)4−Dox and
cyclic [W(RW) 4]−Dox, was evaluated in a comparative study with the noncovalent
physical mixtures of linear (RW)4 + Dox and cyclic [RW]4 + Dox, and Dox alone
(Figure 2). Cyclic [W(RW)4]−Dox exhibited higher antiproliferative activity than
linear (RW)4−Dox in all cancer cells, with the highest activity observed after 72 h.
The effect of compounds was found to be time dependent. The cell
proliferation inhibitory activity of compounds was enhanced at longer incubation
period of compounds with cells presumably because of the hydrolysis of the conjugate
to Dox. Cyclic [W(RW)4]−Dox inhibited the cell proliferation of CCRF-CEM
(62−73%), SK-OV-3 (51−74%), HTC-116 (50−67%), and MDA-MB-468 (60−79%)
cells at a concentration of 1 μM after 72−120 h of incubation, while linear (RW)4−Dox
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exhibited antiproliferative activity against CCRF-CEM (46−69%), SK-OV-3
(28−34%), HTC-116 (21−61%), and MDA-MB-468 (60−74%) under similar
conditions.
These data suggest that cyclization of peptide provided a more effective
transporter for Dox. The antiproliferative activity of cyclic [W(RW)4]−Dox was in the
order MDA-MB-468 > CCRF-CEM > SK-OV-3 > HTC-116. In general, the physical
mixture of linear (RW)4 and cyclic [RW]4 with Dox derivative showed less
antiproliferative activity in comparison to cyclic [W(RW)4]−Dox conjugate after
72−120 h against CCRF-CEM (52−68%), SK-OV-3 (47−67%), and HTC-116
(38−62%), and showed slightly better or comparable activity against MDA-MB-468
(71−78%). Dox exhibited also similar antiproliferative activity in comparison to the
physical mixture against CCRF-CEM (59−71%), SK-OV-3 (48−59%), HTC-116
(37−64%), and MDA-MB-468 (71− 77%) after 72−120 h of incubation, indicating
that conjugation of the cyclic peptide with Dox in cyclic [W(RW)4]−Dox improved
the antiproliferative activity of Dox in some of the tested cancer cells. The cyclic
peptide−Dox conjugate showed comparable antiproliferative activity against CCRFCEM and MDA-MB-468 when compared to Dox after 96 and 120 h incubation.
However, the antiproliferative activities of cyclic [W(RW)4]−Dox conjugate in SKOV-3 and HCT-116 cells were higher than those of Dox at a concentration of 1 μM
after 96 and 120 h incubation. For example, cyclic [W(RW)4]−Dox inhibited the cell
proliferation of SK-OV-3 (67−74%) and HTC-116 (65−67%) cells at a concentration
of 1 μM after 96−120 h of incubation, while Dox exhibited antiproliferative activity
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against SK-OV-3 (57−59%) and HTC-116 (57−64%) under similar conditions. Cyclic
[W(RW)4]−Dox showed higher cellular retention Than Dox and Linear (RW)4−Dox.
Dox is easy to track by using fluorescence-based techniques, due to the
inherent red fluorescence. Because of the higher antiproliferative activity of cyclic
[W(RW)4]−Dox after 72 h compared to linear (RW)4−Dox and Dox, this compound
was selected for further cellular uptake studies in comparison to other compounds to
determine whether the higher activity of this compound is consistent with enhanced
uptake of the compound. The cellular uptake of all derivatives was examined in Doxresistant SK-OV-3 cells using fluorescence-activated cell sorter (FACS) analysis
(Figure 3). To obtain the primary influx, cells were allowed to be incubated with
covalent cyclic [W(RW)4]−Dox and linear (RW)4−Dox peptides, noncovalent physical
mixtures, cyclic [W(RW)4] + Dox and linear (RW)4 + Dox, and Dox for 1 h. This
process was followed by 24 h incubation with media to allow the cells to start the
efflux process through pumping the compounds out. Then the amounts of Dox in cells
were evaluated by using FACS in Dox-resistant SK-OV-3 cells. The data showed
3.3−3.6-fold more cellular uptake of cyclic [W(RW)4]−Dox compared to Dox alone
and noncovalent physical mixtures, cyclic [W(RW)4] + Dox and linear (RW)4 + Dox,
in SK-OV-3 (Figure 3). Between linear and cyclic peptide−Dox covalent conjugates,
the retention of cyclic [W(RW)4]−Dox was found to be 2.6-fold higher compared to
that of linear (RW)4−Dox. These data suggest that cyclic peptide−Dox, cyclic
[W(RW)4]−Dox, enhanced the cellular uptake of the compound. The cyclic nature of
the peptide was found to contribute in inhibition of the efflux. These data are
consistent with higher antiproliferative activity of cyclic [W(RW)4]−Dox versus linear
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(RW)4−Dox and Dox, suggesting that the presence of cyclic peptide in the conjugate
reduces efflux, increases cellular uptake and retention of Dox, and enhances
antiproliferative activity.

Cyclic [W(RW)4]−Dox Nuclear Localization in SK-OV-3 Cells. The cellular
localization of free Dox and conjugate cyclic [W(RW)4]−Dox was compared in SKOV-3 cells after 1 and 24 h incubation at 37 °C. A noncytotoxic concentration of 5 μM
was chosen to ensure Dox fluorescence detection by confocal microscopy. Confocal
microscopy images of SK-OV-3 cells are shown after 1 h incubation. Free Dox and
cyclic [W(RW)4]−Dox were localized mainly in the nucleus (Figure 4a). The results
showed that the covalent conjugation of Dox with cyclic [W(RW)4] did not prevent
the nuclear accumulation of the drug. To compare the retention ability of cyclic
[W(RW)4]−Dox versus Dox alone against efflux effects, SKOV-3 cells were
incubated with both compounds for 1 h followed by incubation in drug-free media for
24 h at 37 °C. The fluorescence intensity of Dox in cells treated with cyclic
[W(RW)4]−Dox was found to be significantly higher than that in cells treated with
Dox alone (Figure 4b), indicating that cyclic [W(RW)4]−Dox was retained in cells
much longer than free Dox. Thus, this conjugate has a potential to be used as a tool for
enhancing the nuclear retention of Dox.

Stability of Cyclic [W(RW)4]−Dox. Cyclic [W(RW)4]−Dox was incubated with
phosphate-buffered saline (PBS) and fetal bovine serum (FBS) solution at 37 °C at
different time intervals. The results indicated that cyclic [W(RW)4]−Dox is relatively
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stable in both systems with half-life values of 10.77 and 26.20 h in PBS and FBS,
respectively. No interaction between serum proteins and cyclic [W(RW)4]−Dox was
observed since the mixture was clear and no precipitation or turbidity was found
during the assay. Cyclic [W(RW)4]−Dox was found to be stable in PBS (97%) and
FBS (84%) after 1 h. For cellular uptake studies using FACS, the cells were incubated
by cyclic [W(RW)4]−Dox for 1 h followed by 24 h incubation with drug-free media.
During the 1 h period, the compound showed minimal hydrolysis in serum, suggesting
that most of the compound is hydrolyzed intracellularly (Figures S5 and S6 in the
Supporting Information).

Intracellular Hydrolysis. Intracellular hydrolysis results for cyclic [W(RW)4]−Dox
were monitored in CCRF-CEM cells. CCRF-CEM cells (1.37 × 107) were incubated
with the conjugate (1 μM) for 4 h followed by drug-free medium to determine the
possibility of the intracellular hydrolysis to Dox. Drug-free medium was used to rule
out the continuous cellular uptake of the conjugate, while the compound is hydrolyzed
intracellularly. HPLC analysis with detection at 490 nm and at specific time intervals
after cellular lysis was used to measure the ratio of the cyclic [W(RW)4]−Dox and
released Dox. The cellular hydrolysis data exhibited that the cyclic peptide−Dox
conjugate was hydrolyzed intracellularly and released Dox in a time-dependent
manner. More than 46% of cyclic [W(RW)4]−Dox was hydrolyzed intracellularly
within 12 h. Approximately 86% of cyclic [W(RW)4]−Dox was hydrolyzed
intracellularly within 48 h (Figure 5). These data suggest that the enhanced uptake,
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retention, and sustained intracellular hydrolysis of cyclic [W(RW)4]−Dox to Dox
contribute to overall activity of the conjugate as a potential prodrug

Cell Cycle Distribution Analysis. In addition to apoptosis,35,36 Dox treatment causes
cell cycle arrest in cancer cells.37 The impact of cyclic [W(RW)4]−Dox on cell cycle
distribution was investigated in colorectal carcinoma cells (HCT-116) compared to
Dox. All experiments were performed under similar conditions, and appropriate
controls were used to confirm the results. An hour incubation was selected followed
by 24 h incubation in drug-free medium, due to the significant difference in the
cellular uptake of cyclic [W(RW)4]−Dox and Dox. Control cells were found in G0/G1
phase (46.8 ± 1.0%), S phase (36.5 ± 0.7%), and G2/M phase (16.5 ± 0.2%). The
percentage of the pre-G0/G1 population indicates the apoptosis rate of cells. There
was no significant pre-G0-G1 population as shown in the histograms because the cells
were incubated with Dox and the prodrug only for 1 h. Cells treated with compounds
(Dox and cyclic [W(RW)4]−Dox) showed different patterns than control cells for
G0/G1 phase (53.0 ± 1.0% and 42.2 ± 1.4%), S phase (21.8 ± 3.0% and 23.5 ± 0.2%),
and G2/M phase (25.1 ± 2.0% and 34.1 ± 1.2%), respectively (Figure 6). The data
showed that, in cells treated with cyclic [W(RW)4]−Dox, the proportion of cells in
G0/G1 phase was decreased nearly 10% compared to values for Dox. On the other
hand, the proportion of cells in G2/M phase increased nearly 10% compared to values
for Dox. These data suggest that cyclic [W(RW)4]−Dox led to a significant reduction
of cells in G0/G1 phase, and caused more accumulation in G2/M phase in HCT-116
cells. This pattern is slightly different when compared to Dox. This could be due to the
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requirement for cyclic [W(RW)4]−Dox to get hydrolyzed to Dox. Based on the
population of cells at different phases, prodrug follows a different pattern when
compared with Dox. Some of the antiproliferative activity by cyclic [W(RW)4]−Dox
could be due to the differential pattern of cell cycle distribution by the conjugate, in
addition to intracellular hydrolysis to Dox. The histograms were also provided in the
Supporting Information (Figure S4).

Topo II Inhibitory Activity. One of the major anticancer mechanisms of Dox is the
inhibition of topoisomerase II.2 Thus, a comparative study was performed between
cyclic [W(RW)4]−Dox and Dox to determine whether the conjugate has Topo II
inhibitory activity similar to that of the parent drug. Topo II is responsible for
catalyzing the DNA double-stranded cleavage process by isolating catenated DNA
duplexes. Kinetoplast DNA (kDNA) is used as a DNA substrate in the in vitro
decatenation assay. The potency of Dox and cyclic [W(RW)4]−Dox to inhibit Topo II
enzyme for the decatenation of kDNA was used to analyze the comparative inhibitory
activity of the compounds. Topo II decatenation assay exhibited that Dox inhibited
Topo II at concentrations between 10 and 20 μM; however cyclic [W(RW)4]−Dox
inhibited the Topo II activity at concentrations between 20 and 30 μM (Figure 7)
under similar reaction conditions. As expected, the conjugate acts at higher
concentration compared to Dox since the conjugate is required to get hydrolyzed to
Dox to be able to inhibit Topo II more efficiently. Under the in vitro conditions used
here, the conjugate is not hydrolyzed and the reduced Topo II inhibitory activity is
possibly due to the conjugation to the peptide and associated steric hindrance.
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Hydrolysis to Dox is required to generate maximum Topo II inhibitory activity
associated with Dox. The conjugate does not undergo hydrolysis under in vitro
conditions in this assay.

CONCLUSIONS
In summary, linear and cyclic peptide−Dox conjugates were synthesized as
prodrugs, were evaluated for their activities against various cancer cell lines, and were
compared with the corresponding physical mixtures. The conjugation of Dox with a
specific cyclic peptide, cyclic [W(RW)4]−Dox, improved the antiproliferative activity
compared to the corresponding physical mixtures in all tested cell lines. Cyclic
peptide−Dox conjugate showed comparable antiproliferative activity against CCRFCEM and MDA-MB-468 when compared to Dox. However, the antiproliferative
activities of cyclic [W(RW)4]− Dox conjugate in SK-OV-3 and HCT-116 cells were
higher than those of Dox and linear (RW)4−Dox at a concentration of 1 μM after 96
and 120 h incubation. Dox has short retention time in some cancer cells (e.g., ovarian
adenocarcinoma SKOV-3) due to the efficient efflux effect. Thus, the differential
cytotoxicity of cyclic [W(RW)4]−Dox with Dox in SK-OV-3 could be due to the
retention of Dox in the presence of the cyclic peptide. Since the system was designed
as a prodrug, we did not expect to detect a huge difference between Dox and cyclic
[W(RW)4]−Dox in cytotoxicity. Furthermore, we demonstrated that the prodrug
approach for Dox using a cyclic peptide conjugate significantly improved the cellular
uptake and retention time of Dox in SK-OV-3 cancer cells. Flow cytometry analysis
showed 3.3−3.6-fold higher cellular uptake of cyclic [W(RW)4]−Dox than Dox alone
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and the physical mixtures, cyclic [W(RW)4] + Dox and linear (RW)4 + Dox, in SKOV-3 cells after 24 h incubation. The conjugate exhibited nuclear localization and
retention after 24 h, and underwent intracellular hydrolysis to Dox in CCRF-CEM
cells, suggesting to be a potential prodrug for delivery of the drug. The cellular
hydrolysis study showed that 99% of cyclic [W(RW)4]−Dox was hydrolyzed
intracellularly within 72 h and released Dox. These data suggest that cyclic
[W(RW)4]−Dox can be used as a potential prodrug for improving the biological
profile, cellular delivery, and retention of Dox.
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ABBREVIATIONS USED
CCRF-CEM, human leukemia carcinoma cell line; CPPs, cellpenetrating peptides;
DCM, dichloromethane; Dox, doxorubicin; DIPEA, N,N-diisopropylethylamine;
HBTU, DDS, drug delivery systems; FACS, fluorescence activated cell sorter; FBS,
fetal bovine serum; DCM, dichloromethane; HCT-116, human colorectal carcinoma;
HOBt,

hydroxybenzotriazole;

HBTU,

1,1,3,3-tetramethyluronium

hexafluorophosphate; MDA-MB- 468, human breast adenocarcinoma; MRPs,
multidrug resistance proteins; NMM (N-methylmorpholine); P-gp, P-glycoprotein;
PBS,

phosphate

buffered

saline

solution;

PyBOP,

benzotriazol-1-

yloxytripyrrolidinophosphonium hexafluorophosphate; SK-OV-3, human ovarian
adenocarcinoma,

1,1,3,3-tetramethyluronium

topoisomerase II
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hexafluorophosphate;

TOPO

II,
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Figure Legends:
Figure 1: Cytotoxicity assay of cyclic [WR]4 and cyclic [W(RW)4K]-(β-Ala) in
MDA-MB-468, HCT-116, CCRF-CEM, and SK-OV-3
Figure 2: Inhibition of (a) CCRF-CEM, (b) SK-OV-3, (c) HCT-116, and (d) MDAMB-468 cells by compounds (1 μM) after 24−120 h incubation. The results are shown
as the percentage of the control DMSO that has no compound (set at 100%). All the
experiments were performed in triplicate (±SD)
Figure 3: FACS analysis of cellular uptake assays of cyclic [W(RW)4]−Dox (5 μM) in
SK-OV-3 cells compared with linear (RW)4−Dox (5 μM) and the physical mixtures,
cyclic [RW)4] (5 μM) + Dox (5 μM) and linear (RW)4 (5 μM) + Dox (5 μM)
Figure 4: (a) Confocal microscopy images of Dox and cyclic [W(RW)4]−Dox (5 μM)
uptake in SK-OV-03 cells after 1 h. Red represents the fluorescence of Dox. (b)
Confocal microscopy images of Dox and cyclic [W(RW)4]−Dox (5 μM) uptake in SKOV-03 cells. SK-OV-3 cells were treated with the compound for 1 h. The compound
was removed, and the cells were incubated with complete media for 24 h. Red
represents the fluorescence of Dox)
Figure 5: HPLC chromatograms for the cellular uptake studies of cyclic
[W(RW)4]−Dox using CCRF-CEM cells after incubation for 1−72 h
Figure 6: Comparison of cell cycle arrest by Dox and cyclic [W(RW)4]-Dox
Figure 7: Topo II assay for Dox (middle) and cyclic [W(RW)4]−Dox (right). The lines
A1 and A2 were linear markers and decatenated DNA markers, respectively. Line A3
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represents the blank kDNA in the absence of any compound. kDNA was incubated
with compound Dox (10−50 μM, lanes B1−B5) and cyclic [W(RW)4]−Dox (10−50
μM, lanes C1−C5) and decatenated using topoisomerase II for 30 min at 37 °C. The
decatenation was monitored by gel electrophoresis and imaged by ethidium bromide
fluorescence

Scheme Legends:

Scheme 1: Synthesis of Linear (RW)4 Peptide
Scheme 2: Synthesis of Cyclic [W(RW)4K](β-Ala) Peptide
Scheme 3: Synthesis of Dox−Peptide (Linear or Cyclic) Conjugates
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ABSTRACT

A number of cyclic peptides were synthesized and evaluated as simultaneous reducing
and capping agents for generation of cyclic peptide-capped gold nanoparticles
(CPAuNPs). Among them, direct dissolution of cyclic peptides containing alternate
arginine and tryptophan [WR]n (n = 3−5) into an aqueous solution of AuCl4− led to the
formation of CPAuNPs, through the reducing activity of tryptophan residues and
attraction of positively charged arginine residues toward chloroaurate anions in the
reaction environment. Differential interference contrast microscopy of fluorescencelabeled lamivudine in the presence of [WR]4-capped AuNPs showed significantly
higher cellular delivery of antiviral drug versus that of parent drug alone. Flow
cytometry studies also showed that the cellular uptake of fluorescence-labeled
lamivudine, emtricitabine, and stavudine was significantly enhanced in human ovarian
adenocarcinoma (SK-OV-3) cells in the presence of [WR]4-AuNPs. For example,
fluorescence labeled lamivudine loaded [WR]4-AuNPs exhibited approximately 12and 15-times higher cellular uptake than that of fluorescence labeled lamivudine alone
in CCRF-CEM cells and SK-OV-3 cells, respectively. Confocal microscopy revealed
that the presence of the [WR]4-AuNPs enhanced the retention and nuclear localization
of doxorubicin in SK-OV-3 cells after 24 h. These data suggest that these complexes
can be used as potential noncovalent prodrugs for delivery of antiviral and anticancer
agents.

KEYWORDS: arginine, cellular delivery, cyclic peptide, gold nanoparticle,
tryptophan
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INTRODUCTION
Gold nanoparticles (AuNPs) have become subjects of major interest because of
their broad applications in biosensing,1 imaging,2 drug delivery,3 and cancer
therapy.4−6 AuNP-based drug delivery systems (DDS) have become attractive due to
their low toxicity, nonimmunogenicity, and biocompatibility.7 To date, most current
prodrug strategies for cellular delivery of compounds with limited cell permeability
have taken advantage of covalent conjugation with carriers. These strategies require
cleavage and release of the cargo compounds from the conjugate. The covalent
conjugation of gold and drugs through functionalization of AuNPs by −SH and −NH
moieties has been also investigated as an efficient strategy for drug delivery.8
We have previously reported the application of a number of cyclic peptides as nuclear
targeting molecular transporters.9 Herein, we report evaluation of L-cyclic peptides as
simultaneous reducing and capping agents for generation of cyclic peptide-capped
gold nanoparticles (CP AuNPs). We used cellpenetrating properties of both cyclic
peptides and capped AuNPs for in situ generation of a DDS. To the best of our
knowledge, this is the first report of using cyclic peptides in generation of cellpenetrating CP-AuNPs and as drug delivery tools.
Multifunctional CP-AuNPs with Au3+ reducing, capping, and cell-penetrating
properties are distinct from the previously reported AuNPs for the following reasons:
(1) Cell-penetrating properties of both cyclic peptides and capped AuNPs are used for
cellular drug delivery applications. Positively charged and hydrophobic residues in the
peptides can be designed to perturb and/or permeate membranes by interacting with
the corresponding negatively charged and hydrophobic residues, respectively, in the
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phospholipid bilayer and to promote a higher uptake of molecular cargo than
conventional delivery routes. (2) No chemical modification or functionalization is
required on the surface of the generated AuNPs by the cyclic peptides. Furthermore,
no covalent conjugation is needed between biologically active compounds and CPAuNPs. Hydrophobic amino acids of the peptide generate a pocket for noncovalent
entrapment of drugs. (3) Amino acid residues in the structure of the cyclic peptide
work as simultaneous reducing and capping agents. Amino acids and linear peptides
have been studied as reducing agents.10−13 Linear peptides incorporating amino acids
containing nitrogen heteroaromatics are strong metal binders. Tryptophan (W) has
been shown as the most efficient reducing agent among 20 amino acids.13
Furthermore, positively charged linear peptides found to enhance the reduction
because of the favorable charge interactions can bring the chloroaurate anions in
proximity for reaction.13 The application of cell-penetrating cyclic peptides as
simultaneous reducing and capping agents in AuNP formation remains unexplored. (4)
The enhancement of intracellular delivery of biologically active cargos by employing
linear cationic cell-penetrating peptides (CPPs) has been previously reported.14,15
Compared to linear peptides that are susceptible to hydrolysis by endogenous
peptidases, cyclic peptide counterparts are chemically and enzymatically more
stable.16 (5) CP-AuNPs in combination with antiviral and anticancer drugs can be used
as potential scaffold for generation of noncovalent prodrugs.
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EXPERIMENTAL SECTION
Materials and Methods. The synthesis of cyclic peptides was carried out according to
the previously reported procedure.7 All reactions were carried out in Bio-Rad
polypropylene columns by shaking and mixing using a Glass-Col small tube rotator in
dry conditions at room temperature unless otherwise stated. Chlorotrityl chloride resin,
trityl chloride resins, coupling reagents, and Fmoc-amino acid building blocks were
purchased from Chempep (Miami, FL).
Other chemicals and reagents were purchased from Sigma-Aldrich Chemical Co.
(Milwaukee, WI). All peptides were synthesized using a solid-phase synthesis method
employing N-(9-fluorenyl)methoxycarbonyl (Fmoc)-based chemistry and Fmoc-Lamino acid building blocks. In the solid-phase synthesis 2-(1H-benzotriazol-1-yl)1,1,3,3-tetramethyluronium

hexafluoro

phosphate

(HBTU)

and

N,N-

diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) were used as
coupling and activating reagents, respectively. Piperidine in DMF (20% v/v) was used
for Fmoc deprotection at each step. Side chain protected peptides were cleaved from
the resins by shaking the resins with a mixture of trifluoroethanol (TFE)/acetic acid/
dichloromethane (DCM) (2:2:6, v/v/v, 15 mL) for 2 h. The resins were filtered off,
and the liquid was evaporated to dryness to obtain side-chain protected linear peptide.
In general, the cyclization of the peptides was carried out in the presence of a mixture
of 1-hydroxy-7-azabenzotriazole (HOAt, 163.3 mg, 1.2 mmol) and N,N′diisopropylcarbodiimide (DIC, 187.0 μL, 1.2 mmol) in dry DMF (100 mL) and dry
DCM (40 mL) for 24 h. DMF and DCM were evaporated. The side chain deprotection
was carried with trifluoroacetic acid (TFA)/thioanisole/anisole/1,2-ethanedithiol
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(EDT) (90:5:2:3 v/v/v/v) for 2 h. The crude peptides were precipitated by the addition
of cold diethyl ether (Et2O) and purified by reversed-phase Hitachi HPLC (L-2455) on
a Phenomenex Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) with
using a gradient system on a Phenomenex Prodigy 10 μm ODS reversed-phase column
(2.1 cm × 25 cm). The peptides were purified by eluting the crude peptides at 10.0
mL/min using a gradient of 0−100% acetonitrile (0.1% TFA) and water (0.1% TFA)
over 60 min, and then, they were lyophilized to yield cyclic. The chemical structure of
[WR]4 was characterized by nuclear magnetic resonance spectra (1H NMR)
determined on a Varian NMR spectrometer (500 MHz). The chemical structures of all
final products were confirmed by a high-resolution Biosystems QStar Elite time-offlight electrospray mass spectrometer as described previously7 or MALDI AXIMA
Performance TOF/ TOF mass spectrometer (Shimadzu Biotech.). The purity of final
products (>95%) was confirmed by analytical HPLC. The analytical HPLC was
performed on the Hitachi analytical HPLC system on a C18 Shimadzu Premier 3 μm
column (150 cm × 4.6 mm). As representative examples, the synthesis of cyclic [WE]4
and linear (WR)4 is outlined in Scheme S1 in the Supporting Information. A similar
procedure was employed for the synthesis of other cyclic peptides by using
appropriate resins and protected amino acids as described previously.7

Linear (WR)4. H-Trp(Boc)-2-chlorotrityl chloride resin (385 mg, 0.30 mmol, 0.78
mmol/g) was swelled in anhydrous DMF for about 15 min under dry nitrogen. The
excess of the solvent was filtered off. The swelling and filtration steps were repeated
for 2 more times before the coupling reactions. Fmoc-Arg(Pbf)-OH (584 mg, 0.9
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mmol) was coupled to the N-terminal of tryptophan trityl resin in the presence of
HBTU (340 mg, 0.894 mmol) and DIPEA (313.4 μL, 1.8 mmol) in DMF (6 mL) by
mixing for 1.5 h. After the coupling was completed (confirmed by Kaiser test), the
reaction solution was filtered off, and the resin was collected by filtration and washed
with DMF (7 × 15 mL), followed by N-terminal Fmoc deprotection using piperidine in
DMF (20% v/v, 10 mL, 2 times, 5 and 10 min). The resin was washed with DMF (7 ×
15 mL). The subsequent amino acids, Fmoc-Trp(Boc)-OH (474 mg, 0.9 mmol) and
Fmoc-Arg(Pbf)-OH (584 mg, 0.9 mmol), were coupled alternatively three times,
respectively, in a similar manner. Fmoc-deprotection at the N-terminal was carried out
in the presence of piperidine in DMF (20% v/v, 10 mL, 2 × 10 min) to afford the
linear peptide on solid phase. The resin was washed with DMF, DCM, DMF-MeOH,
and MeOH, respectively (each 2 × 25 mL). The resins were dried in vacuum for 24 h.
Freshly prepared cleavage cocktail, reagent R, TFA/thioanisole/EDT/anisole (90:5:3:2
v/v/v/v, 10 mL), was added to the resins. The mixture was shaken at room temperature
for 2 h. The resin was collected by filtration and washed with another 2 mL of
cleavage cocktail. Combined filtrates were evaporated to a minimum volume under
dry nitrogen. The crude peptide was precipitated by the addition of cold diethyl ether
(75 mL, Et2O), lyophilized, and purified by reversed-phase Hitachi HPLC (L-2455) on
a Phenomenex Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a
gradient system to yield linear (WR)4. MALDI-TOF (m/z) [C68H90N24O9]: calcd,
1386.7323; found, 1387.5351 [M + H]+, 1409.5862 [M + Na]+.
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Synthesis of Cyclic Peptides. The synthesis of cyclic peptides was carried out
according to the previously reported procedure.9 As a representative example, the
synthesis of [WE]4 is described here.

Cyclic [WE]4. The linear peptide was assembled on the H-Trp(Boc)-2-chlorotrityl
chloride resin (513 mg, 0.40 mmol, 0.78 mmol/g) in 0.40 mmol scale as described
above except with the use of Fmoc-Glu(OtBu)-OH in place of arginine. After the final
deprotection of the N-terminal Fmoc group by piperidine in DMF (20% v/v), the side
chain protected peptide was cleaved from trityl resin in the presence of the cleavage
cocktail acetic acid/TFE/DCM (1:2:7 v/v/v, 50 mL) by shaking for 1 h at room
temperature to yield the side chain protected linear peptide. The resin was collected by
filtration and washed with TFE/DCM (2:8 v/v, 2 × 10 mL). The combined filtrates
were evaporated to dryness under reduced pressure. To the residue were added hexane
(2 × 25 mL) and DCM (1 × 25 mL) to remove the acetic acid from the mixture and to
solidify the crude material as white solid. The crude protected peptide was dried in
vacuum overnight. Examining a small portion of the crude showed a main peak by
HPLC analysis. Thus, the crude was used directly for the cyclization reaction. The
dried crude linear protected peptide was dissolved in DMF/DCM (5:1 v/v, 250 mL).
HOAt (223 mg, 1.64 mmol, 4 equiv) and DIC (290 μL, 1.86 mmol, 4.5 equiv) were
added to the mixture, and the solution was stirred for 4 h. After completion of the
cyclization, as shown by the MALDI-TOF, the solvents were removed under reduced
pressure on a rotary evaporator. The crude product was dried overnight in vacuum
before the final cleavage. Freshly prepared cleavage cocktail, reagent R,
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TFA/thioanisole/EDT/ anisole (90:5:3:2 v/v/v/v, 20 mL) was added to the crude
product. The mixture was stirred at room temperature for 2 h. The cleavage cocktail
was concentrated to a minimum volume under reduced pressure by a rotary
evaporator. After precipitation of crude peptide in cold diethyl ether (75 mL, Et2O)
and centrifugation, the crude peptide was lyophilized and purified by reversed-phase
Hitachi HPLC (L-2455) on a Phenomenex Prodigy 10 μm ODS reversed-phase
column (2.1 cm × 25 cm) using a gradient system to yield [WE]4. MALDI-TOF (m/z)
[C64H68N12O16]: calcd, 1260.4876; found, 1261.3163 [M]+, 1283.3769 [M + Na]+,
1299.3489 [M + K]+.

Synthesis of AuNPs. The formation of AuNPs was studied in the presence of the
peptides. In general, a peptide stock solution (1−2 mM) was mixed with an aqueous
solution of HAuCl4 (1−2 mM) at room temperature, and the absorbance was read
using SpectraMax M2 spectrophotometer (Molecular Devices, CA). The color of the
solution turned red after 4−8 h due to the formation of peptide capped AuNPs.
Furthermore, UV−vis spectroscopy study was carried out using HAuCl4 (1 mM) and
[WR]4 (100 μM to 2 mM) on a 96-well plate, and the absorbance was read after 4 h
incubation using a SpectraMax M2 spectrophotometer to determine the optimized
concentration ratio for the reduction. The visible range was chosen because of the
characteristic surface plasmon peak of AuNPs appearing around 520−550 nm. All
experiments were performed in triplicate.
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Fluorescence Study of [WR]5 in the Presence of HAuCl4. A fluorescence study was
carried out in the presence of HAuCl4 (1 mM) solution in deionized water and various
concentrations of [WR]5 (1 μM to 2 mM) in deionized water. After mixing, the
solutions were transferred into a 96-well plate and fluorescence intensity was read
using a SpectraMax M2 fluorescence spectrophotometer (Molecular Devices, CA). At
lower concentrations of the peptide, the fluorescent intensity remained constant. At
peptide concentrations of 250 μM and higher the intensity proportionally increased,
demonstrating maximum binding at 1 mM concentration of the peptide. These data
were consistent with visible spectroscopy data described above. Thus, 1:1 equivalent
([WR]5/HAuCl4) and 1 mM optimal concentration were selected for further studies.

Transmission Electron Microscopy (TEM), Selected Area Electron Diffraction
(SAED), Energy Dispersive Xray Spectroscopy (TEM-EDS), and Scanning
Electron Microscopy (SEM). To prepare a sample for TEM or SEM microscopy,
[WR]4-AuNPs (5 μL of 0.5 mM solution in H2O) solution was spotted onto a carboncoated copper grid (300 mesh). The liquid drop was then allowed to stay on the carbon
film for 10 min. The excess of the solution was removed from the surface of the grid,
and the sample was kept overnight to get dried. TEM analyses were conducted in a
JEOL transmission electron microscope (Tokyo, Japan) at an accelerating voltage 80
keV as described in the Supporting Information. SEM analyses of [WR]5-AuNPs were
conducted in an FEI Nova NanoSEM using the directional backscatter (DBS) electron
detector.
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Cell Culture. Human ovarian adenocarcinoma cell line (SKOV-3, ATCC No. HTB77), human leukemia cell line (CCRFCEM, ATCC No. CCL-119), and normal human
colon myofibroblast (CCD-18Co, ATCC No. CRL-1459) cell lines were obtained
from American Type Culture Collection. The cells were grown on 75 cm2 cell culture
flasks with RPMI-16 medium for CCRF-CEM cells and with EMEM (Eagle’s
minimum essential medium) for SK-OV-3 and CCD-18Co cells, supplemented with
10% fetal bovine serum (FBS), and 1% penicillin−streptomycin solution (10,000 units
of penicillin and 10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of
5% CO2, 95% air at 37 °C. Cytotoxicity Assay of [WR]4 and [WR]4-AuNP
Complexes. SK-OV-3 (5,000 cells), CCRF-CEM (40,000 cells), and CCD 18Co
(3,000 cells) were seeded in 0.1 mL per well in 96-well plates 24 h prior to the
experiment. The old medium (EMEM containing FBS (10%) for SK-OV-3 and CCD18Co) was replaced by different concentrations of [WR]4 or [WR]4-AuNPs (100 μM)
in serum containing medium and incubated for 24 or 72 h at 37 °C in a humidified
atmosphere of 5% CO2. For CCRF-CEM the concentration was calculated after
addition of the compounds. Cell viability was then determined by measuring the
fluorescence intensity of the formazan product at 490 nm using a SpectraMax M2
microplate spectrophotometer. The percentage of cell survival was calculated as [(OD
value of cells treated with the test mixture of compounds) − (OD value of culture
medium)]/[(OD value of control cells) − (OD value of culture medium)] × 100%.
Other cell-penetrating peptides polyArg CR7, TAT (YGRKKRRQRRRC) (100 μM),
and oligofectamine 2000 (Invitrogen, a cationic lipid formulation) were used as
controls.
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Cytotoxicity of Dox in the Presence or Absence of [WR]4-AuNPs. The cell viability
in the presence of Dox and [WR]4-AuNPs and Dox alone against ovarian carcinoma
cells SK-OV-3 was determined by MTT assay. All cells were plated overnight in 96well plates with a density of 5000 cells per well in 0.1 mL of appropriate growth
medium at 37 °C. Dox alone (5 μM) or a combination of Dox (5 μM) and [WR]4AuNPs (25 μM) were incubated with the cells for 8 h. Excess of compounds were
removed and washed by fresh media. The cells were kept in an incubator for 24−120
h. The cells without compounds were included in each experiment as controls. After
24 h, 48 h, 72 h, 96 h, and 120 h incubation, 20 μL of MTT was added and incubated
for 2 h. The absorbance of the formazan product was measured at 490 nm using
microplate reader. The percentage of cell viability was calculated as (OD value of
untreated cells - OD value of treated cells)/OD value of untreated cells × 100%.

Loading of Doxorubicin. Aqueous Dox solution (10 μL, 10−3 M) was mixed with
aqueous [WR]4-AuNP solution (100 μL, 10−4 M) to obtain 1:1 molar ratio. Dox in
H2O was mixed with water as a negative control. Mixed solution was incubated in a
96-well plate at room temperature for 2 h. Fluorescence of the solution was measured
using SpectraMax M2 fluorescence spectrophotometer (Molecular Devices, CA) with
excitation at 480 nm and emission at 550 nm.

Fluorescence Microscopy. Fluorescence-Labeled Peptide-AuNP Uptake. The cellular
uptake studies of carboxyfluorescein- labeled peptide-AuNP were imaged using a
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ZEISS Axioplan 2 light microscope equipped with transmitted light microscopy with a
differential-interference contrast method and an Achroplan 40X objective. Human
leukemia cells (CCRF-CEM) were taken in 6-well plates (2 × 106 cells/well) in serumfree media. Then F′-[W5R4K]-AuNPs (10 μM) was added. After 1 h incubation at 37
°C, the media containing peptide were removed. The cells were digested with 0.25%
trypsin/EDTA (0.53 mM) for 5 min to remove any artificial cell surface association
and to detect only intracellular uptake. Then the cells were washed twice with PBS,
resuspended in media, and were observed under a fluorescent microscope under bright
field and FITC channels (480/520 nm).

Differential Interference Contrast Microscopy. The cellular uptake studies of
fluorescence labeled beta alanine-3TC (F′-3TC) were imaged using a ZEISS Axioplan
2 light microscope equipped with transmitted light microscopy with a differential
interference contrast method and an Achroplan 40X objective. In the case of SK-OV-3
cell line, ovarian carcinoma cells (SKOV- 3) were grown on a coverslip in a 6-well
plate. The cells were incubated with F′-3TC (5 μM) and [WR]4-AuNPs (25 μM), F′3TC alone (5 μM), and [WR]4-AuNPs alone (25 μM, SK-OV-3 and CCRF-CEM cells)
in opti-MEM for 1 h at 37 °C. Then the cells were washed with PBS three times, fixed
with 3.5% paraformaldehyde followed by washing with PBS three times, and observed
under a fluorescence microscope as described above.

Flow Cytometry. Human leukemia cells (CCRF-CEM) were taken in 6-well plates (1
× 107 cells/well) in serum-free medium. Then F′-3TC, F′-GpYEEI, fluorescence-
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labeled FTC (F′-FTC), or fluorescence-labeled d4T (F′-d4T) (5 μM) was added to the
different wells containing [WR]4 (25 μM) or [WR]4-AuNPs (25 μM) in serum-free
medium. [WR]4-AuNPs (25 μM) were used as a control. The plates were incubated for
1 h at 37 °C. DMSO and 5(6)-carboxyfluorescein (FAM) were used as negative
controls. After 1 h incubation at 37 °C, the medium containing the peptide was
removed. The cells were digested with 0.25% trypsin/EDTA (0.53 mM) for 5 min to
remove any artificial surface association and to detect only intracellular uptake. Then
the cells were washed twice with PBS. Finally, the cells were resuspended in flow
cytometry buffer and analyzed by flow cytometry (FACSCalibur:Becton Dickinson)
using FITC channel and CellQuest software. The data presented were based on the
mean fluorescence signal for 10,000 cells collected. All assays were performed in
triplicate. In the case of Dox, SK-OV-3 cells were seeded in 6-well plates (3 × 105
cells/well) in opti-MEM. The drugs (Dox, F′- 3TC, F′-GpYEEI, F′-FTC, and F′-d4T)
(5 μM) were added to the various wells containing [WR]4 (25 μM) or [WR]4-AuNPs
(25 μM) in opti-MEM. The plates were incubated for 1 h at 37 °C. A well containing
cells and drug alone was used as negative control. After 1 h incubation, the medium
was removed. The cells were digested with 0.25% trypsin/EDTA (0.53 mM) for 5 min
to remove any artificial surface association and to detect only intracellular uptake.
Then the cells were washed twice with PBS. Finally, the cells were resuspended in
flow cytometry buffer and analyzed by flow cytometry (FACSCalibur: Becton
Dickinson) using FL2 channel and CellQuest software. The data presented are based
on the mean fluorescence signal for 10,000 cells collected. All assays were performed
in triplicate. Doxorubicin Retention Assay. Human ovarian cancer cells (SK-OV-3)
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were seeded in 6-well plates (3 × 105 cells/ well) in EMEM including 10% FBS. The
cells were incubated overnight. The medium was removed, and Dox (5 μM) was
added to the various wells containing [WR]4 (25 μM) or [WR]4-AuNPs (25 μM) in
opti-MEM (reduced serum). The plates were incubated for 1 h at 37 °C. Two wells
containing cells and Dox and cells and [WR]4-AuNPs alone were used as negative
controls. The medium was removed after 1 h incubation, and complete medium
including 10% FBS (EMEM) was added to the cells and incubated for 48 h. The
medium was removed after 48 h, and the cells were digested with 0.25% trypsin/0.53
mM EDTA for 5 min to remove any artificial surface association and to detect only
intracellular uptake. Then the cells were washed twice with PBS. Finally, the cells
were resuspended in flow cytometry buffer and analyzed by flow cytometry
(FACSCalibur: Becton Dickinson) using FL2 channel and CellQuest software. The
data presented are based on the mean fluorescence signal for 10,000 cells collected.
All assays were performed in triplicate.

Confocal Microscopy of [WR]4-AuNPs and Dox or F′- d4T in Live Cells. Adherent
SK-OV-3 cells were seeded with EMEM media overnight on coverslips in 6-well
plates. Then the medium was removed and washed with opti-MEM (reduced serum).
The cells were treated with Dox or F′-d4T (5 μM), the mixture of Dox (5 μM) and
[WR]4 (25 μM), and the mixture of Dox or d4T (5 μM) and [WR]4-AuNPs (25 μM) in
opti-MEM for 1 h at 37 °C. After 1 h incubation, the medium containing the peptide
was removed followed by washing with PBS three times, and treated with complete
EMEM including 10% of FBS. Then, the coverslips were mounted on a microscope
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slide with mounting medium with cell-attached side facing down. Laser scanning
confocal microscopy was carried out using Carl Zeiss LSM 510 system. The cells
were imaged using rhodamine and phase contrast channels. In the case of drug efflux
studies, after a 1 h incubation period, the medium containing drugs was removed and
washed with opti-MEM. Then fresh medium with serum was added into the cells.
After 24 h, the medium was removed and washed with PBS three times, and then the
cells were visualized under confocal microscopy.

RESULTS

Chemistry. Synthesis of Cyclic Peptides. Cyclic octapeptides, [WR]4, [FK]4, [AK]4,
[EL]4, [RFEF]2, [EK]4, and [FR]4, containing hydrophobic residues (W, F, L) and
charged residues (K, R, E) (Figure 1) were synthesized by using 9fluorenylmethyoxycarbonyl (Fmoc)-based chemistry.9

Evaluation of Cyclic Peptides for Generation of CP-AuNPs. The generation of
AuNPs was studied in the presence of the synthesized cyclic peptides. The formation
of AuNPs using peptides includes two key steps: reduction reaction of Au3+ solution
(HAuCl4) and capping the newly nanosized gold particles. The surface plasmon
maximum band for generated AuNPs was observed in the range of 520−550 nm by
using UV−vis spectroscopy. Among all cyclic peptides, direct dissolution of [WR]4
into an aqueous solution of AuCl4− led to the formation of AuNPs showing maximum
absorption at 539 nm (Figure 1B) and change in the color of the solution to red. The
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broad absorption peak at >954 nm represents the surface plasmon resonance (SPR)
peak associated with the excitation of surface plasmons in AuNPs. [WR]4-AuNP
formation is a controlled process by the balance between reduction, nucleation, and
growth steps. In general, anisotropy in the nanoparticle product is caused by the
asymmetric adsorption of capping peptides on different crystallographic planes of the
nuclei.
Because peptides were also used here as the reducing agent, the reduction
kinetics affected both the size and the shape of the nanoparticles. The presence of
extremely smaller particles indicated that the growth of the AuNP nanoparticles to
spherical forms occurs via an initial nucleation step. Triangular and hexagonal shapes
exhibit SPR bands in the near-infrared region 800−1100 nm,16 suggesting the
formation of anisotropic Au particles. Generally, synthesis of AuNPs is a kinetically
controlled process where a slow growth environment favors the selective adsorption of
the capping molecules on the nuclei and the development of anisotropy.13 Cyclic
peptides were used as the reducing agent. Thus, the reduction process affected both the
size and the shape of the nanoparticles. [WR]4-AuNP formation is a controlled process
by the balance between reduction, nucleation, and growth steps. The presence of
spherical AuNPs is consistent with a single localized surface plasmon resonance
(LSPR) in visible spectroscopy around 539 nm. UV−vis spectroscopy demonstrated
that the formation of [WR]4-AuNPs from [WR]4 and HAuCl4 was concentration
dependent. The main experiment was performed by mixing a fixed concentration of an
aqueous solution of HAuCl4 with the same volume of different concentrations of
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aqueous solutions of peptides. The intensity of the SPR band was altered as the
concentration of peptides changed (Figure S3, Supporting Information).
Because of the capability of [WR]4 in generating AuNPs, other cyclic peptides
with similar amino acids, [WR]3 and [WR]5 (Figure 1A), were investigated under
similar conditions to determine whether the ring size has any effect in the AuNP
formation. UV−vis spectroscopy suggested that all the peptides in the [WR]n (n = 3−5)
series were able to generate AuNPs from Au3+, but [WR]5 and [WR]4 generated higher
intensity of SPR band at 537−539 nm (Figure 1B). These data suggest that the number
of tryptophan residues has an impact on the SPR band intensity. The intensity of the
SPR band of [WR]4-AuNPs is less than that of [WR]5-AuNPs. The intensity difference
in the SPR band showed more efficient generation of AuNPs in the presence of [WR]5
compared to [WR]4. Tryptophan works as reducing agent for generating AuNPs. Thus,
the number of tryptophan residues is critical in reducing efficiency of the peptide.
[WMeR]4, a cyclic peptide containing N-methyl-L-tryptophan showed no color
change in the presence of HAuCl4 even after 1 week. These data suggest that the
presence of a free amino group in the indole of tryptophan for reduction is critical in
generating AuNPs. Furthermore, [WE]4 as a cyclic peptide containing tryptophan and
glutamic acid was synthesized to determine whether the presence of arginine residues
was required for AuNP formation. This peptide was not capable of generating AuNPs.
The presence of glutamic acid was detrimental (Figure 1B), possibly because the
negatively charged amino acid has unfavorable electrostatic interaction with
negatively charge AuCl4−, reducing the accessibility of reducing tryptophan residue
with Au3+. The [WR]n series (n =3−5) generated AuNPs with higher intensity in SPR
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band at 537−539 nm, possibly because tryptophan acted as a reducing agent and
positively charged arginine residues attracted and absorbed AuCl4− anions.
[WR]4-AuNPs were characterized using transmission electron microscopy
(TEM), selected area electron diffraction (SAED), scanning electron microscopy
(SEM), and energy dispersive X-ray spectroscopy (TEM-EDS) (Supporting
Information). As described in the Supporting Information, TEM images (Figures
S3−S5 in the Supporting Information) exhibited nanosized structures with
approximate size of 5−50 nm after 4 days incubation. AuNPs were obtained in a
mixture of spherical and triangular shapes (Figures S3−S5 in the Supporting
Information). [WR]4-AuNP formation is a controlled process by the balance between
reduction, nucleation, and growth steps. In general, anisotropy in nanoparticle product
is caused by the asymmetric adsorption of capping peptides on different
crystallographic planes of the nuclei. AuNP formation includes nucleation from
spherical forms to triangular. Hexagonal shapes, growth, and aggregation were
obtained at higher concentration and incubation times. Because peptides were also
used here as the reducing agent, the reduction kinetics affected both the size and the
shape of the nanoparticles. Some of the [WR]4-AuNPs form aggregates as seen in
some parts of the TEM grid perhaps because of hydrophobic interactions between
oxidized tryptophan residues in CP-AuNPs. In summary, these data showed, there is a
formation of spherical and trigonal platelets and particles with diameters of 5−50 nm.
Longer incubation times and higher concentrations led to the hexagonal shapes
(100−200 nm) and aggregation of the particles.
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Two methods were used for preparing the samples for TEM analysis. The
samples (1 mM of peptide and HAuCl4 each) were prepared by depositing a droplet of
a mixture of gold and peptide on a carbon-coated Cu support grid of mesh size 300
and drying at room temperature overnight. Alternatively, another method for the
preparation of peptide-capped AuNPs was the direct addition of peptide powder to the
aqueous Au solution. When the peptide was added to HAuCl4 as a powder, TEM
showed a layer of peptide surrounding AuNPs, suggesting the capping of the formed
AuNPs by the peptide (Figure S4C in the Supporting Information). Some of the CPAuNPs form aggregates as seen in some parts of TEM grid perhaps because of
hydrophobic interactions between oxidized tryptophan residues in CP-AuNPs. This
observation is consistent with earlier investigation with tryptophan-reduced AuNPs
that showed a membrane surrounding the synthesized AuNPs.11
Cyclic [WR]4 and linear (WR)4, which have the same number and sequence of
amino acids, were compared using visible spectroscopy under similar conditions. Both
peptides generated AuNPs (Figure 1B), but a weaker SPR band was observed for
linear (WR)4 in the region higher than 600 nm. We have previously reported
significantly higher cellular uptake of a cyclic peptide compared to that of the
corresponding linear peptide.9 Thus, [WR]4-AuNPs were selected for further cellular
studies.
It is important to emphasize that UV−vis and TEM studies were carried out at
high concentration peptides (500 μM to 2 mM) and long incubation times that may not
correlate with significantly lower concentrations (10−25 μM) of peptides prepared in
short incubation time and used for the cell-based and cellular delivery studies. At this
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low concentration, only spherical AuNPs were observed for cyclic peptides because of
nucleation steps and the number of AuNPs decreased dramatically. Herein, we have
provided some details about the characterization of [WR]4-AuNPs under high
concentration that is beyond the scope of this work for cellular studies. We focused on
using generated cyclic peptide-capped nanoparticles formed under mild conditions as
molecular transporters. In all comparative experiments, [WR]4 and [WR]4-AuNPs
were used under similar conditions. In general, the stock solution of [WR]4-AuNPs
was generated by mixing the same volume of aqueous solution of [WR]4 and HAuCl4.
The concentration of [WR]4-AuNPs was based on the concentration of peptide
solutions. All the particles are in the form of [WR]4-AuNPs instead of AuNPs +
[WR]4. The solution was filtered by using 0.2 μm and diluted with water for further
cell-based assays. The inductively coupled plasma mass spectrometry (ICP-MS) data
for the [WR]4-AuNPs showed that the conversion of [WR]4 and HAuCl4 to [WR]4AuNPs was in high yield.

Cytotoxicity of [WR]4-AuNPs. [WR]4-AuNPs did not show any significant toxicity in
human ovarian adenocarcinoma (SK-OV-3) and human leukemia (CCRF-CEM)
cancer cells and normal human colon myofibroblast (CCD-18Co) cells at a
concentration of ≤25 μM (Figure S5 in the Supporting Information) while other cellpenetrating peptides polyArg CR7, TAT (YGRKKRRQRRRC), and oligofectamine
2000 (Invitrogen, a cationic lipid formulation) reduced the viability by 21−55%
(Figure S6 in the Supporting Information). After formation of [WR]4-AuNPs at higher
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concentrations (>1 mM), the solution was diluted and a noncytotoxic concentration of
≤25 μM was selected for cell-based studies.

Cellular Uptake of CP-AuNPs. A 5(6)-carboxyfluorescein (FAM)-labeled conjugate
of [WR]5 as F′-[K-W-R-W-R-W-RW-R-W] (F′-[W5R4K]) was synthesized as
described previously, where F′ = fluorescein.9 F′-[W5R4K] was reacted with HAuCl4
solution to generate CP-AuNPs. Incubation of F′-[W5R4K]-capped AuNPs with
CCRF-CEM cells showed significantly higher cellular uptake when compared with
that of FAM (Figure 2A). Flow cytometry studies exhibited the cellular uptake of F′[W5R4K]-capped AuNPs to be rapid even after 10 min (Figure 2B). The cellular
uptake of cyclic F′-[W5R4K]-capped AuNP was approximately 1.5-, 1.7-, and 3.2- fold
higher than that of linear F′-(W5R4K)-capped AuNP, cyclic F′-[W5R4K], and linear F′(W5R4K), respectively, after 1 h incubation (Figure S7 in the Supporting Information).
Further evidence of the accumulation of AuNPs in SK-OV-3 cells was
obtained by inductively coupled plasma mass spectrometry (ICP-MS) for quantifying
the cellular uptake of gold. [WR]4-AuNPs (25 μM) were incubated with SK-OV-3
cells for 3 and 24 h. The cell lysate was subjected to digestion and analysis by ICPMS. The data showed the 163 ng (3 h) and 233 ng (24 h) corresponding to 33−47%
cellular uptake (Figure S8 in the Supporting Information), suggesting the intracellular
accumulation of AuNPs in cells.
The cellular membrane integrity in SK-OV-3 cells was examined in the
presence of [WR]4-AuNPs and using propidium iodide and showed no significant
modification (Figure S9 in the Supporting Information), ruling out the damage of the
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plasma membrane by [WR]4-AuNPs (50 μM) and confirming that the highly efficient
transport of the complex was not a result of decreased cellular membrane integrity.

Entrapment of Drugs by CP-AuNPs. To study the potential of [WR]4-AuNPs as
molecular transporters, doxorubicin (Dox) were selected as a model drug for loading
studies using fluorescence spectroscopy. Incubation of Dox with [WR]4-AuNPs
demonstrated significant decreased in emission intensity (Figure S10 in the Supporting
Information), possibly due to the self-quenching of bound drug and/or the result of the
partitioning and entrapment in the hydrophobic pocket generated by the CP-AuNPs.

Evaluation of CP-AuNPs as Molecular Transporters. Cellular Delivery of
Lamivudine. To evaluate [WR]4-AuNPs as DDS, lamivudine ((−)-2′,3′ dideoxy-3′thiacytidine, 3TC), an anti-HIV and anti-HBV nucleoside reverse transcriptase
inhibitor,17 was selected as a cargo drug. To monitor the molecular transport ability of
the CP AuNPs, a carboxyfluorescein derivative of 3TC (F′-3TC, Figure 3A) was
synthesized. 18 SK-OV-3 cells were incubated with F′-3TC in the presence or absence
of carrier [WR]4-AuNPs for 1 h at 37 °C and then treated with trypsin to remove cell
surface-bound drugs. F′-3TC uptake was monitored by fluorescence microscopy,
showing significantly higher fluorescence signals in cells treated with F′-3TC-loaded
[WR]4-AuNPs (Figure 3A) as compared to those treated with controls F′-3TC alone
(Figure S11 in the Supporting Information). Furthermore, nuclear localization of F′3TC was observed as shown by overlapping of green (FITC) and blue (4′,6 diamidino2-phenylindole, DAPI) colors as the result of fluorescence of F′-3TC and stained
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nuclei, respectively (Figure 3A). In a control experiment, the incubation of [WR]4AuNPs alone with CCRFCEM cells and SK-OV-3 cells showed no fluorescence or the
cellular autofluorescence (Figure S12 in the Supporting Information), suggesting that
the enhanced fluorescence signal in the presence of F′-3TC is related to the increased
cellular drug uptake.
Cellular uptake of F′-3TC (5 μM) was examined in CCRF-CEM cells using
fluorescence activated cell sorter (FACS) in the presence or absence of [WR]4 and
[WR]4-AuNPs (25 μM) with trypsin treatment (Figure 3B). FACS showed
significantly higher fluorescence signals in cells treated with F′-3TC-loaded [WR]4AuNPs compared to those treated with F′-3TC alone and F′-3TC-loaded with [WR]4,
suggesting that the uptake of F′-3TC is facilitated by [WR]4 AuNPs. F′-3TC-loaded
[WR]4-AuNPs exhibited approximately 12- and 15-times higher cellular uptake than
that of F′-3TC alone in CCRF-CEM cells (Figure 3B) and SK-OV-3 cells (Figure S13
in the Supporting Information), respectively. F′-3TC-loaded [WR]4-AuNPs (25 μM)
exhibited approximately 2.0-, 2.50-, and 7.5-fold higher cellular uptake than F-3TCloaded linear (WR)4-AuNPs, cyclic [WR]5, and linear (WR)5, respectively (Figure
S14 in the Supporting Information). [WR]4-AuNPs showed minimal fluorescence
intensity in the absence of the fluorescence-labeled compounds as shown with FACS,
suggesting that the increased fluorescence is due to the cellular drug uptake.

Cellular Delivery of Emtricitabine and Stavudine. Furthermore, anti-HIV drugs
2′,3′-dideoxy-5-fluoro-3′-thiacytidine (emtricitabine, FTC) and 2′,3′-didehydro-2′,3′dideoxythymidine (stavudine, d4T) were attached to 5(6)-carboxyfluorescein (FAM)
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through β-alanine to afford fluorescently labeled conjugates F′-FTC and F′-d4T,
respectively.18,19 F′- FTC and F′-d4T showed 12- and 15-times higher cellular uptake
in CCRF-CEM cells, respectively, in the presence of [WR]4-AuNPs, while control
peptide-capped AuNPs did not show significant fluorescence intensity (Figure 4A).
Significantly higher cellular uptake for F′-FTC and F′-d4T in the presence of [WR]4AuNPs than the parent analogs alone was also observed in SK-OV-3 cells (Figure 4B).
Confocal microscopy of F′-d4T in the presence of [WR]4-AuNPs in SK-OV-3 live
cells demonstrated significant cellular delivery, while F′-d4T alone showed minimal
uptake (Figure 4C).

Cellular Delivery of Doxorubicin. Cellular uptake studies of Dox in the presence of
[WR]4 and [WR]4-AuNPs also exhibited slightly higher cellular uptake than Dox after
1 h, but the enhancement was modest since Dox itself has a high inherent cellular
uptake (Figure S15 in the Supporting Information). Confocal microscopy was
employed in order to study the application of [WR]4-AuNPs on the intracellular
retention of Dox in SK-OV-3 cells. Dox is effluxed efficiently within 1 h in ovarian
cancer SK-OV-3 cells. The cells were treated with free Dox (5 μM) and Dox-loaded
[WR]4-AuNPs alone (Figure 6A). The data showed higher Dox retention in the
presence of CP-AuNPs.
These data show that more Dox is retained in cells even after 48 h. Cellular viability
studies showed that when Dox is used in the presence of [WR]4-AuNPs, cyctoxicity
increases in a time-dependent manner. The cytotoxicity of Dox in the presence of
[WR]4-AuNPs is approximately 13% and 15% more than Dox alone after 96 and 120
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h, respectively (Figure 6B). Time-dependent cell proliferation data showed that there
is a time-dependent inhibitory effect on the cell proliferation of SK-OV-3 cells,
suggesting sustained release of Dox. Binding between [WR]4-AuNPs and Dox has a
noncovalent nature, and the release will not be in the same nature of the conversion of
prodrug to the parent drug. These data indicate that [WR]4-AuNPs may have a
prolonged effect possibly due to the sustained intracellular release of Dox. Dox is
possibly trapped between AuNPs and the cyclic peptide and is released in a sustained
pattern. We have been previously shown the binding affinity of Dox with [WR]4 using
isothermal calorimetry.9 Dox (free or encapsulated with [WR]4) was placed inside a
dialysis membrane (molecular weight cut off 250) immersed in PBS (pH 7.4) or HCl
(0.02 N). The dialysis membrane was sampled at predetermined time increments, and
the amount of Dox was determined by UV. Monitoring of in vitro drug release
revealed sustained release for over 10 days. These data indicate that [WR]4 may have
a prolonged effect possibly due to the sustained intracellular release of Dox.
Thus, acute cytotoxicity is not observed immediately even when higher
concentration of Dox is retained intracellularly. [WR]4-AuNPs are composed of
charged (R) and hydrophobic (W) residues and are able to noncovalently entrap or
bind therapeutic molecules for delivery. The peptide portion of the [WR]4-AuNPs is
responsible for binding with the drug.

DISCUSSION
AuNPs are usually synthesized under sometimes harsh conditions in the
presence of Au(III) ions and inorganic (e.g., sodium borohydride, hydrazine) or
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organic (e.g., sodium citrate, ascorbic acid) reducing agents to control the size and
shape of particles. It has been previously reported that AuNPs generated by peptides
exhibited less toxicity compared to chemical methods.13 As described above, [WR]4AuNPs did not show any significant toxicity in SK-OV-3 and CCRF-CEM cancer
cells, and normal human colon myofibroblast (CCD-18Co) cells at a concentration of
≤25 μM. Formed AuNPs are usually stabilized by peptides, proteins, DNA,
surfactants, or carbohydrates.20−23 Traces of remaining reagents are unsuitable for use
in biomedical and cellular uptake studies.24−26 CPAuNPs were generated under mild
reaction conditions using cyclic peptides as reducing and capping agents. The
formation of capped structures was confirmed by TEM showing tryptophan-reduced
AuNPs with a membrane surrounding the synthesized nanostructures.
[WR]4-AuNPs did not exhibit any significant toxicity against normal human
colon myofibroblast (CCD-18Co) cells, human ovarian adenocarcinoma (SK-OV-3),
and human leukemia (CCRF-CEM) cancer cells at a concentration of of ≤25 μM.
Thus, the [WR]n series (n = 3−5) could provide alternative potential noncytotoxic
simultaneous reducing and capping reagents.
Flow cytometry studies showed the cellular uptake of the corresponding
fluorescence-labeled CP-AuNPs to be rapid even after 10 min in CCRF-CEM cells.
Inductively coupled plasma mass spectrometry further confirmed the intracellular
presence of gold after incubation of [WR]4-AuNPs in SK-OV-3 cells. The mechanism
of cellular uptake is under investigation, but it is presumably through cellular uptake
of AuNPs and the interactions of positively charged and hydrophobic residues of the
cell-penetrating peptide9 with the corresponding negatively charged and hydrophobic
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moieties in the phospholipid bilayer. Both the peptide and AuNPs have cellpenetrating properties. We previously reported that the cyclic peptides can act as
nuclear targeting molecular transporters.9 Cyclic peptide-capped AuNPs presented a
new complex system including both AuNPs and the cyclic peptide.
[WR]4-capped AuNPs showed significantly higher cellular delivery of antiviral
drugs versus that of parent drug alone. Flow cytometry studies showed that the cellular
uptake of fluorescence-labeled 3TC, FTC, and d4T was significantly enhanced in
CCRF-CEM and SK-OV-3 cells in the presence of [WR]4-AuNPs. F′-3TC-loaded
[WR]4-AuNPs exhibited approximately 12- and 15-times higher cellular uptake than
that of F′-3TC alone in CCRF-CEM cells and SK-OV-3 cells, respectively. Similarly
F′-FTC and F′-d4T showed 12- and 15-times higher cellular uptake in CCRF-CEM
cells, respectively, in the presence of [WR]4-AuNPs. Thus, biologically active
compounds can be loaded onto AuNPs through noncovalent interactions without any
structural modification to the drug for release. The presence of tryptophan makes an
appropriate hydrophobic cavity for loading different drugs. The interactions between
drugs and [WR]4 and AuNPs containing hydrophobic pockets have been previously
reported.9,27,28
Confocal microscopy revealed that the presence of the [WR]4-AuNPs enhances
the retention of Dox in SK-OV-3 cells after 24 h. Our previous report showed that
there are intermolecular interactions between the cyclic peptide and drugs, including
Dox as shown by isothermal titration calorimetry.9 The peptide portion of the [WR]4AuNPs is responsible for binding with the drug. UV titration analysis of [WR]4 and
Dox also confirmed the complex formation. The cyclic peptide forms a complex with
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Dox possibly through intermolecular noncovalent interactions. We assume that there is
interaction through entrapment of the drug in the hydrophobic pocket part of this
complex due to the available tryptophan.

CONCLUSIONS
In summary, CP-AuNPs containing tryptophan and arginine residues were
generated under a mild reaction condition without any surface functionalization of
gold. To the best of our knowledge this is the first study for designing AuNPs using
cyclic peptides as both reducing and capping agents. CP-AuNPs offered several
advantages including low cytotoxicity, hydrophobic drug entrapment through
noncovalent interactions, and improving cellular uptake by both cell-penetrating cyclic
peptide and AuNPs. CP-AuNPs were able to act as molecular transporters of
fluorescence-labeled lamivudine, emtricitabine, and stavudine intracellularly and to
improve the Dox intracellular retention. High cellular internalization of the labeled
drugs and retention of Dox by [WR]4-AuNP suggest the potential application of CPAuNPs as molecular transporters and for generation of noncovalent prodrugs. The
peptide nature of CP-AuNPs should make this system highly amenable to targeting
strategies.
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Figure Legends:

Figure 1: (A) Chemical structures of synthesized peptides. A = alanine, E = glutamic
acid, F = phenylalanine, K = lysine, L = leucine, R = arginine, W = tryptophan. (B)
UV– Vis absorption spectra of HAuCl4 and/or AuNP formation in the presence of
cyclic peptides (1 mM), [WR]n (n = 3−5), linear (WR)4, and [WE]4 (1 mM)
Figure 2: (A) Cellular uptake of F′-[W5R4K]-capped AuNP compared with FAM (10
μM) in CCRF-CEM cells. (B) Rapid uptake of F′-[W5R4K]-AuNPs versus FAM (10
μM) in CCRF-CEM cells (FACS) (mean ± SD)
Figure 3: (A) Differential interference contrast microscopy of fluorescence-labeled
lamivudine (F′-3TC) (5 μM) in the presence of [WR]4-AuNP (25 μM) in SK-OV-3
cells. (B) Flow cytometry studies for F′-3TC (5 μM) in the presence or absence of
[WR]4 or [WR]4-AuNPs (25 μM) in CCRF-CEM cells (mean ± SD, n = 3)
Figure 4: Flow cytometry studies in (A) CCRF-CEM and (B) SK-OV-3 cells for
fluorescence-labeled FTC and fluorescence-labeled d4T alone (5 μM) and in the
presence or absence of [WR]4 (25 μM) or [WR]4-AuNPs (25 μM) after 1 h (mean ±
SD). (C) Confocal microscopy of F′-d4T (5 μM) uptake in the presence of [WR]4AuNPs (25 μM) in SK-OV-3 cells (live cells)
Figure 5: Confocal microscopy images of Dox (5 μM) and [WR]4-AuNPs (25 μM)
uptake in SK-OV-3 cells. SK-OV-3 cells treated with drug for 1 h. The compound was
removed, and the cells were incubated with complete medium for 24 h. Red represents
fluorescence of Dox
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Figure 6: (A) Flow cytometry studies in SK-OV-3 cells for Dox alone (5 μM) and in
the presence of [WR]4 (25 μM) or [WR]4-AuNPs (25 μM) for 1 h (mean ± SD). The
compound was removed, and the cells were incubated with complete medium for 48 h.
(B) Cytotoxicity assay of Dox (5 μM) in the absence and presence of [WR]4-AuNP
(25 μM) in SK-OV-3 cells (24−120 h) (mean ± SD)
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ABSTRACT
Gold nanoparticles (AuNPs) were synthesized in situ in a green and rapid method
from the reaction of reducing linear and cyclic peptides containing tryptophan and
lysine residues, (KW)5 and cyclic [KW]5, with an aqueous solution of HAuCl4 and
were evaluated as cellular nanodrug delivery systems. The cyclic or linear nature of
the peptide was found to determine the morphology and size of the formed peptideAuNPs and their in vitro molecular transporting efficiency. While cyclic [KW]5AuNPs formed sponge-like agglomerates, linear (KW)5-AuNPs demonstrated ballshaped structures. A comparative flow cytometry study showed that the cellular
uptake of fluorescence-labeled anti-HIV drugs (emtricitabine (FTC) and lamivudine
(3TC)) in human Leukemia (CCRF-CEM) cells, and a negatively charged cellimpermeable phosphopeptide (GpYEEI) in human ovarian adecarcinoma (SK-OV-3)
cells was significantly higher in the presence of cyclic [KW]5-AuNPs than that of
linear (KW)5-AuNPs, parent cyclic [KW]5, and linear (KW)5 peptides. For example,
the cellular uptake of F-GpYEEI was enhanced 12.8-fold by c[KW]5-AuNPs.
Confocal microscopy revealed the localization of fluorescence-labeled-3TC in the
presence of c[KW]5-AuNPs mostly in nucleus in SK-OV-3 cells after 1 h. On the other
hand, l(KW)5-AuNPs delivered fluorescence-labeled-3TC in cytoplasm. These data
suggest that non-cell penetrating peptides can be converted to efficient molecular
transporters through peptide-capped AuNPs formation.

Keywords: cellular uptake, cyclic peptide, drug delivery, gold nanoparticles, lysine,
nuclear targeting, tryptophan

128

INTRODUCTION
The cellular delivery of hydrophobic and poorly water-soluble compounds to
enhance the efficacy using Drug delivery systems (DDS) is a subject of major
interest.1 Among all delivery systems, nuclear targeting nanodrug delivery systems
(nano-DDS) have attracted significant attention. Common approaches in gene therapy
involve using DNA as a pharmaceutical agent to replace or correct a mutated gene.2
Moreover, the nucleus is a target for a diverse number of anticancer and antiviral
drugs,3 due to the presence of the genetic information and transcription systems.
The nuclear membrane (envelope) is composed of a double lipid bilayer that
works as a physical barrier between cell nucleus content and the cytoplasm. The
nuclear membrane contains many nuclear pore complexes (NPCs) that facilitate and
regulate the exchange of proteins and RNA between the cell nucleus and the
cytoplasm. Depending on the cell line, NPCs have different sizes from 20 to 60 nm.4
Although NPCs operate as available passages for all exchange between the
nucleoplasm and cytoplasm, they can be exploited as pathways for nanoparticle
delivery.5,6 Therefore, the delivery of the therapeutic agents to the nucleus by using
nano-DDS offers several advantages compared to other systems.
The application of prodrug strategy among researchers is now well established.
Prodrugs are chemically modified analogs of the active metabolite that can improve
pharmacokinetics and pharmacodynamic (PK/PD) properties of the active drug.
However, intracellular chemical transformation needed to be occurred in the presence
of different enzymes to convert prodrugs to their corresponding pharmacologically
potent compounds in in vivo systems. Prodrug approach offers several advantageous,
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such as enhancing water solubility, improved chemical stability, decreased toxicity,
and insufficient brain penetration.7
Gold nanoparticles (AuNPs) have received an increased attention due to their
unique potential use as nano-DDS.8 Most of the known AuNPs as nano-DDS lead to
the intracellular localization of nanoparticles mainly in the cytoplasm.9 However,
appropriate functionalization of AuNPs with other compounds can be used for their
optimization as nano-DDS for a specific application.
Peptide-mediated drug delivery has been widely used for a broad range of
cargo molecules including drugs, siRNA, and genes due to their versatility and the
presence of a wide range of amino acids.10 Thus, the peptides have the potential to be
used for decoration of the surface of metal nanoparticles. Recently, AuNPs
functionalized by peptides have been used as biocompatible systems in drug
delivery.11 For example, AuNPs capped by linear Tat was reported to be able to get
internalized into the cytoplasm of 3T3 and HepG2 cells.11c
After the localization of DDS in the destination, it should release the cargo.
Thus, drug loading and release issues are critical for optimized DDS function. Two
major strategies for drug loading include covalent and non-covalent binding between
AuNPs and drugs.12 Non-covalent loading offers two main advantages, including ease
of the drug loading and facilitating drug release in intact form over covalent loading.13
Thus, the entrapment of unmodified drugs into functionalized AuNPs through noncovalent interaction is introduced as one of the prodrug strategies for the delivery of a
broad range of drugs. Employing appropriate surface functionalization provides a
hydrophobic pocket for the loading of drugs.
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We have previously reported cyclic peptides containing alternative arginine
(R) and tryptophan (W) as efficient molecular transporters that showed improving the
cellular uptake of different cargos.14 Subsequently, it was found that a physical
mixture of the cell-penetrating cyclic peptide [WR]4 and HAuCl4 led to the formation
of peptide-capped gold nanoparticles (P-AuNPs) and enhanced the cellular uptake of
drugs significantly.15 It remains to be determined whether non-cell penetrating
peptides can be converted to a nuclear targeting DDS through generation of peptideAuNPs.
Herein, we report the generation of a novel nuclear-targeting nano-DDS
containing AuNPs and a non-cell penetrating peptide containing alternative lysine and
tryptophan residues. The presence of these amino acids was found to be appropriate to
generate in situ biocompatible AuNPs. To the best of our knowledge, this is the first
report of converting a non-cell penetrating peptide to an efficient nuclear targeting
nano-DDS through cyclic peptide-capped AuNPs formation.

EXPERIMENTAL SECTION
General
All reactions were carried out in Bio-Rad polypropylene columns by shaking
and mixing using either a Glass-Col small tube rotator or PS3 automated peptide
synthesizer in dry conditions at room temperature unless otherwise stated. In general,
all cyclic and linear peptides were synthesized by the solid-phase synthesis strategy
employing N-(9-fluorenyl)methoxycarbonyl (Fmoc)-based chemistry and Fmoc-Lamino acid building blocks. 2-(1HBenzotriazole-1-yl)-1,1,3,3-tetramethyluronium
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hexafluorophosphate (HBTU) and N,N-diisopropylethylamine (DIPEA) in N,Ndimethylformamide (DMF) were used as coupling and activating reagents,
respectively. 2-Chlorotrityl chloride resin, Fmoc-amino acid trityl chloride resins,
coupling reagents, and Fmoc-amino acid building blocks were purchased from
Chempep (Miami, FL). Other chemicals and reagents were purchased from SigmaAldrich Chemical Co. (Milwaukee, WI). Fmoc deprotection at each step was carried
out using piperidine in DMF (20%). Side chain protected peptides were cleaved from
the resins by shaking the resins with a mixture of trifluoroethanol (TFE)/acetic
acid/dichloromethane (DCM) (1:2:7 v/v/v, 15 ml) for 2 h. The resins were filtered off,
and the liquid was evaporated to dryness to get side-chain protected linear peptide.
Generally, the cyclization of the peptides was carried out in the presence of a mixture
of 1-hydroxy-7-azabenzotriazole (HOAt) and N,N′-diisopropylcarbodiimide (DIC) in
dry DMF and dry dichloromethane (DCM) for 24 h. DMF and DCM were evaporated.
The side chain deprotection was carried with TFA/thioanisole/anisole/1,2ethanedithiol (EDT) (90:5:2:3 v/v/v/v) for 2 h. The crude peptides were precipitated
by the addition of cold diethyl ether (Et2O) and were purified by using a reversedphase Hitachi HPLC (L-2455) on a Phenomenex Prodigy 10 μm ODS reversed-phase
column (2.1 cm × 25 cm) and a gradient system. The peptides were separated by
eluting the crude peptides at 10.0 mL/min using a gradient of 0-100% acetonitrile
(0.1% TFA) and water (0.1% TFA) over 60 min, and then were lyophilized to yield
cyclic peptides (Figure 1). The purity of final products (95%) was confirmed by
analytical HPLC. The analytical HPLC was performed on a Hitachi analytical HPLC
system using a C18 Shimadzu Premier 3 μm column (150 cm × 4.6 mm) and a
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gradient system (water/CH3CN), and a flow rate of 1 mL/min with detection at 220
nm. The chemical structures of final products were confirmed by high-resolution
MALDI AXIMA performance TOF/TOF mass spectrometer (Shimadzu Biotech) or a
high-resolution Biosystems QStar Elite time-of-flight electrospray mass spectrometer.
As a representative example, the synthesis of linear (KW)4 is outlined here.

Synthesis of Linear (KW)4 and Linear (KW)5. Fmoc-Trp(Boc)-Wang resin (555 mg,
0.54 mmol/g, 0.3 mmol) was swelled in anhydrous DMF for about 15 min under dry
nitrogen. The excess of the solvent was filtered off. The swelling and filtration steps
were repeated for 2 more times before the coupling reactions. Fmoc-Lys(Boc)-OH
(325 mg, 0.75 mmol) was coupled to the N-terminal of tryptophan Wang resin in the
presence of HBTU (285 mg, 0.75 mmol) and DIPEA (262 μL, 1.50 mmol) in DMF (7
mL) by mixing for 1.5 h. After the coupling was completed, the reaction solution was
filtered off, and the resin was collected by filtration and washed with DMF (7 × 15
mL), followed by N-terminal Fmoc deprotection using piperidine in DMF (20% v/v,
10 mL, 2 times, 5 and 10 min). The resin was washed with DMF (7 × 15 mL). The
subsequent amino acids, Fmoc-Trp(Boc)-OH (395 mg, 0.75 mmol) and FmocLys(Boc)-OH (325 mg, 0.75 mmol), were coupled alternatively three times,
respectively, in a similar manner (Scheme S2). Fmoc-deprotection at the N-terminal
was carried out in the presence of piperidine in DMF (20% v/v, 10 mL, 2 × 10 min) to
afford the linear peptide on solid phase. The resin was washed with DMF and DCM
respectively (each 2 × 25 mL). The resins were dried under vacuum for 24 h. Fresh
cleavage cocktail, reagent R, TFA/thioanisole/ EDT/anisole (90:5:3:2 v/v/v/v, 10 mL),
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was added to the resins. The mixture was shaken at room temperature for 2 h. The
resin was collected by filtration and washed with another 2 mL of cleavage cocktail.
Combined filtrates were evaporated to a minimum volume under dry nitrogen. The
crude peptide was precipitated by the addition of cold diethyl ether (75 mL, Et2O),
lyophilized, and purified by reversed-phase Hitachi HPLC (L-2455) on a Phenomenex
Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system
as described above to yield linear (KW)4. MALDI-TOF (m/z) [C68H90N16O9]: calcd,
1274.7077; found, 1275.1780 [M + H]+, 1297.1747 [M + Na]+. A simliar procedure
was performed for the synthesis of the linear (KW)5. l(KW)5: MALDI-TOF (m/z)
[C85H112N20O11]: calcd, 1588.8819; found, 1589.7442 [M + H]+, 1611.7890 [M +
Na]+, 1627.7601 [M + K]+.

Synthesis of Cyclic Peptides. The synthesis of cyclic peptides was carried out
according to the previously reported procedure.14,16 As a representative example, the
synthesis of cyclic [KW]4 is described here.

Cyclic [KW]4. The linear protected peptide (KWKWKWKW) was assembled on the
H-Trp(Boc)-2-chlorotrityl chloride resin (975 mg, 0.41 mmol/g) in 0.40 mmol scale as
described above. After the final deprotection of the N-terminal Fmoc group by
piperidine in DMF (20% v/v, 15 mL, 2 times, 5 and 10 min), the side chain protected
peptide was cleaved from assembled trityl resin in the presence of the cleavage
cocktail TFE/acetic acid/DCM (1:2:7 v/v/v, 50 mL) by shaking for 1 h at room
temperature to yield the side chain protected linear peptide. The filtrates were
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evaporated to dryness under reduced pressure. To the residue was added hexane (2 ×
25 mL) and DCM (1 × 25 mL) to remove the acetic acid from the mixture and to
solidify the crude material as white solid. The crude protected peptide was dried under
vacuum overnight. Examining a small portion of the crude by MALDI analysis
confirmed the formation of the linear protected peptide. Thus, the crude was used
directly for the cyclization reaction. The dried crude linear protected peptide was
dissolved in DMF/DCM (2:1 v/v, 150 mL). HOAt (135 mg, 1 mmol) and DIC (137
μL, 0.88 mmol) were added to the mixture, and the solution was stirred for 12 h under
the nitrogen atmosphere. After completion of the cyclization as confirmed by the
MALDI-TOF, the solvents were removed under reduced pressure on a rotary
evaporator. The crude product was dried overnight in vacuum before the final
cleavage. Freshly prepared cleavage cocktail, reagent R, TFA/thioanisole/EDT/anisole
(90:5:3:2 v/v/v/v, 15 mL) was added to the crude product. The mixture was stirred at
room temperature for 2 h. The cleavage cocktail was concentrated to a minimum
volume under reduced pressure by a rotary evaporator. After precipitation of crude
peptide in cold diethyl ether (75 mL, Et2O) and centrifugation, the crude peptide was
lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) on a Phenomenex
Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system
to yield cyclic [KW]4. A similar procedure was employed for the synthesis of other
cyclic peptides by using appropriate resins and protected amino acids. The mass
spectra data for c[KW]5, c[KF]4, c[KA]4, c[RFEF]2, and c[KE]4 have been previously
reported by us.16
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c[KW]4: MALDI-TOF (m/z) [C68H88N16O8]: calcd, 1256.6971; found, 1257.2083 [M
+ H]+, 1281.2555 [M + H + Na]+, 1295.2420 [M + K]+; C[EL]4: HR-MS (ESI-TOF)
(m/z): C44H72N8O16 calcd, 968.5066 ; found, 969.4220 [M + H]+, 485.2551 [M +
2H]2+; C[RF]4: HR-MS (ESI-TOF) (m/z): C60H84N20O8: calcd, 1212.6781; found,
1212.6052 [M + H]+, 607.3026 [M + 2H]2+, 405.5428 [M+ 3H]3+, 304.1588 [M +
4H]4+; C[RC]4: HR-MS (ESI-TOF) (m/z): C36H68N20O8S4 calcd, 1036.4412; found,
1037.4096 [M + H]+, 345.1323 [M + 3H]3+, 259.1024 [M + 4H]4+.

Synthesis of Fluorescence Labeled-A-Cyclic[KWKWKWKWKW] (F-[KW]5).
The linear peptide (Dde-K(Fmoc)-WKWKWKWKW) was assembled on solid phase
using Fmoc/tBu solid phase methodology. Appropriately protected amino acids were
assembled on H-Trp(Boc)-2 chlorotrityl resin (513 mg, 0.40 mmol, 0.78 mmol/g)
according to the solid-phase synthesis strategy described above. Dde-Lys(Fmoc)-OH
was used at the N-terminal of the peptide. The Fmoc protecting group was removed
from the side chain of lysine using piperidine in DMF (20%, 10 mL, 2 times, 5 and 10
min) and a short linker Fmoc-β-alanine (312 mg, 1 mmol) was coupled with the
unprotected side chain amine group of lysine using HBTU/DIPEA (380 mg, 1
mmol/349 uL, 2 mmol) in DMF (8 mL). Fmoc of β-alanine was removed in the
presence of piperidine in DMF (20%, 10 mL, 2 times, 5 and 10 min) to attach
carboxyfluorescein. 5(6)-Carboxyfluorescein diisobutyrate (CFDI, US Biological)
(516 mg, 1 mmol) was used for labeling the peptide. This was achieved by adding
resin-bound linear peptide (0.4 mmol) into a solution of CFDI (516 mg, 1 mmol),
azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP,
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520 mg, 1 mmol), HOAT (135 mg, 1 mmol), and DIPEA (350 μL, 2 mmol) in dry
DMF (12.0 mL). The mixture was shaken for 3 h at room temperature and then the
solvents were filtered off. The resin was washed with DMF (3  10 mL). The ester
group of carboxyfluorescein was deprotected with 20% piperidine (20 mL) for 30 min.
The N-terminal Dde protection was deprotected by treating the resin-bound peptide
with hydrazine hydrate in DMF (2% v/v, 20 mL, 2 × 5 min). Finally, the side chain
protected peptide was cleaved from the resin by shaking the resins with a mixture of
TFE/acetic acid/DCM (15 mL, 1:2:7 v/v/v) for 1 h. The resin was filtered off, and the
solution was evaporated to dryness under reduced pressure to yield side-chain
protected linear peptide. The cyclization and purification was carried out according the
described general method above used for other cyclic peptides to yield fluorescencelabeled cyclic [KW]5. MALDI-TOF (m/z) [C109H127N21O17]: calcd, 2001.9719; found,
2000.9316 [M]+, 2023.0032 [M + Na]+, 2038.9458[M + K]+.

Synthesis of Fluorescence Labeled-A-Linear(KWKWKWKWKW) (F-(KW)5).
The labeled linear sequence was assembled on H-Trp(Boc)-2 chlorotrityl resin (513
mg, 0.40 mmol, 0.78 mmol/g). The synthesis of the fluorescence-labeled side chainprotected linear peptide was carried out according to the similar procedure that
described above. The peptide was assembled on resin using Dde-Lys(Fmoc)-OH at Nterminal. The Fmoc was removed in the presence of piperidine (20%, DMF). After the
coupling of -alanine and carboxyfluorscein in the side chain, the Dde protection at
the N-terminal was removed by reacting with 2% hydrazine hydrate in DMF followed
by washing with DMF. Then, the linear peptide was removed from the resin by using
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TFA/thioanisole/anisole/EDT (15 mL, 90:5:2:3 v/v/v/v) for 2 h to obtain the crude
product. The crude peptide was precipitated by the addition of cold diethyl ether (75
mL, Et2O). Reversed-phase Hitachi HPLC (L-2455) and the gradient system described
above were used for the purification of the peptide. MALDI-TOF (m/z)
[C109H129N21O18]: calcd, 2019.9824; found, 2019.8717 [M]+, 2042.8717 [M + Na]+,
2058.8717 [M + K]+.

HAuCl4 Reduction by Peptides Dissolved in DMSO/Water Mixtures. The peptides
were dissolved in 1 mL of deionized water in order to prepare a stock solution of 1
mM. The stock solution (1 mL, 1 mM) was physically mixed with HAuCl 4 solution (1
mL, 1 mM) in deionized water to obtain AuNPs. The final concentrations of gold and
peptides were 500 μM. The formation of purple AuNPs was observed by the apparent
change in the color of solution and confirmed by UV-Vis spectroscopy.

UV-Vis Spectroscopy Studies. The formation of P-AuNPs was studied in the
presence of different peptides. In general, a peptide stock solution (1 mM) was mixed
with an aqueous solution of HAuCl4 (1 mM) at room temperature. The color of
solution turned red after 1 h due to the formation of peptide capped-AuNPs. UV-Vis
spectroscopy study was carried out using HAuCl4 (1 mM) and different cyclic peptides
(1 mM) using 96-well plate, and the absorbance was read using SpectraMax M2
spectrophotometer (Molecular Devices, CA) (Figure S16). The visible range was
chosen because of the characteristic maxima peak of AuNPs appeared around 520-560
nm. All experiments were performed in triplicate.
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Encapsulation of Camptothecin (CPT). CPT was dissolved in DMSO, and 10 µL of
10-3 M camptothecin solution was mixed with 100 µL of 10-4 M aqueous peptide
solution in a 1:1 molar ratio. CPT in DMSO was mixed with water as a negative
control. Mixed solution was incubated in a 96 well plate at room temperature for 4 h.
Fluorescence of the solution was measured using SpectraMax M2 fluorescence
spectrophotometer (Molecular Devices, CA) with excitation at 290 nm and emission at
360 nm.

Drug Loading. Doxorubicin (Dox) aqueous solution (100 μL, 100 μM) was added
into [KW]5-AuNPs solution (900 μL, 500 μM) with the concentration ratio of 1:5 for
Dox to peptide-capped AuNPs. The mixture was transferred into a 1 mL dialysis
membrane (with the cutoff molecular weight 1000 D; Float-A-Lyzer G2, Spectrum
Labs). The membrane was sealed and submerged into water (500 mL) as a medium.
After stirring in dark for 24 h, unloaded Dox in the mixture was collected and
evaporated to reduce the volume. The concentration of Dox was measured using a
reverse phase HPLC system installed with Hitachi premier C18 column (3 m, 4.6 x
150 mm) at UV/Vis 490 nm wavelength. Mobile phases were water (0.1%
trifluoroacetic acid) and acetronitrile (0.1% trifluoroacetic acid). The gradient of 10%
to 90% acetonitrile was applied to separate the Dox peak from other impurities. The
calibration standard solutions were injected to quantify Dox in the sample solution.
The loading efficiency was calculated using the following equation:
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To measure the loading capacity, the amount of the AuNPs in the dialysis membrane
was measured after 24 h by using ICP-MS. The ICP-MS results showed the amount of
AuNPs were responsible for the encapsulation of Dox. Thus, the loading capacity was
calculated based on the following equation.

Transmission Electron Microscopy (TEM). TEM analyses were conducted in JEOL
Transmission Electron Microscope (Tokyo, Japan) at an accelerating voltage 80 keV.
The stock solution (1 mL, 1 mM) was physically mixed with HAuCl4 solution (1 mL,
1 mM) in deionized water to obtain AuNPs. The final concentrations of gold and
peptides were 500 μM. The mixture was incubated for 12 days. TEM samples of
c[KW]5-AuNPs and l(KW)5-AuNPs were prepared by depositing a droplet of 5 μL of
0.5 mM solution in H2O on a carbon-coated Cu support grid of mesh size 300 that
were dried in air overnight.

Cell Culture. Human leukemia cell line CCRF-CEM (ATCC no. CCL-119), ovarian
carcinoma SK-OV-3 (ATCC no HTB-77), and colon myofibroblasts CCD-18Co
(ATCC no. CRL-1459) were obtained from American Type Culture Collection. Cells
were grown on 75 cm2 cell culture flasks with RPMI-16 medium (for leukemia cells)
and EMEM medium (for SK-OV-3 and CCD-18Co cells), supplemented with 10%
fetal bovine serum (FBS), and 1% penicillin-streptomycin solution (10,000 units of
penicillin and 10 mg of streptomycin in 0.9 % NaCl) in a humidified atmosphere of
5% CO2, 95% air at 37 ºC.
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Cytotoxicity Assay. SK-OV-3, CCRF-CEM, and CCD-18Co cells were seeded at
5,000 cells, 30,000 cells, and 3,000 cells, respectively, in 0.1 ml per well in 96-well
plates 24 h prior to the experiment. The old medium (EMEM containing FBS (10%))
was replaced (not in case of CCRF-CEM) by different concentrations of c[KW]5,
l(KW)5, c[KW]5-AuNPs or l(KW)5-AuNPs in serum containing medium and
incubated for 24 h (or 72 h) at 37 °C in a humidified atmosphere of 5% CO2. Cell
viability was then determined by measuring the fluorescence intensity at 490 nm using
a SpectraMax M2 microplate spectrophotometer. The percentage of cell survival was
calculated as [(OD value of cells treated with the test mixture of compounds) − (OD
value of culture medium)]/[(OD value of control cells) − (OD value of culture
medium)] × 100% (Figure S17).

Flow Cytometry Studies. Human leukemia and ovarian carcinoma cells (CCRFCEM and SK-OV-3) were taken in 6-well plates (1 × 107 cells/well (CCERF-CEM)
and 3 × 105 cells/well (SK-OV-3)) in opti-MEM. Then the fluorescence-labeled
compound (F′-3TC, F′-FTC, or F′-GpYEEI) (5 µM) was added to the different wells
containing c[KW]5-AuNPs (25 M), l(KW)5-AuNPs (25 M), l(KW)5 (25 M), or
c[KW]5 (25 M) in serum-free media. The plates were incubated for 1 h at 37 C.
Cells, P-AuNPs, and the fluorescence-labeled compound alone were used as negative
controls. After 1 h incubation, the media containing the peptide was removed. The
cells were digested with 0.25% trypsin/EDTA (0.53 mM) for 5 min to remove any
artificial surface binding. Then the cells were washed twice with PBS. Finally, the
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cells were resuspended in flow cytometry buffer and analyzed by flow cytometry
(FACSCalibur™:Becton Dickinson) using FITC channel and CellQuest software. The
data presented were based on the mean fluorescence signal for 10,000 cells collected.
All assays were performed in triplicate.
In the case of fluorescence-labeled peptide gold nanoparticles (F′-Peptide-AuNPs) and
their corresponding peptides (F′-Peptide), SK-OV-3 cells were seeded in 6-well plates
(3 × 105 cells/well) in opti-MEM. The F′-labeled compound (F′-c[KW]5, F′-l(KW)5,
F′-c[KW]5-AuNPs, or F′-l(KW)5-AuNPs (5 μM) was added to the various wells. The
plates were incubated for 1 h at 37 °C. Wells containing no treatment and 5-(6)
carboxyfluorescein (FAM) were used as negative controls. After 1 h incubation, the
medium was removed. The cells were digested with 0.25% trypsin/EDTA (0.53 mM)
for 5 min to remove any artificial surface association and to detect only intracellular
uptake. Then the cells were washed twice with PBS. Finally, the cells were
resuspended in flow cytometry buffer and analyzed by flow cytometry (FACSCalibur:
Becton Dickinson) using FL2 channel and CellQuest software. The data presented are
based on the mean fluorescence signal for 10,000 cells collected. All assays were
performed in triplicate.

Cellular Uptake Studies in the Presence of Inhibitors. Human ovarian
adenocarcinoma cells (SK-OV-3) were seeded in six well plates (3 × 105 cells/well) in
opti-MEM. The cells were pre-incubated by various inhibitors including, nystatin (50
µg/ml), chloroquine (100 µM), chlorpromazine (30 µM), methyl-β-cyclodextrin (2.5
mM), and 5-(N-ethyl-N-isopropyl)amiloride (EIA, 50 µM) for 30 min. The treatment
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was removed, and the cells were incubated with F-l(KW)5-AuNPs or F-c[KW]5AuNPs (5 μM) a similar concentration of inhibitors for 1 h. Consequently, similar
FACS protocol was performed as described above.

Membrane Integrity Test. Ovarian carcinoma cells SK-OV-3 were grown in six well
plates (1 × 105 cells/ well). Cells were treated with [KW]5-AuNPs (50 μM) and
(KW)5-AuNPs (50 μM) in serum-free media for 1 h at 37 ⁰C. After 1 h incubation, the
cells were detached with trypsinization for 5 min followed by washing twice with
PBS. Then they were resuspended in serum-free media. Trypan blue (2 μL) was added
into the cell suspension (18 μL) and incubated for 5 min. Finally, trypan blue-stained
cells were counted using cellometer vision (Nexcelom Bioscience, Lawrence, MA,
USA) (Figure S18).

Confocal Microscopy on Live Cells. Adherent SK-OV-3 cells were seeded with
EMEM media overnight on coverslips in six well plates (1×105 cells per well). Then,
the media were removed and washed with opti-MEM. The cells were treated with the
mixture of F′-3TC (5 µM) and c[KW]5-AuNPs (25 M), and the mixture of F′-3TC (5
µM) and l(KW)5-AuNPs (25 M) in opti-MEM for 1 h at 37 ºC. After 1 h incubation,
the media containing the treatments were removed followed by washing with PBS
three times. To stain the nuclei, cells were incubated with 4,6-diamidino-2phenylindole (DAPI, 0.5 mL) solution in PBS for 5 min. After the incubation, the cells
were softly washed twice with PBS to remove the excessive DAPI. The coverslips
were mounted on a microscope slide with mounting media with cells-attached side
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facing down. Laser scanning confocal microscopy was carried out using Carl Zeiss
LSM 700 system. The cells were imaged using FITC and phase contrast channels. The
fluorescence images were taken under 20 × objective. Blue and green luminescent
emissions from DAPI and FITC were excited at the wavelength of 405 nm and 488
nm, respectively. The emission wavelengths were ranged from 425 nm to 475 nm for
DAPI and 500 nm to 550 nm for FITC. There was no interference between these two
channels. The scanning mode was in sequential frame.

Time-Dependent Antiproliferative Assay. The antiproliferative activity of CPT
alone and in the presence of c[KW]5-AuNPs against SK-OV-3 cells was determined
by MTS assay. All cells were plated overnight in 96-well plates with a density of 5000
cells per well in 0.1 mL of appropriate growth medium at 37 °C. CPT alone (5 μM) or
a combination of CPT (5 μM) and c[KW]5-AuNPs (25 μM) were incubated with the
cells for 4 h. Excess of compounds was removed and washed by fresh media. The cells
were kept in an incubator for 24−72 h. The cells without compounds were included in
each experiment as controls. After 24 h, 48 h, and 72 h incubation, 20 μL of MTS
solution was added and incubated for 2 h. The absorbance of the formazan product
was measured at 490 nm using microplate reader. The percentage of cell viability was
calculated as (OD value of untreated cells - OD value of treated cells)/OD value of
untreated cells × 100%.

Intracellular Release of Dox. Intracellular release and accumulation of Dox were
determined in CCRF-CEM cells by HPLC analysis. CCRF-CEM cells were grown in
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75 cm2 culture flasks with RPMI medium (containing 10% FBS and 1% penicillinstreptomycin) to achieve ∼70−80% confluence (1.2 × 107 cells/mL). The cells were
partitioned/transferred to culture plates (six well) having 1.2 × 107 cells per well in 2
mL of medium. The treatment in fresh RPMI medium containing Dox-loaded c[KW]5AuNPs (7.5/37.5 μM) was added to cells, and they were incubated at 37 °C for
different incubation times including 2, 12, 24, and 48 h. After the incubation time, the
cells were collected by centrifugation. The medium was removed and cell pellets were
washed with ice-cold PBS (5 mL) twice to remove any medium. The cell pellets were
thoroughly extracted with an equal volume of methanol, chloroform, and isopropanol
mixture (4:3:1 v/v/v) and filtered through 0.2 μm filters. The solvents were evaporated
under N2 gas. The released Dox was quantified by reverse phase HPLC system with
UV/Vis detector (490 nm) (Figures S4-S9, Supporting Information). The HPLC
condition was using mobile phase water (0.1% trifluoroacetic acid) and acetronitrile
(0.1% trifluoroacetic acid) and the gradient of 10% to 90% acetonitrile as described
above in drug loading section.

RESULTS AND DISCUSSION
Chemistry
A number of cyclic octapeptides containing diverse combination of amino
acids including c[KW]4, c[KF]4, c[KA]4, c[EL]4, c[RFEF]2, c[EK]4, c[RF]4, and
c[RC]4 (Figure S16) were synthesized by employing 9-fluorenylmethyoxycarbonyl
(Fmoc)-based chemistry according to the previously reported procedure.14,16 Synthesis
of c[KW]4 and l[KW]4 is described in Supporting Information (Schemes S1 and S2).
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Fluorescently-labeled conjugates of linear (KW)5 and cyclic [KW]5 were synthesized
as described previously.14 For example, F-l(KW)5 was synthesized by the Fmoc
protection group at the N-terminal was removed. Subsequent conjugation reaction with
5(6)-carboxyfluorescein isobutyrate was performed in the presence of HOAt, PyAOP,
and N,N-diisopropylethylamine (DIPEA) in DMF:DCM followed by deprotection and
cleavage from the resin in the presence of reagent R afforded the crude product that
was purified by preparative reversed-phase HPLC (Scheme S2). The structures of all
the final compounds were confirmed by high-resolution MALDI TOF/TOF and/or
high-resolution electrospray mass spectrometry.

Evaluation of Cyclic and Linear Peptides for Generation of Peptide-AuNPs and
Characterization
All peptides were examined for their ability to generate AuNPs by direct
addition of the peptide solution (1 mM) into an aqueous solution of HAuCl 4 (1 mM) at
room temperature. UV-Vis spectra and monitoring of surface plasmon resonance peak
at ~550 nm showed that among all peptides, c[KW]4 and the corresponding linear
peptide l(KW)4 were able to produce peptide capped AuNPs (P-AuNPs) (Figure S16).
Mechanistically, c[KW]4 acts as reducing and capping agent, making this method a
one-step (one-pot) reaction without any need for chemical modification on the surface
of AuNPs. Amino acids have been used as reducing agents. Among them, tryptophan
(W) has been shown to be the most efficient reducing agents among 20 amino acids.17
Addition of positively charged residues, such as lysine (K) in the structure of the
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peptide enhances the reduction through the favorable charge interactions with the
chloroaurate anions.18
To optimize the yield of P-AuNPs by increasing the reducing and capping efficiency
of the peptide, cyclic c[KW]5 containing ten alternative tryptophan and lysine (Figure
1) was synthesized. The corresponding linear peptide l(KW)5 (Figure 1) was also
designed and synthesized to determine the effect of the peptide cyclic nature of the
peptide on the shape and size of P-AuNPs. UV-Vis spectra of both c[KW]5-AuNPs
and l(KW)5-AuNPs showed also a SPR peak at approximately 550 nm.
Further studies were conducted by Transmission electron microscopy (TEM) to
characterize the size and shape of P-AuNPs. TEM images of c[KW]5-AuNPs and
l(KW)5-AuNPs showed that these two systems formed entirely different nanosized
structure. c[KW]5-AuNPs formed sponge-like agglomerates containing peptide and
AuNPs containing peptide and AuNPs with an approximate diameter size of 250-450
nm (Figure 2) along with some isolated AuNPs in mostly spherical and triangular
shapes (6-60 nm). Compared to cyclic peptide-capped AuNPs, TEM images of
l(KW)5-AuNPs demonstrated ball-shaped structures with the approximate diameter
size of 900-1000 nm composed of a large number of AuNPs (Figure 3). The majority
of individual l(KW)5-AuNPs were found to be spherical and approximately in the size
range of 4-35 nm. The distribution pattern of AuNPs in the ball-shape structure of
l(KW)5-AuNPs showed an organized arrangement (Figure 3). No visible peptide
agglomerates were observed. Cavities between AuNPs were found to be tailored in a
similar range size (approximately 45 ± 2 nm). The presence of the tryptophan in the
structure of the linear peptide induces presumably hydrophobic interactions that could
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be an efficient driving force for the formation of this specific structure. c[KW]5 and
l(KW)5 alone did not form any specific nanostructures under similar conditions,
suggesting that the binding between AuNPs and peptides contributes to different
morphology in P-AuNPs.
cyclic nature and rigidity of the peptide in c[KW]5-AuNPs and different
orientation of amino acids in the skeleton of peptide generated a different environment
surrounding the complex that led to aggregation or agglomeration of the peptides. This
orientation altered the number of available tryptophan and/or lysine residues in
reduction of Au3+ reaction.18 However, l(KW)5 has more flexible conformation
compared to the corresponding conformationally constrained cyclic counterpart
c[KW]5 during the AuNPs formation. The presence of additional positively charge
amino group and negatively charge carboxylate at N-terminal lysine and C-terminal
tryptophan, respectively, could also contribute in intermolecular interactions of the
peptide. Thus, the cyclic and linear nature of the peptide and the orientation of amino
acids were found to be responsible for the different morphology and size of formed PAuNPs.
Circular dichroism (CD) was used to obtain a better understanding about the
effect of AuNPs formation on the secondary structure of these peptides. CD
experiment of aqueous solution of peptides and their corresponding P-AuNPs (100
μM) was performed at room temperature. CD spectra of c[KW]5 (Figure 4) revealed a
negative band at approximately 216 nm and a positive band around 230 nm.
Compared to c[KW]5, the linear counterpart l(KW)5 showed a different CD spectra
pattern with a negative band at 201 nm and a positive band at 227 nm. However, the
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CD spectra of both c[KW]5-AuNPs and l(KW)5-AuNPs exhibited relatively similar
pattern with a minima at 204 ± 2 nm and a maxima at maxima at 229 ± 1 nm.
Although two P-AuNPs showed approximately similar pattern and intensity, l(KW)5AuNPs (206 nm) minima was shifted compared to that of c[KW]5-AuNPs (203 nm).
The CD spectra demonstrated a significant decrease in spectral elipticity of both PAuNPs compared to their corresponding parent peptides, suggesting significant
modification of secondary structures upon reducing Au3+ and/or binding to AuNPs.
These data show the binding between peptides and AuNPs leads to the formation of
c[KW]5-AuNPs and l(KW)5-AuNPs with differential CD spectra pattern compared to
the parent peptides.

Encapsulation of Camptothecin by Peptide-AuNPs
To evaluate the potential of c[KW]5-AuNPs and l(KW)5-AuNPs to encapsulate
drugs, camptothecin (CPT), a hydrophobic potent anticancer drug targeting
topoisomerase I19 was selected as a model drug for evaluation of loading using
fluorescence spectroscopy. Incubation of CPT with c[KW]5-AuNPs and l(KW)5AuNPs demonstrated significant shift in emission maxima of CPT. A characteristic
maxima band of CPT alone at 458 nm was shifted to 433 nm and 430 nm in the
presence of c[KW]5-AuNPs and l(KW)5-AuNPs, respectively (Figure S19). The
spectral blue shift in the presence of c[KW]5-AuNPs and l(KW)5-AuNPs was possibly
due to partitioning of CPT into a hydrophobic core and hydrophobic interactions.
Moreover, the intensity of the maxima band was decreased that could be due to the
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self-quenching of bound-drug and/or the result of the partitioning and entrapment in
the hydrophobic pocket generated by the P-AuNPs.20 These data exhibited that the PAuNPs were able to encapsulate CPT due to the generated hydrophobic pocket
possibly by tryptophan in the structure of the peptide.

Drug Loading. To get a better understanding of the quantitative drug loading
efficiency of the system, Dox was selected as a model drug because of its stability and
fluorescence property. The loading measurement was performed based on the
previously reported method.27 Aqueous Dox solution (100 μL, 100 μM) was mixed
with aqueous c[KW]5-AuNPs solution (900 μL, 500 μM) to obtain 1:5 molar ratio.
The unloaded Dox was separated by using dialysis to analyze the Dox loading
efficiency and loading capacity in the c[KW]5-AuNPs. After 24 h stirring, the loading
efficiency was found to be 72 ± 1% when the weight ratio of Dox to c[KW] 5-AuNPs
in feed is 1:5. The loading capacity was calculated to be 16 ± 1 % based on the weight
ratio of Dox to c[WK]5-AuNPs (1:5) when the amount of AuNPs was determined
using inductively coupled plasma mass spectrometry (ICP-MS).

Cytotoxicity of Peptide-AuNPs. Generated c[KW]5-AuNPs and l(KW)5-AuNPs did
not show any significant toxicity in human ovarian adecarcinoma (SK-OV-3), human
leukemia (CCRF-CEM) cancer cells, and normal human colon myofibroblast (CCD18Co) cells at a concentration of 100 μM after 24 and 72 h incubation times (Figure
S17). Thus, concentration of ˂100 μM was selected for further cell-based studies. It is
important to emphasize that the cytotoxicity of c[KW]5 and l(KW)5 (100 μM) was
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decreased through P-AuNPs formation dramatically. For example, c[KW]5 was found
to be toxic in normal colon CCD-18Co cells (61.3% cell viability) compared to
c[KW]5-AuNPs (99.3% cell viability) after 24 h at a concentration of 100 M. These
data indicate that the cytotoxicity of the parent peptide significantly reduces upon
generation of P-AuNPs.

Cellular Uptake of Peptide-AuNPs. To confirm the internalization of P-AuNPs
alone, F-l(KW)5-AuNPs and F-c[KW]5-AuNPs were prepared as described above by
incubating of fluorescently-labeled conjugates of linear (KW)5 and cyclic [KW]5, Fl(KW)5 and F-c[KW]5, with HAuCl4 solution according to the previously reported
procedure.15 Incubation of F-l(KW)5-AuNPs and F-c[KW]5-AuNPs with SK-OV-3
cells showed 3.3- and 4.3-fold higher cellular uptake compared to the corresponding
fluorescently-labeled peptides F-l(KW)5 and F-c[KW]5, respectively, thus suggesting
the formation of P-AuNPs is crucial for the enhanced cellular permeability (Figure 5).
FACS results confirmed that F-c[KW]5-AuNPs showed approximately 1.6-fold higher
cellular uptake than F-l(KW)5-AuNPs, suggesting that the cyclic nature of the peptide
in P-AuNPs contributes to improving the cellular uptake.
To investigate whether c[KW]5-AuNPs and l(KW)5-AuNPs localize in
different locations in the cell, F-l(KW)5-AuNPs (5 μM) and F-c[KW]5-AuNPs (5
μM) were incubated with SK-OV-3 for 1 h. 4',6-Diamidino-2-phenylindole (DAPI)
was employed as a marker of nucleus. Confocal microscopy showed significantly
higher nuclear localization of the cyclic peptide-capped AuNPs (F-c[KW]5-AuNPs)
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versus the corresponding linear system (F-l(KW)5-AuNPs) as shown by overlayed
picture with DAPI (Figure 6).
Cells use different mechanisms to internalize macromolecules and particles,
such as phagocytosis, micropinocytosis, and receptor-mediated endocytosis (RME)
pathways including clathrin-mediated, caveolae-mediated, and caveolae/clathrin
independent endocytosis.21 To get a better understanding of the mechanism of peptidecapped gold nanoparticles uptake by cells, the cellular uptake of fluorescein-labeled
peptide capped gold nanoparticles, F-l(KW)5-AuNPs and F-c[KW]5-AuNPs (5 μM),
were tested quantitatively in the presence of several inhibitors by using FACS
including, nystatin, chloroquine, chlorpromazine, methyl-β-cyclodextrin, and 5-(Nethyl-N-isopropyl)- amiloride (EIA).
As it is shown in Figure 7, the intracellular uptake of F-l(KW)5-AuNPs and Fc[KW]5-AuNPs did not significantly change in SK-OV-3 cells in the presence of
different endocytic inhibitors after 1 h incubation, suggesting that the mechanism of
cellular uptake is not exclusively clathrin-mediated or caveolae-mediated endocytosis,
and macropinocytosis. These peptide-AuNPs provide an advantage to known gold
nanoparticles and cell-penetrating peptides that their uptake is dependent mainly on
endocytotic entry.22
The surface decoration of AuNPs by amphipathic c[KW]5 and l(KW)5 peptides
could improve the interactions of lysine and tryptophan residues with the
corresponding negatively charged phospholipids and hydrophobic residues in lipid
bilayer. This interaction could be a strong driving force for the initial entry into the
cell membrane. Hydrophobic interactions generated by tryptophan residues and the
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lipids can potentially distort the outer phospholipid monolayer. This process will be
followed by peptide internalization and enhanced cellular uptake of the cargo. The
nature of the peptide in surface of AuNPs is an important parameter that can alter the
mechanism of nanoparticle uptake by cells. Further investigation is required to
pinpoint the detailed mechanism of cell entry by these P-AuNPs.
The cellular membrane integrity in SK-OV-3 cells was examined in the
presence of c[KW]5-AuNPs and l(KW)5-AuNPs and using trypan blue and showed no
significant difference to the control cells (Figure S18), ruling out the damage of the
plasma membrane by P-AuNPs at 50 μM and confirming that the highly efficient
transport of the complex was not a result of decreased cellular membrane integrity.

Evaluation of Peptide-AuNPs as Molecular Transporters. To evaluate P-AuNPs as
molecular transporters, model experiments with anti-HIV drugs 2',3'-dideoxy-5fluoro-3'-thiacytidine (emtricitabine, FTC) and 2',3'-didehydro-2',3'-dideoxythymidine
(lamivudine, 3TC) as cargo drugs were performed. FTC and 3TC are nucleoside
reverse transcriptase inhibitors those blocks HIV-1 and hepatitis B virus replication.22
The efficient cellular uptake of FTC and 3TC are critical for anti-HIV activity. To
monitor the molecular transporter ability of P-AuNPs, carboxyfluorescein derivatives
of FTC (F-FTC) and 3TC (F-3TC) were synthesized as described previously, where
F= fluorescein.24,25
CCRF-CEM cells were incubated with F-FTC and F-3TC (5 μM) in the
presence or absence of diluted carriers c[KW]5-AuNPs and l(KW)5-AuNPs (25 μM)
and their parent peptides for 1 h at 37 ºC and then treated with trypsin to remove cell

153

surface-bound drugs. Intracellular uptake of F-FTC and F-3TC (5 μM) was measured
in cells using fluorescence activated cell sorter (FACS). FACS showed significantly
higher fluorescence signals in cells treated with F-Drug-loaded P-AuNPs compared to
those with drug alone. The cellular uptake of F-drug-loaded c[KW]5-AuNPs and Fdrug–loaded l(KW)5-AuNPs were found to be 5.2–5.3- and 2.5–2.9-fold higher for FFTC and F-3TC, respectively, than those of drug alone respectively (Figure 8),
suggesting that the uptake of drugs is facilitated by P-AuNPs. The results showed that
parent cyclic or linear parent peptides did not improve the cellular uptake of drugs.
However, after the formation of P-AuNPs, the cellular uptake of drugs was increased
significantly. c[KW]5-AuNPs were found to be more efficient transporter than l(KW)5AuNPs, while c[KW]5 and l(KW)5 exhibited similar results. These data suggest that a
non-cell penetrating cyclic peptide can be converted to cell-penetrating P-AuNPs,
presumably due to the new orientation of amino acids and the secondary structure in
peptides as shown with CD in the presence of generated AuNPs for drug entrapment.
To visualize the enhancement of the cellular uptake of drugs, F-3TC was used
as a model for confocal microscopy in SK-OV-3 cells. Confocal microscopy showed
nuclear localization of F-3TC–loaded c[KW]5-AuNPs compared to the corresponding
linear system and drug alone. F-3TC-loaded l(KW)5-AuNPs exhibited a modest
fluorescence mostly in the cytoplasm of the cells. However, incubation of cells with
F-3TC alone did not show any fluorescence intensity in cells. These data confirm that
the cyclic nature of the peptide is critical for the enhanced cellular permeability
(Figure 9) and the nuclear targeting delivery of cargos.
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Thus, differential application of linear and cyclic [KW]5-AuNPs was
discovered for localization of fluorescence-labeled-3TC. Confocal microscopy
revealed the localization of fluorescence-labeled-3TC in the presence of c[KW]5AuNPs mostly in nucleus in SK-OV-3 cells after 1 h. On the other hand, l(KW)5AuNPs delivered fluorescence-labeled-3TC in cytoplasm. Furthermore, c[KW]4AuNPs offered two major advantages over c[RW]4-AuNPs that we previously
reported.15 First, the reaction time for the formation of c[KW]4-AuNPs (1 h) was
significantly shorter compared to that of c[RW]4-AuNPs (4-8 h). The Surface Plasmon
Resonance peak for both c[KW]4-AuNPs and c[RW]4-AuNPs15 was compared by
using UV-Vis spectroscopy (Figure S20) after 1 h. The results showed that c[KW]4AuNPs formed faster than c[RW]4-AuNPs. Second, the size and morphology of
nanoparticles can be used to control the amount of intracellular uptake of AuNPs by
cells. Intracellular accumulation of 233 ng and 288 ng of c[RW]4-AuNPs and c[KW]4AuNPs was detected, respectively, in SK-OV-3 cells after 24 h incubation15 as
measured by ICP-MS.
The molecular transporting efficiency of P-AuNPs for cell-impermeable
negatively charges phosphopeptides was also evaluated using flow cytometry. The
phosphopeptide do not cross the cell-membrane readily because of the presence of the
negatively charged phosphate group. The pTyr-Glu-Glu-Ile (GpYEEI) peptide
template has been reported to be an optimal binding sequence for the Src SH2 domain
of Src kinase.25 The cellular uptake of F-GpYEEI was monitored in the presence of PAuNPs in SK-OV-3 cells. FACS analysis showed that the cellular uptake of FGpYEEI was enhanced 3.5- and 12.8-fold by l(KW)5-AuNPs and c[KW]5-AuNPs,
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respectively (Figure 10), suggesting that these systems may function as a delivery
tools for F-GpYEEI. c[KW]5-AuNPs improved the cellular uptake of F-GpYEEI 4.2fold higher when compared to l(KW)5-AuNPs, suggesting the critical role of the cyclic
peptide in improving the cellular uptake. These results are consistent with cellular
uptake studies of lamivudine and emtricitabine.
Considering the significant enhancement of F-GpYEEI in the presence of PAuNPs (Figure 10), confocal microscopy was used to confirm the cellular uptake of
this negatively charged phosphopeptide in the presence and absence of P-AuNPs.
Thus, confocal microscopy was conducted by measuring the fluorescence intensity of
F-GpYEEI-loaded P-AuNPs compared to F-GpYEEI alone in SK-OV-3 cells. 4',6Diamidino-2-phenylindole (DAPI) was employed as a marker of nucleus. The cells
were incubated with F-GpYEEI-loaded c[KW]5-AuNPs, F-GpYEEI-loaded L[KW]5AuNPs, and F-GpYEEI alone. No green fluorescence was observed for the parent
fluorescence-labeled phosphopeptide, suggesting that F-GpYEEI alone did not cross
the membrane because of the presence of negative charge phosphate. As shown in
Figure 11, the cell nuclei stained by DAPI (blue) were circumvented by the green
fluorescence showing the fluorescent-labeled phosphopeptide localized in the
cytoplasm in the presence of L[KW]5-AuNPs (Figure 11b). However, the presence of
c[KW]5-AuNPs led an overlay of green and blue fluorescence signals revealing the
localization of the phosphopeptide mostly in the nuclei of SK-OV-3 cells (Figure 11c).
These results indicated that the presence of P-AuNPs is critical to improve the cellular
uptake of cell-impermeable phosphopeptide. Furthermore, the linear or cyclic nature
of the peptide determines the final destination of the cargo.
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Time-Dependent Antiproliferative Assay. To determine whether c[KW]5-AuNPs
can be exploited for the delivery of biologically relevant doses of CPT to cells, the
antiproliferative activity of CPT was evaluated in SK-OV-3 cells in the presence and
absence of peptide-capped AuNPs in a time-dependent manner. The antiproliferative
activity of CPT (5 M) in the presence of the c[KW]5-AuNPs was improved by
approximately 9%, 32%, and 33% compared to that of CPT alone after 24, 48, and 72
h incubation, respectively (Figure 12). Time-dependent inhibitory effect on the cell
proliferation of SK-OV-3 cells suggests that the sustained intracellular release of CPT
and improved efficacy of the compound. c[KW]5-AuNPs alone did not show any
toxicity in SK-OV-3 cells under similar condition, suggesting that the higher
antiproliferative is possibly related to the enhanced uptake of the drug in the presence
of the peptide-capped AuNPs and intracellular release of CPT.

Intracellular Release of Dox. To investigate the kinetics of drug release in cells, Dox
was selected as a model drug. The intracellular release of Dox in the presence of the
c[KW]5-AuNPs in CCRF-CEM cells was monitored by HPLC. The CCRF-CEM cells
(1.2 × 107) were incubated with Dox (7.5 μM)-loaded c[KW]5-AuNPs (37.5 μM) for
different times including 2, 12, 24, and 48 h. HPLC analysis at 490 nm and a specific
time intervals after cellular lysis was used to measure the quantity of the released Dox.
The data exhibited that the intracellular release of Dox occurred in a time-dependent
manner. Dox was observed at 15.8-15.9 min in the HPLC profile (Figures S4-S9,
Supporting Information). HPLC data showed that approximately 30, 35, 55, and 88%
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of Dox was released intracellularly within 2, 12, 24, and 48 h, respectively. These data
suggest the sustained release of Dox contributes to overall activity of the Dox–loaded
c[KW]5-AuNPs as a potential prodrug.

Conclusions
In conclusion, a new class of DDS containing AuNPs and peptides with
tryptophan and lysine residues were generated under a mild reaction condition. Cyclic
and linear peptide capped-AuNPs (l(KW)5-AuNPs and c[KW]5-AuNPs) exhibited
entirely different morphology and sizes. Both l(KW)5-AuNPs and c[KW]5-AuNPs
showed minimal cytotoxicity at 100 M. P-AuNPs were able to entrap hydrophobic
CPT through non-covalent interactions, and act as molecular transporters of
fluorescence-labeled lamivudine, emtricitabine, and a phosphopeptide (GpYEEI)
intracellularly. High cellular internalization of the labeled drugs by P-AuNPs suggests
the potential application of P-AuNPs as molecular transporters. Confocal microscopy
showed that l(KW)5-AuNPs and c[KW]5-AuNPs delivered cargos to different
destinations in cells e.g. cytoplasm and nucleus, respectively. The present results
provide insights for generation of a new class of peptide-capped metal nanoparticles as
cellular delivery transporters.
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Additional synthetic Scheme and Figures, UV-VIS spectroscopy, cytotoxicity, and
encapsulation with CPT. This information is available free of charge via the Internet at
http://pubs.acs.org/.
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Figure Legends:
Figure 1: Chemical structures of synthesized cyclic peptides
Figure 2: TEM images of c[KW]5-AuNPs
Figure 3: TEM images of l(KW)5-AuNPs
Figure 4: Comparative CD of cyclic c[KW]5, linear l(KW)5, and compared to c[KW]5AuNPs and l(KW)5-AuNPs
Figure 5: Cellular uptake of F-l(KW)5-AuNPs and F-c[KW]5-AuNPs (5 M) versus
the corresponding fluorescently-labeled peptides F-l(KW)5 and F-c[KW]5 (5 M)
after 1 h incubation
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Figure 6: Confocal microscope images of F-l(KW)5-AuNPs (5 μM) and F-c[KW]5AuNPs (5 μM) uptake by SK-OV-3 cells after 1 h incubation
Figure 7: Cellular uptake of (a) F-l(KW)5-AuNPs (5 μM) and (b) F-c[KW]5-AuNPs
(5 μM) in the absence or presence of different endocytic inhibitors in SK-OV-3 cells
after 1 h
Figure 8: Cellular uptake studies for F-FTC and F-3TC alone (5 M) in the presence
of cyclic and linear peptides and their corresponding P-AuNPs (25 µM) after 1 h
incubation
Figure 9: Confocal microscope images of F-3TC (5 M) uptake by SK-OV-3 cells in
the presence of l(KW)5-AuNPs and c[KW]5-AuNPs (25 M) after 1 h incubation
Figure 10: Cellular uptake of F-GpYEEI (5 M) in the presence of l(KW)5-AuNPs,
c[KW]5-AuNPs, l(KW)5 and c[KW]5 (25 M) after 1 h incubation
Figure 11: Confocal microscope images of F-GpYEEI (5 M) uptake by SK-OV-3
cells in the presence of l(KW)5-AuNPs and c[KW]5-AuNPs (25 M) after 1 h
incubation
Figure 12. Time-dependent antiproliferative assay of CPT in the absence and presence
of c[KW]5-AuNPs.
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SUPPORTING FIGURES AND SCHEMES
Figure S1. Stability of cyclic [W(RW)4]-Dox after incubation with (a) PBS and (b)
FBS.
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Figure S2. Comparison of cell cycle arrest by Dox and cyclic [W(RW)4]-Dox.
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Figure S3. Detection of AuNP formation by UV-Vis absorption spectroscopy by
HAuCl4 (1 mM) with different concentrations of [WR]4 (100 M-2 mM).
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Figure S4. TEM images of [WR]4-AuNPs generated from incubation of [WR]4 with
HAuCL4.
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Figure S5. Cytotoxicity assay of [WR]4-AuNP and [WR]4 in SK-OV-3 cells (24 h and
72 h), CCRF-CEM (24 h), and CCD-18Co (24 h) (mean ± SD).
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Figure S6. Cytotoxicity assay of [WR]4-AuNP and [WR]4 compared with polyArg
CR7, TAT (YGRKKRRQRRRC) (100 µM), and oligofectamine 2000 in CCD-18Co
(48 h) (mean ± SD, n = 3).
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Figure S7. Cellular uptake of cyclic F-[W5R4K] capped-AuNP compared with FAM
(10 M) and linear F-(W5R4K) capped-AuNP in CCRF-CEM cells.
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Figure S8. ICP-MS of [WR]4-AuNPs (50 M) in SK-OV-3 cells after 3 h and 24 h
incubation (mean ± SD, n = 3).
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Figure S9. Membrane integrity of SK-OV-3 cells in the presence of (50 µM) and
control (cells with serum-free media without any treatment with AuNPs) (mean ± SD,
n = 3).
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Figure S10. Fluorescence of Dox in the presence of [WR]4-AuNPs (1:1 molar ratio)
after 2 h incubation.
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Figure S11. Differential interference contrast microscopy of fluorescence-labeled
lamivudine (F-3TC) (5 M) in the absence of [WR]4-AuNP in SK-OV-3 cells.
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Figure S12. Cellular uptake of [WR]4 capped-AuNP without a fluorescent label (10
M) in CCRF-CEM and [WR]4 capped-AuNP (25 M) in SK-OV-3 cells.
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Figure S13. Flow cytometry studies for F-3TC (5 M) in the presence or absence of
[WR]4 or [WR]4-AuNPs (25 M) in SK-OV-3 cells, (mean ± SD, n = 3).
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Figure S14. Flow cytometry studies for F-3TC (5 M) in the presence of linear
(WR)4, cyclic [WR]4, linear [WR]4-AuNPs, and cyclic [WR]4-AuNPs (25 M) in
CCRF-CEM cells, respectively (mean ± SD, n = 3).
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Figure S15. Flow cytometry studies in SK-OV-3 cells for Dox alone (5 M) and in
the presence of [WR]4 (25 M) or [WR]4-AuNPs (25 M) after 1 h (mean ± SD, n =
3).
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Figure S16. UV-Vis spectroscopy of peptide-capped gold nanoparticles.
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Figure S17. Cytotoxicity of peptides and corresponding P-AuNPs.

140

CCD-Co 18Co (24h)

CCRF-CEM (24h)

SK-OV-3 (24h)

SK-OV-3 (72h)

120

Cell Viability (%)

100

80

60

40

20

0

Figure S18. Membrane integrity of SK-OV-3 cells in the presence of P-AuNPs (50
μM) (mean ± SD, n =3).
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Figure S19. Fluorescence of CPT in the presence of c[KW]5-AuNPs and l[(KW)5AuNPs (1:1 molar ratio) after 4 h incubation.
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Figure S20. UV-Vis spectroscopy of c[KW]4-AuNPs and c[RW]4-AuNPs.
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Scheme S1. Solid-phase synthesis of [WE]4 and linear (WR)4.
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Scheme S2. Solid-phase synthesis of l(KW)4, c[KW]4, and F-l(KW)5.
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